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Tandem-repeat proteins are a class of proteins ubiquitous in nature and exploited in recent 
years in biotechnological and pharmaceutical applications due to their favourable biophysical 
properties. One such repeat motif, the tetratricopeptide repeat (TPR), has already been 
exploited for biotechnological applications and here the consensus-designed TPR (CTPR) 
sequence was used as a scaffold to create novel arrays of binding molecules. The platform 
allows us to display single and multiple functions with diverse geometrical arrangements by 
grafting short binding sequences onto the loops between adjacent repeats or at the terminal 
alpha-helices. As proof of concept, proteins were designed to bind to and inhibit the human 
tankyrase (TNKS), a key regulatory protein involved in Wnt signalling and overexpressed in 
cancer and other disorders. For this purpose, a tankyrase-binding peptide (TBP) was grafted 
between two adjacent repeats to create a solvent-exposed loop. A series of mono- and multi-
valent TNKS binders, named TBP-CTPR, was assembled by repeating the TNKS-binding unit 
in tandem in both a monomeric format and also in a trimeric arrangement. The folding and 
thermodynamic stability of these TBP-CTPR proteins were characterised and the interaction 
with TNKS was measured using a range of biophysical approaches. Both the engineered TBP-
CTPR proteins and TNKS are multivalent, and the effects of multivalency were explored both 
in the test tube and in the cell. The results show that the proteins interact to form large 
assemblies. Moreover, the TBP-CTPR proteins were found to have exceptional activity in 
inhibiting the Wnt signaling pathway upon delivery by encapsulation in fusogenic liposomes. 
Lastly, hetero-bifunctional constructs were generated by grafting two different binding 
sequences onto the CTPR scaffold, and a preliminary analysis of their activities was performed. 
In conclusion, these results point to the tremendous potential of the CTPR scaffold as a 
platform to build synthetic protein binders, with a particular focus on multivalent interactions.  
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1.1 Protein engineering in the last decade 
In the last few years, protein biotherapeutics have gained increased attention. Biologic drugs 
are characterised by much larger binding interfaces than small molecules, thereby increasing 
target specificity and reducing off-target effects. Although a few decades ago antibodies would 
have been regarded as the only option available, nowadays a great variety of biotherapeutics 
based on alternative protein scaffolds have been developed. One such alternative is provided 
by the class of proteins known as tandem-repeat proteins. The emergence of protein 
engineering techniques has allowed the diversification of antibody technologies and the 
conversion of repeat proteins into stable, scaffolding units that can be functionalised to bind to 
a specific target of interest. This Chapter highlights the properties that have contributed to the 
success of alternative scaffolds in the past few years, with a particular focus on repeat proteins.  
 
1.1.1 Antibody engineering 
Antibodies are protein complexes produced by the immune system to defend the body from 
the threats of external pathogens and microorganisms. Among the five isotypes of natural, 
human antibodies, IgG is the most abundant class and consists of two heavy chains (50 kDa 
each) and two light chains (23.5 kDa each) that assemble to form a Y-shaped complex with a 
high molecular weight of about 150 kDa (Figure 1.1). Each chain consists of a variable region 
and a constant region. Selectivity towards a specific antigen is provided by the variable region, 
which adapts and evolves to maximise its binding affinity against a determined pathogen. 
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Three, hypermutable, flexible loops in each variable domain give rise to the so-called 
complementary-determining region (CDR) of an antibody, responsible for its specificity.1 
In the past few years, antibodies have been extensively modified and engineered for 
drug development purposes. Starting from humanised antibodies, progressively smaller 
antibody fragments have been developed to obtain recombinant, monomeric, easier to produce 
antibody derivatives, with identical binding efficiency but improved tissue penetration (Figure 
1.1). Apart from mono-specific antibodies, bi- and tri-specific antibody variants have also been 
explored to recruit multiple targets or extend their half-life in the blood stream.2 
 
 
Figure 1.1: Schematic representation of an IgG antibody and its recombinant antibody derivatives of 
progressively smaller molecular weight size. Figure obtained from the tebu-bio blog.3 
 
1.1.2 The concept of multivalency  
Protein-protein and antibody-antigen complexes are formed when one or more binding events 
occur between two or more interacting partners. When describing the binding interaction for 
complex formation, both affinity and valency should be taken into account. Affinity 
corresponds to the strength of the interaction at a single site, and valency indicates the number 
of identical or similar binding sites within a protein, engaging with the same target. Although 
the majority of natural proteins interact through only one binding site, some proteins have 
  General introduction 
 3 
multiple binding sites for their ligand, and multivalency often counterbalances a weak binding 
affinity.4 
Antibodies provide an obvious example of multivalency. Each antibody has between 
two and ten identical binding sites, depending on the isotype: antibodies with fewer binding 
sites tend to have high affinities, whereas antibodies with a greater number of binding sites 
(such as IgM) tend to have low affinities. For intracellular proteins, multivalency has been 
frequently observed for intrinsically-disordered proteins (IDPs), as their intrinsic structural 
flexibility allows the epitopes to adapt more easily to the complementary binding surface of 
the interacting partner. Multivalency has therefore been more extensively studied in this 
particular class of proteins, and it can occur through different mechanisms:5 
- Avidity occurs when two or more binding sites located on the ligand bind and 
complement two or more binding sites on the binding partner. Avidity is therefore only 
possible in the presence of two multivalent binders. Avidity is described as the 
accumulated strength generated by multiple affinities: once the ligand has bound one 
site, the probability of establishing a second binding event is much higher than for the 
first one, introducing cooperativity. As the number of binding events increases, the 
affinity between the two interacting proteins also accumulates. 
- Allovalency occurs when multiple and identical receptor-binding sites are positioned 
in tandem on a ligand and they compete for a single binding site on the receptor. Despite 
only one binding event can occur, the presence and competition by multiple tandem 
sites creates cooperativity and increases the overall affinity.  
- Fuzzy complexes: this term, introduced by Tompa and Fuxreiter in 2007,6 refers to the 
ensemble of various conformational states that occur when two or more binding sites 
on the ligand bind two or more binding sites on the receptor in different combinations. 
As various binding conformational states are allowed, the fuzzy complex is dynamic in 
the bound state and individual binding events continuously form and break, while the 
two interacting partners are still in complex.7 
 
Multivalent interactions are a recurrent feature across all biological systems, in the macro as 
well as in the nano scale. Multivalency is exploited in nature to provide increased molecular 
affinity and specificity to binding interactions, compared to monovalent counterparts.4 The 
many advantages induced by multivalent interactions have therefore led to the development of 
artificial, multivalent systems. Many multivalent antibody technologies leverage and expand 
the natural modularity (i.e. multi-domain nature) of immunoglobulins, to achieve higher 
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valency and dual-targeting within the same construct.8,9 Likewise, other proteins used as 
alternative scaffolds, have been designed and used for multivalent recognition, as mentioned 
below. In alternative, functional peptide motifs have been assembled on synthetic chemical 
scaffolds,10,11 DNA12,13 and protein scaffolds.14–20 
 
1.1.3 Antibody versus alternative scaffolds 
In the past few years, a wide variety of biologic drugs have been developed as alternatives to 
antibody therapeutics. These therapeutics are usually based on small protein scaffolds. 
Alternative scaffolds have similar properties to antibodies in terms of affinity and functionality, 
but they are differentiated by their greater solubility and stability, smaller size and simplified 
manufacturing. Other liabilities of antibodies, such as redox sensitivity and the need of targets 
with poor host homology for effective immunisation, can also be avoided. For these reasons, 
alternative scaffolds are becoming a new powerful modality in drug development, in particular 
for targets considered “undruggable” by conventional approaches.21 
Alternative scaffolds are generally characterised by a relatively small size (less than 
~150 amino acids) and an independent folded unit with rigid tertiary structure, providing 
stability and folding efficiency.22 Generally, target binding of the scaffold molecule comes 
from randomised sequences within one or multiple loops (in a similar way to the CRD of 
antibodies), helices, flat surfaces, cavities or an inserted random peptide.22 In practical terms, 
target binding can be achieved in several ways. Binding can be introduced by random 
mutagenesis within non-conserved residues of the scaffold followed by library generation and 
screening, most commonly through phage, bacterial, ribosome or direct nucleic acid display. 
As an alternative, new binding functions can be introduced by rational engineering approaches, 
where known binding sequences (i.e. loops or α-helices) involved in naturally occurring 
protein-protein interactions are transferred (grafted) onto a novel scaffold. This method 
requires the epitope to be a contiguous sequence and is facilitated by having a crystal structure 
of the native protein-protein interaction, allowing identification of the critical binding residues 
and their conformation required for binding. In this way, the binding epitope is “cut-and-
pasted” onto an appropriate site within the scaffold.20,22,23 The scaffold thus constrains the 
grafted peptide in its native, bioactive (binding-competent) conformation. Similar to chemical 
macrocyclisation or “stapling”, the scaffold also provides the grafted peptide with enhanced 
proteolytic stability relative to the isolated peptide.22 Another alternative method to introduce 
target specificity onto a scaffold is by computer-aided design. Protein design algorithms such 
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as the Rosetta software (from David Baker’s lab, Seattle, USA) allow one to screen in silico 
for target binding using a three-step process: grafting, docking, and design. The user-supplied 
binding fragment is grafted onto a proposed scaffold, and the grafted protein is then tested in 
silico by docking onto the target. If the fit is deemed to be favourable, the binding interface can 
be further optimised by introducing additional contact interactions. Nowadays, small proteins 
can also be designed de novo with customised shape, stability and binding specificity towards 
a target of interest.24–27 Recently, algorithms such as Rosetta and DeepMind’s AlphaFold have 
advanced to such an extent that it is now possible to predict with atomic-level accuracy the 3D 
shape of proteins just from their amino-acid sequences. 
Finally, as for antibody engineering, multivalency has also been attempted in alternative 
scaffolds.28 It is generally achieved by connecting monovalent domains in “beads-on-a-string” 
manner,29 by fusing them onto an antibody scaffold30 or a smaller immunoglobulin fragments 
or an albumin-binding domain (ABD, which also provides the multivalent construct with 
extended half-life),31,32 or by fusing other oligomerisation domains to the protein.33 
The list of the most relevant examples of engineered alternative protein scaffolds used 
as novel biotherapeutics is provided in Table 1.1, with an indication of their origin, fold, 
number of amino acid and stage of development. 
 
Name Scaffold origin Fold (AA) Stage of development 
Affibodies Z domain of protein A α3 (58) Clinical trials (ABY-025) 
Affilins gamma-B crystallin α/β (183) Preclinical studies 
Affimers (adhiron) Cystatin α/β (79) Preclinical studies  
Anticalins Lipocalins β-barrel (160-180) Clinical trials (PRS-050) 
DARPINs Ankyrin repeat α2β2 repeated (33) Clinical trials (MP0112) 
Fynomers SH3 domain of Fyn Mainly β (~60) Ab fusions (FynomAb) 
Monobodies 10th type III domain of fibronectin β-sandwich (94) Clinical trials (Pegdinetanib) 
Table 1.1: List of the most relevant alternative scaffold proteins used for therapeutic purposes. AA 
indicates the number of amino acid residues; Ab is an abbreviation for antibody. 
 
1.2 Tandem-repeat proteins 
Tandem-repeat proteins (also referred to as repeat proteins) are a broad group of ubiquitous 
proteins, characterised by the repetition of a peptide unit in tandem. Tandem-repeat proteins 
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occur in 14% of all known proteins (from both eukaryotes and prokaryotes)34 and in about one-
third of the human proteome.35 Within this group of proteins, the many variations are 
determined by the length of the repeating unit: with units ranging from 1 to over 100 amino 
acid residues, the tandem-repeat proteins represent an extremely diversified group. A more 
recent analysis of the 3D structures obtained from repeat proteins has allowed the classification 
of these into five classes depending on the length of their repeats.36 Proteins with 1-2 amino 
acid repeats (class I) form crystalline aggregates of unlimited size, which are harmful to living 
organisms. When the repetitive unit consists of 30-130 amino acids (class V), the repeat folds 
as an independent stable domain.36 Here we are interested in tandem-repeat proteins that belong 
to class III, comprising repeats of 5-40 amino acids. Each repeat folds into a structural motif 
formed from one to four segments of secondary structure (α-helices, β-strands or a combination 
of the two) connected by turns or loops. Unlike globular proteins, they pack in a linear fashion 
to produce regular, elongated, quasi-one-dimensional architectures (Figure 1.2). Moreover, 
tandem repeats are stabilised by short-range interactions between residues close in sequence 
either within a repeat or between neighbouring repeats. Stabilising contacts are located at the 
interface between consecutive repeats, whereas residues involved in target binding are surface-
exposed. Tandem-repeat proteins belonging to this subgroup, such as ankyrin repeats (ANK), 
tetratricopeptide repeats (TPR), armadillo repeats (ARM) and leucine-rich repeats (LRR), 
generally function as binding partners to other proteins, small molecules or nucleic acids. These 
protein arrays require at least three repeats to be folded, stable and allow the formation of an 
extended binding surface.36 From an evolutionary perspective, repeats are thought to arise from 
intragenic duplications and recombination events, with the resulting advantage of enlarging the 
available binding surface area.37 
Increasing interest in class III of repeat proteins has arisen recently due to their simple, 
modular, stable and regular architectures. They are also chemically homogeneous due to their 
repeating nature, and there is no limit to their size or the number of repeats. These 
characteristics make repeat proteins straightforward both to dissect and to rationally redesign 
in a LEGOTM-like manner.38 Several types of repeat proteins have recently been functionalised 
and used as building blocks to create artificial biologics and biomaterial for clinical and 
biotechnological purposes, respectively.39–44 Interestingly, new repeat-protein folds, consisting 
of repeats of a helix-loop-helix-loop motif and not found in nature, have also been de novo 
designed by the Baker lab. These proteins allow one to expand beyond natural repeat protein 
shapes and to generate completely novel repeat proteins with customised geometries.45 
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Figure 1.2: Examples of tandem repeat proteins and their repeated motif: ANK – ankyrin (PDB 
3TWR)46, ARM – armadillo (PDB 2Z6H)47, TPR – tetratricopeptide repeat (PDB 4I1A)48, HEAT – 
Huntington, elongation factor 3, protein phosphatase 2A, and the yeast kinase TOR1 (PDB 2IAE)49, 
LRR – leucine rich repeat (PDB 2BNH)50, β-helix (PDB 1L0S)51. Images were generated using the 
software UCSF Chimera.52 
 
Among the different types of naturally occurring repeat proteins, ANK repeats have been 
particularly thoroughly exploited by the Plückthun lab and others for the development of 
biotherapeutics, giving rise to a new class of antibody-like proteins named DARPins 
((consensus-)Designed Ankyrin Repeat Proteins), some of which are already in clinical trials 
for a variety of diseases.44 Multivalency in DARPins has been achieved by fusing up to six 
DARPin modules mostly through flexible peptide linkers, or through more rigid linkers such 
as leucine zipper and α-helical connectors.29,53 However, no modular repeat-protein platform 
has been developed to date that is capable of combinatorial incorporation of multiple binding 
motifs in a single, stable and robust scaffold as well as presenting them with varied, precise 
and programmable geometries. The work presented here shows that the repeat protein scaffold 
adopted during my PhD possesses all the necessary features with which to build such a 
platform. 
 
1.2.1 The tetratricopeptide repeat (TPR) 
One of the simplest structures in class III of tandem-repeat proteins is the tetratricopeptide 
repeat (TPR), a 34-residue motif comprising two antiparallel α-helices, named helix A and B, 
connected by a short turn.54 It was first discovered in 1990 within the CDC23 gene of 
Saccharomyces cerevisiae55 and the nuc2+ gene of Schizosaccharomyces pombe.56 To date, 
over 5000 TPR-containing proteins have been identified using bioinformatics tools.57 These 
proteins are involved in a diverse spectrum of cellular functions (protein transcription, folding, 
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transport and cell-cycle progression) and in multiprotein complex assemblies in humans and in 
other organisms.58 The TPR motif occurs in tandem arrays of three to sixteen or more units,59 
and in nature it mediates protein-protein interactions in a variety of molecular recognition 
modes.57,60 The most commonly observed binding mode involves around three repeats forming 
a concave groove and accommodating a short extended peptide that sits roughly perpendicular 
to the repeat array.60 The specificity of each TPR-containing proteins relies on the underlying 
sequence of each repeat, with a particular attention to the solvent-exposed residues. Looking 
closer at the TPR sequence within TPR-containing proteins, Sikorski et al. identified eight 
residues that are particularly conserved, at positions 4 (W/L/F), 7 (L/I/M), 8 (G/A/S), 11 
(Y/L/F), 20 (A/S/E), 24 (F/Y/L), 27 (A/S/L) and 32 (P/K/E).55 Amino acids at positions 4, 7, 8 
and 11 are present within the helix A; amino acids at positions 20, 24 and 27 are within helix 
B; and they are all hydrophobic (with few exceptions in some natural protein sequences). The 
side chains of these residues are clustered along the same face of the corresponding helix, 
allowing hydrophobic interfacial interactions between the two amphipathic helices. The proline 
at position 32 is found at the loop connecting consecutive repeats. This residue is key in forcing 
a turn in direction to occur, leading to a termination of helix B. The backbone of Pro32 also 
interacts with Trp4 of the following repeat, therefore stabilising the turn.54 
In 2003, an artificial consensus-designed TPR sequence, named CTPR, was developed 
by Main et al. for biotechnological and clinical purposes.61 Designing a consensus sequence 
allows one to explore the overall structure and stability of the TPR motif, without the additional 
complications of protein-specific differences between repeats. Moreover, residues required for 
binding are removed, providing an excellent starting-point sequence for structural studies and 
an ideal scaffold on which to introduce novel functionalities. Following sequence alignment of 
1837 TPR motifs from a non-redundant protein database of 107 proteins, the authors selected 
the most preferred residue for each of the 34 amino acids positions within the TPR.61 The eight 
residues previously identified by Sikorski et al. to be highly conserved were among those with 
the highest value of propensity in the Main et al. study.61 
Several changes to this CTPR sequence were introduced to enhance its favourable 
properties, making it more amenable for protein engineering: 
1. At position 10, cysteine was replaced with alanine to avoid unwanted disulphide bond 
formation; 
2. An N-terminal stabilising capping sequence (Gly-Asn-Ser) was introduced; 
3. A solvating helix was grafted to the C-terminal end of the TRP, based on capping 
repeats observed in some natural and previously studied TPR proteins.54 To enhance 
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the protein’s solubility, four large hydrophobic residues within the solvating helix, one 
Trp and three Tyr, which would be packed against the adjacent repeat if they were in 
an internal repeat, were mutated to hydrophilic polar residues Lys and Gln. 
The final CTPR sequence, together with the capping sequence and the solvating helix is shown 
in Figure 1.3. This sequence, with few additional mutations detailed in Section 3.2.1, was 
adopted as the scaffold for the studies presented in this thesis. 
 
 
Figure 1.3: The CTPR motif developed by Main et al. (A) Histogram showing the global propensity 
of the three most frequent amino acids (if greater than 1) at each of the 34 amino acid positions of the 
TPR motif. Residues within boxes and their position correspond to the highly conserved TPR residues. 
(B) Schematic representation of the CTPR sequence, including an N-terminal capping sequence and a 
C-terminal solvating helix. Boxes denote residues that have been mutated by the authors. Figure 
obtained from Main et al.61 
 
The same authors determined the structures of the CTPR2 and CTPR3 constructs, both by 
NMR and X-ray crystallography.61 As for the previous TPR solved structures, the CTPR motif 
also folds into the expected helix-turn-helix conformation with two antiparallel and 
amphipathic α-helices per repeat (Figure 1.4A). Most α-helices in nature are amphipathic, 
meaning that one face of the helix displays hydrophobic residues, while the other is 
hydrophilic, and this characteristic promotes the correct folding of helical domains. Indeed, the 
hydrophobic residues remain buried within the structure and interact with other structural 
elements to avoid contact with an aqueous solvent, whereas the hydrophilic residues are 
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solvent-exposed. This pattern is observed also in the CTPR helices. Within the helix-turn-helix 
CTPR motif, the side chains of the eight highly conserved, hydrophobic residues are 
responsible for the interfacial contacts between helices. In particular, the large, hydrophobic 
side chains along helix A (Trp4, Leu7 and Tyr11) are placed between the preceding and the 
following B helices, forming a network of packing interactions with residues from both helices. 
These inter-repeat interactions lead to an extended hydrophobic core, that stabilises 
consecutive repeats at their interface and the overall CTPR structure.61 It is also interesting to 
note how conserved residues with small side chains (Ala and Gly) accommodate and interact 
with the larger side chain of hydrophobic residues from the same repeat (Figure 1.4B). This 
characteristic pattern, known as “knobs-into-holes”, is crucial to the formation of stabilising 
intra-repeat interactions within the CTPR scaffold.61 
 
 
Figure 1.4: CTPR helix-turn-helix motif. (A) Ribbon structure of the CTPR2-Solvating Helix construct 
obtained by Main et al.61 The CTPR repeats are coloured with different shades of yellow, the solvating 
helix is in orange. (PDB: 1NA3) (B) CTPR repeat with the side chains of the highly conserved residues 
visible and labelled. (PDB: 1NA3) Images were generated using the software UCSF Chimera. 
 
Looking at the helical wheel representation, that illustrates the orientation of each residue along 
the helical axis, it is particularly easy to visualise the amphipathic nature of the helices A and 
B, with the seven highly conserved residues promoting hydrophobic intra-repeat interactions 
being indicated (Figure 1.5). In the solvating helix, the four hydrophobic residues on the 
outward-facing surface are mutated to polar amino acids to enhance the solubility of the protein 
construct. 
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Figure 1.5: Helical wheel representation of Helix A, Helix B (Top) and the Solvating Helix (Bottom). 
For each helix, the signature residues involved in intra-repeat interactions are indicated with a grey 
arch. Polar residues are shown as boxes, nonpolar residues as circles. Colour legend is provided in the 
bottom right corner. Figures were obtained from a the web-based application NetWheels.62 
 
As for other repeat proteins in class III, long arrays of TPRs fold into an extended conformation 
with an overall superhelical architecture, as demonstrated by the crystal structure of TPR-
repeat domain of O-linked GlcNAc transferase (OGT).63 The individual helices within the 
same repeat are arranged in a slightly twisted manner, tilted from each other by ~24º, resulting 
in a right-handed superhelical shape. The same has been observed for the consensus TPR 
proteins, where eight CTPR repeats are required to complete a turn of the superhelix (Figure 
1.6).64 The superhelix presents a regular geometry and consists of two protein surfaces: helices 
A mainly contribute to the inner concave surface, whereas the outer surface includes residues 
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from both helices A and B. The concave face is the one that forms the binding interface for 
each specific target.64 
 
 
Figure 1.6: Superhelical fold of a CTPR8 protein. (A) Crystal structure of CTPR8 construct obtained 
by Kajander et al.64 (PDB: 2FO7) (B) Protein in A observed along its axis, after a 90º rotation. Images 
were generated using the software UCSF Chimera. 
 
The CTPR proteins have been extensively studied by the Regan, Cortajarena, Grove and Main 
groups not only to understand their biophysical properties, but also to exploit them in 
biotechnological applications. Artificial CTPR proteins have been shown to have properties 
favourable for protein engineering, with applications in biomaterial design and biotherapeutics 
development, among others:  
• As a result of the consensus residues, they are extraordinarily stable (much more stable 
than natural TPR proteins) and their stability increases with increasing numbers of 
repeats.61,65 A minimum of two repeats is required for a stable and independently folded 
construct. 
• Due to their high stability, CTPR proteins of different lengths express with very high 
yields in Escherichia coli (typically tens of milligrams per litre of culture) and are 
monomeric, soluble and well folded proteins. 
• The CTPR sequence does not contain cysteine residues, and therefore the protein 
structure is not affected by the reducing and oxidizing environments within and outside 
the cell, respectively. 
• The modular nature of the architecture means that consensus repeats are self-
compatible and can be individually designed and put together in any order. 
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1.2.2 Functionalising CTPRs 
Initial attempts to functionalise the CTPR scaffold have been performed by mimicking how 
natural TPR proteins bind to their target. The binding mode most represented in the PDB 
structures and the most well studied corresponds to a short target peptide binding the concave 
groove formed by 2-3 repeats.60 Binding affinities are generally modest (low micromolar or 
weaker). In the first design study, the Hsp90-binding residues of the TPR protein Hop (Hsp 
Organizing protein) were grafted onto a CTPR scaffold comprising three repeating units to 
generate a functional Hsp90 inhibitor for therapeutic applications.39,66,67 The Cortajarena and 
Regan groups have also produced novel, functional CTPR proteins using rational design 
approaches and library screening.40,68,69 
The CTPR scaffold has also been exploited by the Cortajarena lab for the fabrication 
of bioinspired materials to be used in several biotechnological applications. Firstly, as observed 
in the crystal lattice of crystallised CTPR proteins,64,66 CTPR proteins have intrinsic self-
assembly properties, which allow them to polymerise in a controlled fashion and form 
nanostructured biomaterials through head-to-tail and side-to-side interactions, while 
maintaining their structural and functional properties. Further studies engineered a controlled 
head-to-tail assembly by introducing reactivities (cysteine residues or thioester groups) at the 
end of the CTPR module and produce longer polymers through the formation of more stable 
interactions.41,70 Secondly, this bottom-up approach led to the assembly of stimuli-responsive 
gels, ordered protein films and nanometer-scale fibers with specific ligand recognition function 
and tunability, given the binding specificity of the underlying TPR modules and the possibility 
of mixing and matching different repeats.70–72 Importantly, CTPR modules retained their 
helical structure, and therefore their binding capabilities, within all the different polymeric 
assemblies.70–72 These unique features allowed to further expand the applications of CTPR-
based systems and fabricate well-ordered bio-organic nanostructured materials with varying 
properties depending on the functional component conjugated to the scaffold. More recently, 
CTPR modules have therefore been conjugated to organic functional components or used as 
templates for stabilising metal nanoclusters.73–77 For example, photo- and electroactive films 
were generated by forming CTPR-porphyrin hybrid modules, where the required distance and 
orientation of porphyrin molecules for efficient π-π stacking interactions between the rings is 
guaranteed by the structural integrity of the CTPR scaffold.73 As an alternative, CTPR films 
have been engineered to immobilise the catalase enzyme, expanding the CTPR applications 
towards the production of biocatalytic materials.78 The ability to control the functionalisation 
of the protein, while maintaining its structure and binding properties, represents, therefore, a 
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key advantage for the production of CTPR-based hybrid materials that can find applications in 
drug delivery (for example through their stimuli-dependent encapsulation and release of 
molecules),71 synthetic biology and nanoelectronics, among others.79 
The Itzhaki group has recently shown that the CTPR scaffold can be functionalised in 
other ways. Rather than mimicking the natural binding mode of a binding interface comprising 
residues spanning the surface of two-three repeats, the Itzhaki lab has investigated the 
possibility of extending the 4-residue inter-repeat loop, which corresponds to the DPNN 
sequence in the CTPR sequence. The results showed that the CTPR scaffold can accommodate 
extensions in the inter-repeat loop of 25 amino acids or more without compromising the native 
structure.80,81 The Itzhaki group then demonstrated that it is possible to functionalise the 
scaffold by extending the loop with a linear, target-binding peptide.82 The grafted sequence can 
maintain its binding properties, and this conformational constraint within a structural loop 
represents an alternative to peptide stapling. The same approach has previously been used with 
other protein scaffolds.15,20,23 In this study, the grafted peptide sequence was derived from the 
protein Nrf2 (Nuclear factor erythroid-2-related factor 2) and is known to bind to the oncogenic 
protein Keap1 (Kelch-like ECH-associated protein 1).82 Following loop grafting, the Keap1-
binding affinity was further optimised by varying the loop length and sequence without the 
need of computational modelling. Therefore, the CTPR scaffold could theoretically 
accommodate unstructured binding sequences of various lengths that bind their respective 
targets in an extended conformation. As an alternative, CTPR modules can also be 
functionalised by helix grafting (an approach that has been used to functionalise scaffolds such 
as helix bundles – see Chin et al. and Sia et al. for the earliest examples of this approach83,84), 
as demonstrated in my PhD thesis (Chapter 3). Thus, by combining the possibility to graft 
binding sequence together with the modularity of the scaffold we obtain the capacity for 
possibly limitless functionalisation.82 
 
1.2.3 Functionalising CTPRs to bind Tankyrase (TNKS) 
As proof of concept, in my PhD thesis I explored the possibility of grafting a Tankyrase-
binding peptide (TBP) onto the inter-repeat loop to produce a set of monovalent and 
multivalent CTPR constructs, named TBP-CTPR. The TBP is known to bind and inhibit the 
human poly(ADP) ribose polymerase (PARP) proteins Tankyrase 1 (TNKS1) and Tankyrase 
2 (TNKS2; TNKS when referring to both) according to previous studies,46 including work 
performed in the Itzhaki lab,85 as described in the following sections. 
  General introduction 
 15 
1.3 The PARP family 
The human PARP proteins are a large family of 17 enzymes catalysing the poly(ADP) 
ribosylation (PARylation) of the protein substrate.86 For the PARylation reaction, a molecule 
of ß-nicotinamide adenine dinucleotide (NAD+) is used by the enzyme to add a single or 
multiple ADP-ribose molecules onto the protein substrate via an ester bond with the carboxyl 
group of acidic residues (aspartic acid and glutamic acid) or, more rarely, cysteine and lysine 
residues on the target proteins. The reaction results in ADP-ribosylated protein and the release 
of a molecule of nicotinamide for each NAD+ added (Figure 1.7).86 
 
 
Figure 1.7: PARylation reaction mediated by the PARP enzymes. A molecule of NAD+ is added to the 
L-aspartyl group of a substrate protein, resulting in a 4-O-ADP-D-ribosylated protein and the release 
of a molecule of nicotinamide. 
 
Similar to protein ubiquitination, multiple NAD+ molecules can be added to form a linear or a 
branched chain of poly-ADP-ribosyl units onto the same residue. This post-translational 
modification determines the fate of the modified substrate protein, in most instances causing a 
change in its subcellular localisation or its degradation via the proteasome.86 
 
1.3.1 Structure of Tankyrase (TNKS) 
The human genome encodes two Tankyrase isoforms: Tankyrase 1 (TNKS1, also named 
ARTD5 or PARP-5a) and Tankyrase 2 (TNKS2, also named ARTD6 or PARP-5b). Tankyrase 
1 (TRF1-interacting, ankyrin-related ADP- ribose polymerase) was identified in 1998 and 
named after its interaction with telomeric repeat binding factor-1 (TRF1).87 Tankyrase 2 was 
isolated in 2001 as a binding partner of the adaptor protein Grb14 (Growth factor Receptor 
Bound protein 14).88 TNKS share 83% overall sequence similarity88 and high structural 
homology. TNKS are unique in the PARP family in having a N-terminal ankyrin domain 
(ANK), segmented into five consecutive ankyrin-repeat cluster (ARC) subdomains.87 These 
are followed by a sterile alpha motif (SAM) and a catalytic PARP domain. TNKS1 has an 
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additional histidine, proline, serine-rich (HPS) domain at its N-terminal end. Each of the five 
ARC subdomains contains itself five ankyrin repeats. Four of the five ARCs (ARC I, ARC II, 
ARC IV and ARC V) mediate protein-protein interactions, allowing the formation of large 
macromolecular complexes between TNKS and substrates.46,89–91 Substrates recognise TNKS 
ARCs through a short (8 residue) binding peptide motif having the form 
RXXФ[D/E]GX[D/E], where X is any amino acid, Ф is a small hydrophobic residue, and 
arginine and glycine at position 1 and 6 respectively are essential for the binding, as 
demonstrated by alanine scanning mutagenesis.46 Despite the substantial degree of degeneracy 
tolerated in some positions of the TNKS binding motifs, all TNKS binding peptides engage the 
ARCs in an extended conformation, as shown in the crystal structure of TNKS2 ARC4 in 
complex with the 3BP2 peptide (Figure 1.8).46 Often, this motif is present in multiple copies 
within a TNKS substrate to allow simultaneous binding to multiple ARC subdomains in the 
same TNKS molecule and enhancing affinity by avidity. This effect has been observed in the 
TNKS substrates Axin1/2 and RNF146.89,92 
 
 
Figure 1.8: Structural representation of the TNKS2 ARC4 domain in complex with the TNKS-binding 
peptide of the 3BP2 substrate. (Left) Ribbon representation of TNKS2 ARC4:3BP2 complex, with the 
peptide’s side chains shown in stick representation. The five ANK repeats of TNKS2 ARC4 are 
coloured in shades of red, while the 3BP2 peptide is in purple with the side chains coloured by 
heteroatoms (oxygen in red, nitrogen in blue) (Right) TNKS2 ARC4:3BP2 complex, with TNKS2 
ARC4 in surface representation. (PDB 3TWR) Images were generated using the software UCSF 
Chimera. 
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The SAM domain is a five-helix bundle with acidic and basic residues on opposite surfaces, 
mediating SAM, and therefore TNKS, polymerisation by head-to-tail electrostatic 
interactions.93,94 Purified, wild-type SAM domains can, indeed, form filaments in-vitro.93 The 
PARP domain mediates substrate PARylation once the complex with the substrate has been 
formed. TNKS self-oligomerisation also results in self-PARylation.95 The function of the HPS 
domain of TNKS1 remains unknown. The structure of several domains of TNKS1 and TNKS2 
has been determined (Figure 1.9), and the high sequence homology between the two proteins 
results in almost identical tertiary structural elements. Each ARC subdomain comprises five of 
the 33-residue ANK tandem repeats, that fold into the characteristic two α-helices connected 
by a loop and pack against each other to form a superhelical structure. The five ARC 
subdomains are separated from each other by a semi-conserved, α-helical peptide motif 
(sequence LLEAAR/K), so that there is not one single, continuous superhelical ANK array.89 
All ARC subdomains of TNKS1, with the exception of ARC4, have been crystallised.89,96 
However, the high flexibility of the overall ARC1-5 domain, in particular in the linker region 
between ARC3 and ARC4, has prevented crystallisation of it in its entirety. The α-helical 
LLEAAR/K motifs between ARC1-ARC2 and ARC2-ARC3 are instead more rigid than that 
between ARC3-ARC4, and they induce the formation of the asymmetric “U” shape observed 
in the crystal structure of the ARC1-3 domains (Figure 1.9, TNKS1 ARC1-3).89 For TNKS2, 
only the ARC4 subdomain has been crystallised.46 All ARC subdomains, except ARC3, have 
been crystallised in the presence of binding peptides, which have an extended conformation 
and make contacts predominantly with the middle ANK repeat (Figure 1.8 and Figure 1.9., 
with bound peptides indicated). In both proteins, the SAM domain consists of five α-helices 
arranged in a globular conformation,93 and the PARP domain folds into α-helices and β-
strands.97,98 
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Figure 1.9: TNKS structures. Schematic representation of the structural domains of TNKS1 (top) and 
TNKS2 (bottom). The TBP binding sites within ARC1, ARC2, ARC4 and ARC5 are represented as 
semi-circles. The available crystallographic structures of the individual domains are provided in the 
corresponding colours. For TNKS1, the structures of the ARC1-3 (PDB: 5JHQ), ARC5 (PDB: 5GP7), 
SAM (PDB: 5JU5) and PARP (PDB: 2RF5) domains are provided. For TNKS2, the structures of the 
ARC4 (PDS: 3TWR), SAM (PDB: 5JRT) and PARP (PDB: 3KR7) domains are available. The peptides 
binding to the ARC subdomains are coloured in cyan and the one binding TNKS2 ARC4 is indicated 
with an arrow. Images were generated using the software UCSF Chimera. 
 
Work from Eisemann et al. also revealed that the ARC4-5 subdomains of TNKS1 are highly 
dynamic and can sample different orientations.89 This finding suggests that the ANK domain 
overall acts as a flexible binding platform that can dynamically assume different conformations 
depending on the relative positioning of the binding peptides in the substrate. This is 
particularly relevant for multivalent TNKS substrates that have more than one TNKS binding 
motifs.89 The same authors, therefore, proceeded to study the multivalent interaction between 
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TNKS1 ARC1-5 and the two binding motifs of Axin1 and assessed how different pairs of ARC 
subdomains can cooperatively bind bivalent Axin1 in a 1:1 complex. The results show that an 
increased binding affinity is achieved when both binding motifs engage with TNKS1 ARC1-
5, with a preference for interaction with the ARC2 and ARC5 subdomains. Upon binding, 
TNKS undergoes a compaction of its ANK domain, which brings different ARC units into 
close proximity (Figure 1.10). This compact conformation might also place the PARP domain 
of TNKS closer to Axin1, thereby facilitating Axin1 PARylation. Multivalency, together with 
sequence specificity and conformational docking mediated by different ARC combinations, 
might therefore dictate the substrate specificity of TNKS.89  
 
 
Figure 1.10: TNKS conformational changes upon binding to Axin1. (A) Schematic representation of 
TNKS1, with the flexible linker region highlighted between ARC3 and ARC4. (B) Schematic 
representation of Axin1, with the sequence of the two TNKS binding motif (TBM) provided. (C) 
Schematic representation of the multivalent binding between TNKS1 and Axin1. When Axin1 binds 
ARC2 and ARC5, a conformational compaction is induced in TNKS. Figure obtained from Guettler.99 
 
1.3.2 Localisation and functions of Tankyrase (TNKS) 
TNKS proteins have been implicated in the regulation of a large number of cellular processes 
and have been identified in various subcellular localisations due to the broad spectrum of 
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proteins with which they interact. Overexpression of TNKS has also been reported in several 
types of tumours, further validating TNKS involvement in cancer development through 
different pathways.100–103 A proteomic analysis of the TNKS interaction network has, indeed, 
identified over 100 high-confidence interacting proteins for TNKS (Figure 1.11).104 The same 
study also highlighted that 85% of the hits overlap between TNKS1 and TNKS2, suggesting 
that TNKS share redundant or related functions.104 TNKS1 and TNKS2 ARC subdomains bind 
to RXXФ[D/E]GX[D/E] motifs in their substrates, leading to substrate PARylation.46,90,91 For 
most TNKS substrates, including TNKS itself, PARylation causes the protein to be recognised 
by the PAR-dependent E3 ubiquitin ligase RNF146 (RING finger 146), resulting in protein 
ubiquitination and degradation via the proteasome.105 RNF146, however, can also bind TNKS1 
directly.92,106 TNKS1 was initially identified as being involved in telomere maintenance by 
inhibiting the DNA-binding telomere repeat factor 1 (TRF1) in the nucleus. PARylation of 
TRF1 inhibits the ability of TRF1 to bind the telomeric repeats, resulting in telomere 
elongation.87,91,107,108 More recently, the role of TNKS in the regulation of Wnt pathway 
activity has received particular attention (further described in Section 1.3.3). TNKS play an 
essential role in controlling ß-catenin levels (discussed further in the next section), thereby 
having an effect on many other cellular processes including cell proliferation, embryonic and 
cancer development.109 Both TNKS proteins are also involved in insulin-stimulated glucose 
uptake and homeostasis at the Golgi, through their interaction and co-localisation with IRAP 
(insulin-responsive aminopeptidase)-containing storage vesicles.110 They also regulate the 
tumor-suppressive Hippo signalling pathway through their binding to the angiomotin (AMOT) 
family of proteins,111,112 and regulate the LKB1/AMPK (AMP-activated protein kinase) 
signalling pathway through their interaction with Liver kinase B1 (LKB1).113 TNKS1 but not 
TNKS2 appears to be essential for mitotic spindle formation through the binding with NuMA 
(Nuclear Mitotic Apparatus protein 1)114,115 and for sister telomere resolution during mitosis.116 
Additionally, TNKS1 regulates DNA repair by PARylating the DNA-PK (DNA-dependent 
protein kinase), an important effector of the non-homologous end-joining mechanism of DNA 
repair.117 TNKS2, instead, regulates the Src signalling via binding to the protein 3BP2. 
Mutations in the TNKS-binding motif of 3BP2 abolish TNKS2-mediated degradation and 
underlie a disease called cherubism, characterised by the inflammation of the facial bone.118 
Other TNKS substrates include BLZF1105, CASC3105, CPAP at centrosomes119 and PTEN.120 
However, for many substrates, the details of the TNKS interaction and the biological effects 
remain unclear. 
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Figure 1.11: TNKS protein interaction network. High-confidence interacting proteins are grouped 
according to their cellular function and localisation. Figure obtained from Li et al.104 
 
1.3.3 TNKS in the Wnt signalling pathway 
The canonical Wnt signaling pathway is an evolutionarily conserved pathway that plays a 
major role in tissue homeostasis and regeneration, carcinogenesis and embryogenesis.121 
TNKS controls the Wnt pathway by coordinating two of its major players: Axin1/2 (axis 
inhibition protein 1/2) and, indirectly, ß-catenin. TNKS binds and PARylates Axin1/2, 
targeting it for proteasome-mediated destruction and maintaining it at very low levels.105,109 
Axin1/2 is the concentration-limiting component of the ß-catenin destruction complex (ßDC) 
and directly binds the other core components: APC (adenomatous polyposis coli), GSK3 
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(kinases glycogen synthase kinase 3) and CK1 (casein kinase 1), and ß-catenin. Under basal 
signalling conditions (Figure 1.12, left), the ßDC tightly regulates the intracellular levels of ß-
catenin by its phosphorylation, which leads to ß-catenin ubiquitination by the E3 ubiquitin 
ligase SCFβ-TrCP and to its proteasome-mediated destruction.122 Upon binding of a Wnt protein 
to the extracellular domains of the trans-membrane Frizzled receptor and the co-receptor 
LRP5/6, the Wnt signaling pathway is activated (Figure 1.12, right). Upon Wnt stimulation, 
the ßDC is sequestered to the plasma membrane, forming the so-called Wnt signalosome. 
Although the mechanism is still not fully clear, PARylation of Axin enhances its interaction 
with the Wnt co-receptor LDL receptor-related protein 6 (LRP6), causing the accumulation of 
Axin, and thereby the ßDC, to the plasma membrane.123,124 The ßDC inactivation at the plasma 
membrane results in cytoplasmic β-catenin accumulation, leading to its translocation into the 
nucleus and hence the transcription of Wnt target genes through the T-cell factor/lymphoid 
enhancer factor (TCF/LEF) family of transcription factors.125–127 The Wnt pathway is the 
principle driver of colon cancer, where it is dysregulated in around 90% of cases (most often 
by mutations in APC and less frequently in ß-catenin itself).128,129 
 
 
Figure 1.12: Function of TNKS in the Wnt signalling pathway. Schematic representation of the Wnt 
signalling pathway under basal state (left) and upon Wnt stimulation (right). Under basal state, TNKS 
PARylates Axin, leading to its proteasomal degradation and the regulation of the ß-catenin destruction 
complex (ßDC) levels. Upon activation of the Wnt signalling pathway, the ßDC is stabilised at the 
plasma membrane, resulting in ß-catenin accumulation and its translocation into the nucleus, where can 
induce the transcription of TCF/LEF-dependent genes. Figure obtained from Mariotti et al.130 
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1.3.4 Non-catalytic functions of TNKS 
More recently, non-catalytic functions of TNKS have been identified.93,94 The scaffolding 
functions of TNKS are mediated by the SAM and ARC domains. Studies have demonstrated 
that TNKS can promote Wnt signalling independently of its catalytic activity, as PARP-
inactive TNKS mutants are still able to activate the Wnt-dependent transcription of the reporter 
gene. On the other hand, deletions of the SAM or the ARC domains completely abrogated 
TNKS-dependent reporter activation.93,94 The same studies also showed that SAM 
polymerisation induces TNKS self-oligomerisation, and higher-order TNKS structures 
correlate with enhanced PARP activity. Moreover, SAM-mediated-oligomerisation alters 
TNKS intracellular localisation, with wild-type TNKS displaying a punctate, cytoplasmic 
distribution and SAM-mutant TNKS having a more diffused localisation.93,94 The loss of 
activity of the SAM-mutant TNKS in the Wnt signalling pathway also led to the discovery that 
SAM-mediated TNKS polymerisation promotes its interaction with Axin1 in the formation of 
ß-catenin degradasomes.93 TNKS scaffolding functions have also been observed in other 
processes such as pexophagy104 and apoptosis.131 Overall, the scaffolding functions of TNKS 
remain incompletely understood but are expected to extend beyond Wnt signalling, given the 
varied functions of TNKS-binding proteins. 
 
1.4 Inhibiting TNKS 
Due to their important biological roles, the TNKS proteins have become attractive therapeutic 
targets, and TNKS inhibitors could potentially have a broad clinical utility.132 They have been 
mostly developed and tested for diseases associated with Wnt-dependent dysfunctions, in 
particular colon cancer. Within the Wnt signaling pathway, TNKS inhibition prevents Axin 
PARylation, leading to Axin accumulation and the formation of the ßDC. Consequently, β-
catenin phosphorylation and degradation cause Wnt response gene transcription to be turned 
off. TNKS are potential anticancer targets additionally because of their involvement in 
telomere elongation.133 Within the LKB1-AMPK signalling pathway, instead, TNKS inhibition 
was shown to activate AMPK and induce anti-tumor as well as anti-diabetic effects in mice.113 
Several TNKS inhibitors have been developed to date, and all drug discovery efforts have been 
focused on inhibiting the catalytic PARylation activity.130,132 All small molecule TNKSi 
developed to date, indeed, are mimetics of NAD+ and they engage PARP’s adenosine-binding 
subsite, the nicotinamide subsite or both sites. The most well-characterised small molecule 
inhibitors are XAV939109, IWR-1 and IWR-2134, JW55135, JW74136, and WIKI4137, which were 
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all discovered in phenotypic screens designed to identify Wnt signalling antagonists. A second 
generation of TNKSi has led to the development of G007-LK.138 
 
1.4.1 Effects of TNKS inhibitors (TNKSi)  
Almost all colorectal tumours carry mutations in ß-catenin or the ßDC component APC, 
causing an activation of the Wnt signalling pathway.128,129 Therefore, several small molecule 
TNKSi have been tested as a means of selectively modulating dysregulated Wnt 
signalling.109,130,138,139 G007-LK and G244-LM were shown to attenuate Wnt signalling in 
colorectal cancer cell lines and inhibit tumor growth in APC-mutant xenograft models.138 
Similarly, treatment of colorectal cancer cell lines with XAV939 correlated with increased ß-
catenin degradation, resulting in reduced proliferation and colony formation rate.109 XAV939 
also seemed to attenuate lung fibrosis in mice.140 Effective inhibition of the Wnt signalling was 
also observed when treating colorectal cancer cells with IWR-1 and IWR-2134, JW55135, 
JW74136 and WIKI4.137  
However, as the PARP domain is shared with the other PARP family members, the 
specificity of these small molecule TNKSi for TNKS over other PARP proteins has been found 
to be quite variable, with none being completely selective for TNKS.130 Likewise, many other 
enzymes also use NAD+ as a co-substrate, and therefore targeting the NAD+ donor site of 
TNKS might cause additional off-target effects. This promiscuity, together with the inhibition 
of Wnt signalling, has been shown to cause cellular toxicity in mice, mostly in the 
intestine.138,141 This intestinal toxicity in particular, together with other adverse effects, has 
prevented most TNKSi from entering clinical trials. Additionally, these TNKSi prevent 
substrate PARylation as well as TNKS self-PARylation, causing intracellular accumulation of 
substrates and TNKS itself.109,138 Lastly, current TNKSi only inhibit the catalytic functions of 
TNKS but not the well-documented non-catalytic functions.93,94 
Currently, there is only one ongoing clinical trial testing a new TNKSi in metastatic 
breast cancer patients. 2X-121 is a small molecule inhibitor of PARP1/2 and TNKS1/2, 
administered orally on a daily basis, and developed by Oncology Venture A/S. This PARP 
inhibitor demonstrated clinical activity in a number of solid tumors tested during the prior 
Phase 1 study.142 Other ongoing clinical trials are testing the efficacy of olaparib (AZD2281, 
AstraZeneca), a PARP inhibitor with higher specificity for PARP1 and PARP2 than 
TNKS.142,143 Therefore, the development of a highly specific TNKS inhibitor remains to be 
achieved. As in nature, a high-affinity and high-specificity inhibitor might be obtained through 
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multivalency and avidity, neither of which are straightforward to realise with conventional 
small molecules or peptide technologies. Consequently, new approaches are needed, and 
biologics might represent the answer to this problem. 
 
1.5 Overall thesis motivation and aims 
Cancer remains a major cause of death worldwide, and novel more efficient therapies are 
therefore needed. Driven by this motivation and the absence of effective TNKS inhibitors, the 
aim of this project was to generate highly specific TNKS inhibitors by targeting the substrate-
binding ARC subdomains instead of the PARP domain. Given the fact that the ARC 
subdomains are only found in the TNKS proteins and that the two TNKS share a high degree 
of homology, this strategy would allow selective inhibition of both TNKS1 and TNKS2. 
Guettler et al. described a consensus TNKS-binding peptide (TBP) recognised by ARC 
subdomains 1, 2, 4 and 5.46 The same consensus TBP sequence was further optimised by 
previous members of the Itzhaki group to generate a proteolytically stable constrained (using 
chemical cross-linking) peptide that was shown to have inhibitory functions in the cell.85 In 
this project, the TBP sequence was constrained by grafting it onto the loop between consecutive 
repeats of a CTPR protein to generate a set of potential biotherapeutics as inhibitors of TNKS. 
As proof of concept, a series of single- and multivalent TNKS-binding proteins were generated 
by exploiting the modular architecture of the repeat-protein scaffold. These designed proteins 
were first characterised for their structures, stability and binding and then assayed for their 
TNKS inhibitory activity, and the applicability of this scaffold as a biotherapeutics platform 
was explored. Taking our cue from nature, multivalent TNKS-binding proteins were produced 
to increase binding affinity when they bind to TNKS, which itself is multivalent due to its 
multiple substrate-binding ARC subdomains. A prime example of TNKS multivalency is 
provided by its substrate Axin1, which binds TNKS through two separate TNKS-binding 
peptides.89,144 Another example is RNF146, which contains five TNKS-binding motifs and can 
bind multiple ARCs simultaneously.92 By binding to the ARC subdomains, these designed 
TBP-CTPR proteins might have the ability to block both catalytic and non-catalytic functions 
of TNKS, and they may therefore display enhanced activity compared to small molecule 
inhibitors targeting the catalytic PARP domain. The TBP-CTPR protein series was then 
expanded to generate bi-specific TNKS degraders, being potentially more effective and acting 
catalytically. Overall, the modular repetitive architecture of the CTPR proteins can be exploited 
by grafting onto them one or multiple binding functions and could be used as a platform for 
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intracellular target inhibition and also target degradation. Thus, this new approach paves the 











Materials and Methods 
 
2.1 Buffers and Reagents 
All chemicals, enzymes and buffers for DNA purification, gel extraction, clean up were 
purchased from Sigma-Aldrich, Qiagen or Thermo Scientific unless otherwise specified. All 
unmodified DNA oligo nucleotides were purchased from Integrated DNA Technologies (IDT).  
Listed below are recipes for general buffers and solutions. Specific buffers are described in the 
text were used. Milli-Q standard water was used to make all buffers and all molecular biology 
work. 
• Ampicillin (Amp) stock: 50 mg/mL in H2O, sterile filtered. Used at 1:1000 dilution 
• Dithiothreitol (DTT): 1 M in H2O, sterile filtered. 
• Isopropylthiogalactoside (IPTG): 1 M in H2O, sterile filtered. 
• 50X TAE: 242 g Trizma base, 57.1 mL glacial acetic acid, 18.6 g EDTA to a final 
volume of 1 L with H2O. Stored at room temperature and used at 1X for DNA agarose 
gel electrophoresis and running buffer. 
• Tris(2-carboxyethyl)phosphine (TCEP): 0.5 M in H2O, sterile filtered. 
• 10X TGS: 30 g Trizma base, 144 g glycine, 10 g SDS to a final volume of 1 L with 
H2O. Stored at room temperature and used at 1X for protein gel electrophoresis and 
running buffer. 
All DNA gels were cast at a percentage of agarose (Appleton Woods) ranging between 0.8% - 
1% and stained with SYBR® Safe DNA Gel Stain used at a 1:10000 dilution. All protein gels 
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were casted at a varying percentage of Acrylamide/Bis-acrylamide, 30% solution between 8% 
- 15% and stained with Coomassie Brilliant Blue G250 (Sigma-Aldrich). 
 
2.2 Escherichia coli strains  
Two Escherichia coli (E. coli) strains were used in this work: 
DH5a: K-12 strain derivative optimised for molecular cloning applications. Chemically 
competent cells were propagated in-house for routine cloning needs; cells for high efficiency 
transformations were purchased from New England Biolabs (NEB). 
C41 (DE3) pLysS: derivative of the BL21 strain used for high-level expression of non-toxic 
heterologous genes under the T7 promoter. The strain indeed contains the λDE3 lysogen that 
carries the gene for T7 RNA Polymerase under the control of the lacUV5 promoter. The strain 
was purchased from Lucigen and propagated in-house following the protocol below. pLysS is 
a chloramphenicol-resistant plasmid that expresses T7 lysozyme in small amount.  
 
Chemically competent E. coli cells were prepared from a glycerol stock of the above-
mentioned strains. They were inoculated into 5 mL of LB medium, containing 34 µg/mL of 
chloramphenicol when the C41(DE3) pLysS was propagated, and incubated at 37ºC in a 
shaking incubator (200 rpm) overnight. The overnight culture was diluted 1:100 in fresh LB 
medium (containing antibiotic if appropriate) and grown while shaking at 37ºC until OD600 
reached 0.25-0.30. The cell suspension was transferred into 50 mL tubes and cooled on ice for 
10 minutes to stop growth before centrifugation at 4000 xg for 5 minutes at 4ºC. The pellet in 
each tube was resuspended thoroughly in 10 mL cold Transformation Buffer I (30 mM KOAc 
pH 5.8, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2, 3 mM Hexamine Cobalt Cl, 15% (v/v) 
glycerol), combined together and incubated on ice for 5 minutes before renewed centrifugation. 
The cell pellet was resuspended in 5 mL Transformation Buffer II (10 mM MOPS pH 6.5, 10 
mM RbCl, 75 mM CaCl2, 15% (v/v) glycerol) and incubated on ice for 15 minutes. The 
bacterial suspension was dispensed in 50 µL aliquots into pre-chilled microfuge tubes and 
stored at -80ºC. 
 
All chemically competent E. coli cells were transformed with a few ng of DNA (up to 100 ng) 
by standard heat shock method. The transformed cells were plated onto LB agar plates 
containing the appropriate antibiotic and incubated at 37ºC overnight. 
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2.3 Molecular Biology 
2.3.1 Plasmids 
Two types of E. coli expression vectors were used depending on the desired purification 
method: 
pRSet B vector: a commercially available vector (Thermo Fisher) allowing N-terminal Poly-
(6)-His tagging of recombinant proteins. It is used for high protein expression under the T7 
promoter. It has been altered in-house to replace the XpressTM Epitope with a Thrombin-
cleavage site between the His-tag and the multiple cloning site (MCS).  
pGST vector: an in-house variant of the pRSet B, in which the His-tag has been exchanged to 
a glutathione S-transferase (GST) tag. 
 
For mammalian transfection and expression, two vectors were used: 
pcDNA3.1(-) vector: an in-house variant of the commercially available pcDNA3.1(-) vector 
(Thermo Fisher), which enables C-terminal HA tagging of the gene of interest. It induces high 
protein expression under the CMV promoter.  
HiBiT-pcDNA3.1(-) vector: an in-house variant of the above pcDNA3.1(-) vector, which 
allows to add a HiBiT tag (developed by Promega) at the N-terminal end of the gene of interest, 
as well as a HA tag at the C-terminus. The HiBiT tag is followed by a 6-amino acid linker 
(GSSGGS) to ensure accessibility of the tag, as suggested on the Promega Nano-Glo HiBiT 
Lytic Detection System Technical Manual.145 
 
Inserts encoding for the genes of interest were amplified by polymerase chain reaction (PCR) 
or purchased as double-stranded gBlocksâ Gene Fragments (Integrated DNA Technologies) 
were codon optimised for enhanced expression in E. coli. They were cloned into bacterial 
expression pRSet B or pGST vectors between BamHI and HindIII restriction sites, following 
procedures detailed in Section 2.3.2 and Section 2.3.3. Most constructs were then subcloned 
into the mammalian pcDNA3.1(-) and/or HiBiT-pcDNA3.1(-) vectors between BamHI and 
EcoRI restriction sites, as explained in Section 2.3.5. 
The gene encoding the full-length (FL) human TNKS2 was kindly provided by our 
collaborator Dr. Marc de la Roche in a pLP dMyc SD plasmid. The DNA sequence encoding 
the FL TNKS2 protein or the ARC domains was amplified and subcloned into several 
expression vectors, depending on the need.  
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DNA plasmids for bacterial expression generated in this work are listed in Table 2.1. The vector 
maps are provided in Appendix A. The protein sequence of the generated CTPR constructs is 
provided in Appendix B. 
 
Name Vector Promoter Protein tag Notes 
1TBP-CTPR2 pRSet B T7 N-terminal His6 Linear 
2TBP-CTPR4 pRSet B T7 N-terminal His6 Linear 
3TBP-CTPR6 pRSet B T7 N-terminal His6 Linear 
4TBP-CTPR8 pRSet B T7 N-terminal His6 Linear 
1TBP-CTPR2-foldon pRSet B T7 N-terminal His6 Trimeric 
2TBP-CTPR4-foldon pRSet B T7 N-terminal His6 Trimeric 
3TBP-CTPR6-foldon pRSet B T7 N-terminal His6 Trimeric 
4TBP-CTPR8-foldon pRSet B T7 N-terminal His6 Trimeric 
CTPR6 (*) pRSet B T7 N-terminal His6 Linear, Control 
CTPR6-foldon pRSet B T7 N-terminal His6 Trimeric, Control 
TNKS2 ARC1-3 pRSet B T7 N-terminal His6 Residues 2-485 
TNKS2 ARC1-5 pRSet B T7 N-terminal His6 Residues 2-797 
1TBP-CTPR4-Solv H pGST T7 N-terminal GST Linear, solvating helix 
TNKS2 ARC4 (*) pGST T7 N-terminal GST Residues 488-649 
TNKS2 ARC1-5 pGST T7 N-terminal GST Residues 2-797 
Table 2.1: List of DNA plasmids for bacterial expression.  
(*) This plasmid was already available in the lab.85,146 
 
DNA plasmids for mammalian expression generated in this work are listed in Table 2.2 (single-
function constructs) and Table 2.3 (hetero-bifunctional constructs). The vector maps are 
provided in Appendix A. The protein sequence of the generated CTPR constructs is provided 
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Name Vector Protein tag Notes 
1TBP-CTPR2 pcDNA3.1(-) C-terminal HA Linear 
2TBP-CTPR4 pcDNA3.1(-) C-terminal HA Linear 
3TBP-CTPR6 pcDNA3.1(-) C-terminal HA Linear 
4TBP-CTPR8 pcDNA3.1(-) C-terminal HA Linear 
1TBP-CTPR2-foldon pcDNA3.1(-) C-terminal HA Trimeric 
2TBP-CTPR4-foldon pcDNA3.1(-) C-terminal HA Trimeric 
3TBP-CTPR6-foldon pcDNA3.1(-) C-terminal HA Trimeric 
4TBP-CTPR8-foldon pcDNA3.1(-) C-terminal HA Trimeric 
CTPR2 pcDNA3.1(-) C-terminal HA Linear, Control 
CTPR6 pcDNA3.1(-) C-terminal HA Linear, Control 
3RL-CTPR6 pcDNA3.1(-) C-terminal HA Linear, Control 
CTPR6-foldon pcDNA3.1(-) C-terminal HA Trimeric, Control 
1TBP-CTPR2-mCherry pcDNA3.1(-) C-terminal mCherry Linear 
3TBP-CTPR6-mCherry pcDNA3.1(-) C-terminal mCherry Linear 
3TBP-CTPR6-foldon-mCherry pcDNA3.1(-) C-terminal mCherry Trimeric 
CTPR6-mCherry pcDNA3.1(-) C-terminal mCherry Linear, Control 
1TBP-CTPR2 HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Linear 
2TBP-CTPR4 HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Linear 
3TBP-CTPR6 HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Linear 
4TBP-CTPR8 HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Linear 
1TBP-CTPR2-foldon HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Trimeric 
2TBP-CTPR4-foldon HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Trimeric 
3TBP-CTPR6-foldon HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Trimeric 
4TBP-CTPR8-foldon HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Trimeric 
CTPR2 HiBiT-pcDNA3.1(-) N-terminal HiBiT Linear, Control 
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C-terminal HA 
CTPR6 HiBiT-pcDNA3.1(-) N-terminal HiBiT C-
terminal HA 
Linear, Control 
3RL-CTPR6 HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Linear, Control 
CTPR6-foldon HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
Trimeric, Control 
TNKS2 ARC1-eGFP HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal eGFP, HA 
 
TNKS2 ARC1-5-eGFP HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal eGFP, HA 
 
TNKS2 FL HiBiT-pcDNA3.1(-) N-terminal HiBiT 
C-terminal HA 
 
TNKS2 FL (no HA) HiBiT-pcDNA3.1(-) N-terminal HiBiT No HA-tag 
Table 2.2: List of DNA plasmids for mammalian expression, encoding single-function and control 
CTPR constructs, or TNKS2 constructs of various length. 
 
Name Vector Protein tag Notes 
2TBP-CTPR4-ABBA pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-DBOX pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-KEN pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-Nrf2 pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-p27 pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-p53 pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-PHYL pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-SPOP pcDNA3.1(-) C-terminal HA Hetero-bifunctional 
2TBP-CTPR4-RTPR2 pcDNA3.1(-) C-terminal HA Control 
CTPR2-ABBA pcDNA3.1(-) C-terminal HA Control 
CTPR2-DBOX pcDNA3.1(-) C-terminal HA Control 
CTPR2-KEN pcDNA3.1(-) C-terminal HA Control 
CTPR2-Nrf2 pcDNA3.1(-) C-terminal HA Control 
CTPR2-p27 pcDNA3.1(-) C-terminal HA Control 
CTPR2-p53 pcDNA3.1(-) C-terminal HA Control 
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CTPR2-PHYL pcDNA3.1(-) C-terminal HA Control 
CTPR2-SPOP pcDNA3.1(-) C-terminal HA Control 
Table 2.3: List of DNA plasmids for mammalian expression, encoding hetero-bifunctional and control 
CTPR constructs. 
 
2.3.2 Molecular cloning into pRSet B and pGST vectors 
The standard molecular cloning approach relying on conventional restriction enzymes 
digestion and ligation was adopted for construct insertion into the pRSet B or pGST vectors, 
as illustrated in Figure 2.1. Both vectors present a unique BamHI restriction site immediately 
after the Thrombin site, and a unique HindIII site upstream the stop codon. The insert was 
generated by amplifying the region of interest (10 ng) by mixing it with 5X Q5 Reaction Buffer 
(10 µL), forward and reverse primers introducing the restriction sites (2.5 µL, 10 µM), dNTPs 
(1 µL, 10 mM), Q5 High-Fidelity DNA Polymerase (0.5 µL, NEB) and Milli-Q water to reach 
a final volume of 50 µL. When TNKS2 was amplified, the 5X Q5 High GC Enhancer buffer 
was also included in the reaction mixture, due to the high GC content in the TNKS2 gene. PCR 
was performed on an Eppendorf Mastercycler Nexus PCR Cycler using protocols having 
annealing temperature and extension duration optimised for each reaction. Melting temperature 
(Tm) for each set of primers was calculated using the NEB Tm calculator tool).147 When the 
gene of interest was not available, a gBlockâ Gene Fragment was designed with the appropriate 
restriction sites at each terminus, preceded and followed by at least 5 bp to enhance digestion 
activity of restriction enzymes. 
Cloning was performed by digesting the insert (150 ng of gBlockâ or 1-10 µg of 
purified PCR product) with FastDigest BamHI and HindIII (1 µL each, Thermo Scientific) 
according to the manufacturer’s protocol. When a PCR product was used, DpnI was also added 
to the mixture to digest the methylated template DNA. Reaction was stopped by heat 
inactivation at 85ºC for 20 minutes or by agarose gel electrophoresis followed by gel extraction 
and purification according to the QIAquick gel extraction protocol. Similarly, the vector (~1 
µg) was digested with the same set of restriction enzymes, with the addition of FastAP 
Thermosensitive Alkaline Phosphatase (1 µL, Thermo Scientific) and purified by gel 
extraction. All DNA was eluted with Milli-Q water and stored at -20ºC unless used 
immediately. 
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Ligation was performed by mixing the digested vector and digested insert in a 1:3 
vector:insert molar ratio (total 3 µL) and 1 µL AnzaTM T4 DNA Ligase Master Mix (Thermo 
Scientific) and incubating the reaction for 15 minutes at room temperature. The whole mixture 
was transformed into NEB® 5-alpha Competent E. coli (High Efficiency) (NEB) as specified 
in Section 2.2. Usually, a couple of individual colonies were propagated in suspension culture 
for plasmid standard extraction. Correct incorporation of the insert was verified by renewed 
digestion using the same enzymes and subsequent agarose gel electrophoresis, before sequence 
confirmation by Sanger sequencing (Mix2Seq Kit, Eurofins Genomics) using the T7 forward 
and T7 reverse primers separately. Plasmid concentration was measured using the NanoDrop 
2000 (Thermo Scientific). 
 
2.3.3 Construction of tandem-repeat gene arrays from single repeat unit 
Tandem repeat arrays of higher order, named nTBP-CTPR2n with n between one and four, were 
generated by concatemerization of single units using a previously described method,148 already 
adopted for building long CTPR tandem repeat constructs.149 This cloning strategy is necessary 
as a gBlock® with highly repetitive DNA sequence cannot be purchased. The gBlock® encoding 
the 1TBP-CTPR2 sequence was designed having a BamHI site and a HindIII site at either end 
to allow directional cloning into pRSet B. It also included a BglII site at the 3’ end preceding 
the two stop codons and the HindIII site. Following digestion and ligation into the pRSet B 
vector using the BamHI and HindIII restriction enzymes, the 1TBP-CTPR2 gene cassette was 
PCR amplified using the T7 forward and T7 reverse primers (Figure 2.1A). To generate the 
larger nTBP-CTPR2n gene constructs, the 1TBP-CTPR2 PCR product (insert) was digested 
with BamHI and HindIII and ligated into the n-1TBP-CTPR2n-2 expression vector previously 
digested with BglII and HindIII. This is possible because, although BamHI and BglII recognise 
different 6 bp sequences, they produce complementary sticky ends (Figure 2.1B). The ligation 
product was transformed into NEB® 5-alpha Competent E. coli, DNA extracted and sequenced 
as detailed in Section 2.3.2. Subsequent plasmid digestion and ligation of 1TBP-CTPR2 units 
yielded progressively larger concatemers until the gene encoding for 4TBP-CTPR8 was 
generated. With this method, nTBP-CTPR2n constructs of identical repeats at both the DNA 
and protein level were generated. 
Using the same strategy, the trimeric repeat protein array was generated: the insert 
encoding the foldon domain was digested with BamHI and HindIII and ligated into the nTBP-
CTPR2n expression vectors previously digested with BglII and HindIII. 




Figure 2.1: Construct design for conventional molecular biology cloning strategies. (A) Schematic 
representation of the gBlock® construct encoding for 1TBP-CTPR2 (single repeat unit). The construct 
contains three restriction sites and two stop codons (*). Once inserted into the pRSet B vector, the T7 
forward and reverse primers (shown as arrows) can be used for construct PCR amplification and 
sequencing. (B) The cloning strategy used to generate higher order nTBP-CTPR2n constructs by 
concatemerisation is illustrated. The insert digested with the BamHI and HindIII restriction enzymes is 
introduced into the digested vector between the BglII and HindIII restriction sites. 
 
2.3.4 Round-the-Horn site-directed mutagenesis and primer design 
An alternative method for directing specific changes at the DNA level such as point mutations, 
small insertions or deletions is by Round-the-Horn site-directed mutagenesis PCR.150 The 
whole plasmid is used as template and is amplified using “back-to-back” non-overlapping 
primers carrying the mutation to be introduced. Depending on the mutation to be inserted, the 
primers are designed to contain an internal mismatch, or nucleotides in excess or in defect, 
therefore generating a point mutation, a small insertion or a deletion after the first amplification 
cycle, respectively (Figure 2.2). This method has the advantage of introducing mutations at any 
desired site, without relying on restriction sites present nearby. For Round-the-Horn PCR, 100 
µM primers were phosphorylated using T4 Polynucleotide Kinase (Thermo Scientific) in the 
presence of 1 mM ATP according to the manufacturer’s protocol. The enzyme was heat 
inactivated at 75°C for 10 minutes. PCR was performed as mentioned in Section 2.3.2, allowing 
a long extension time in each cycle to amplify the entire plasmid (~5 minutes). PCR products 
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were gel purified, ligated using 1 µL AnzaTM T4 DNA Ligase Master Mix (Thermo Scientific) 
and transformed into NEB® 5-alpha Competent E. coli (High Efficiency) (NEB). As before, 




Figure 2.2: Round-the-Horn site-directed mutagenesis. Primer design to introduce a point mutation (a), 
an insertion (b) or a deletion (c) is illustrated. 
 
2.3.5 Molecular cloning into pcDNA3.1(-) and HiBiT-pcDNA3.1(-) 
The backbone of the pcDNA3.1(-) vector (Thermo Scientific) contains a BglII restriction site. 
Before subcloning each CTPR construct into this vector, the BglII restriction site was mutated 
by Round-the-Horn site-directed mutagenesis as described in Section 2.3.4 in order to avoid 
having more than one BglII site in the final plasmid.  
The mutated vector was then used as template to introduce the DNA sequence encoding 
the N-terminal HiBiT tag (licensed from Promega) in frame with the start codon by Round-
the-horn PCR, therefore generating the HiBiT-pcDNA3.1(-) vector. 
For cloning into the pcDNA3.1(-) and HiBiT-pcDNA3.1(-) vectors, the unique 
restriction sites BamHI and EcoRI were used. The inserts of interest were amplified by PCR, 
using a forward primer carrying the BamHI site and a reverse primer introducing the EcoRI 
site. Both the insert and the vector were digested with BamHI and EcoRI and the same protocol 
detailed in Section 2.3.2 was followed. Due to the absence of the appropriate restriction sites, 
eGFP-tagged TNKS2 constructs were instead generated using the NEBuilder HiFi DNA 
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Assembly Cloning Kit (New England Biolabs), according to the manufacturer’s instructions. 
Correct clones were confirmed by DNA sequencing (Eurofins Genomics). 
 
2.4 Protein expression and purification 
Recombinant proteins were expressed with a His6- or a GST-tag to allow purification by 
affinity chromatography. Few microliters of the pRSet B or pGST expression vector were 
transformed into chemically competent E. coli C41 (DE3) pLysS cells by heat shock and plated 
on LB-Amp plates. Several colonies were grown at 37ºC in 2xYT medium (Formedium) 
containing ampicillin (50 µg/mL) and shaking at 200 rpm until the OD600 was ~0.6. For all 
protein constructs, expression was induced with isopropyl β-D-1-thiogalactopyranoside 
(IPTG) at a final concentration of 0.5 mM, for 16-20 h at 20ºC. Cells were harvested by 
centrifugation at 8000 xg (4ºC, 10 minutes). Purification protocols of His6- or GST-tagged 
proteins are described below. The buffers used at each purification step are listed in Table 2.4. 
 
2.4.1 Protein solubilisation test 
A small aliquot of the above-mentioned culture (1 mL) was pelleted to perform a protein 
solubilisation test before proceeding with the purification of the entire culture. The bacterial 
pellet was resuspended in 300 µL of 1X BugBuster® Master Mix (Millipore) to induce cell 
wall perforation without denaturing soluble proteins. The resuspension was incubated with 
rotation at room temperature for 30 minutes. The lysate was spun at 12000 xg for 10 minutes 
to pellet the insoluble fraction and cell debris. The supernatant corresponds to soluble fraction. 
The insoluble pellet was washed twice in 0.1X BugBuster® Master Mix and centrifuged again. 
The total lysate, soluble and insoluble fractions were analysed by SDS-PAGE to evaluate the 
solubility of the protein. 
 
2.4.2 Purification of His6-tagged constructs (pRSet B plasmid) 
The bacterial pellet was resuspended in cold Wash Buffer including EDTA-free SIGMAFAST 
protease inhibitors (Sigma-Aldrich), Lysozyme (Sigma-Aldrich) and DNase I (Sigma-
Aldrich). Cells were lysed by high-pressure homogenization using an Emulsiflex C5 
homogenizer (Avestin) at pressures between 10000 and 15000 psi. Cell debris and other 
insoluble fractions were removed by centrifugation at 40000 xg for 40 minutes at 4ºC. All His6-
tagged constructs were purified by immobilised metal ion affinity chromatography (IMAC) on 
a 5 mL HisTrap Excel column (Cytiva) connected to an ÄKTA Pure protein purification system 
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(Cytiva). The column was washed with 20 CV of Wash Buffer mixed with 4% Elution Buffer 
(20 mM imidazole final concentration) to prevent nonspecific interaction of lysate proteins to 
the beads. Proteins were eluted with 5 CV Elution Buffer and the eluted fractions were analysed 
by SDS-PAGE and pooled accordingly. All His6-tagged nTBP-CTPR2n and CTPRn proteins 
were subsequently separated by size-exclusion chromatography (SEC) in isocratic conditions 
using a HiLoad 16/600 Superdex 75 pg column (Cytiva) pre-equilibrated in Elution Buffer. 
Proteins to be analysed by size-exclusion chromatography coupled with multi-angle light 
scattering (SEC-MALS) were instead purified by SEC using a Superdex 200 10/300 GL 
column (Cytiva) pre-equilibrated in Elution Buffer. 
 Occasionally, protein purification of small-scale expression cultures (10-50 mL) was 
performed in batch using Amintra Ni-NTA resin (Expedeon) using the same wash and elution 
buffers. The same method applies, with the only difference that the cell pellet is solubilised 
and lysed in few mL of 1X BugBuster® Master Mix (Millipore) and the supernatant is applied 
on 1 mL of resin slurry. Beads are pelleted by centrifuging at 1000 xg for 1 minute, to allow 
washing and elution steps. 
His6-tagged TNKS2 proteins were also purified by IMAC on the ÄKTA Pure protein 
purification system (Cytiva) using the same method. Following affinity chromatography, His6-
tagged TNKS2 ARC1-3 and His6-tagged TNKS2 ARC1-5 were further purified by SEC using 
a HiLoad 16/600 Superdex 75 pg column and HiLoad 16/600 Superdex 200 pg column 
(Cytiva), respectively, pre-equilibrated in Elution Buffer. The composition of the Wash Buffer 
and Elution Buffer used for each purification step is listed in Table 2.4. 
 
2.4.3 Expression and purification of GST-tagged variants (pGST plasmid) 
E. coli C41 (DE3) pLysS cells expressing GST-tagged recombinant proteins were harvested 
and lysed as previously described in Section 2.4 and 2.4.2. The supernatant obtained from 1 L 
culture was incubated for 2 h at 4°C on a rotating mixer with 5 mL slurry of Glutathione 
Sepharose 4B resin (Cytiva), pre-equilibrated in Wash Buffer. The resin was then washed three 
times with 50 mL of Wash Buffer, followed by overnight on-matrix cleavage of the fusion 
protein using 400 units of bovine thrombin (Sigma Aldrich) per litre of culture, at room 
temperature on a rotating mixer. Cleaved protein was collected by washing the resin with 5 mL 
Elution Buffer five times. The fractions were combined and concentrated to a final volume of 
5 mL. All variants were subsequently separated by SEC in isocratic conditions using a HiLoad 
16/600 Superdex 75 pg column (Cytiva) pre-equilibrated in the corresponding Elution Buffer. 
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The composition of the Wash Buffer and Elution Buffer used for each purification step is listed 
in Table 2.4. 
 
Protein Method Wash Buffer Elution Buffer 
His6-nTBP-CTPR2n HisTrap Excel/ 
Ni-NTA resin 
50 mM Tris-HCl pH 8.0, 
150 mM NaCl  
50 mM Tris-HCl pH 8.0, 
150 mM NaCl, 500mM 
imidazole  
 Size-exclusion  50 mM Tris-HCl pH 8.0, 
150 mM NaCl  
His6-TNKS2 ARC1-3 HisTrap Excel 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 2 mM DTT 
50 mM Tris-HCl pH 8.0, 
300 mM NaCl, 500 mM 
imidazole, 2 mM DTT 
 Size-exclusion  50 mM Tris-HCl, 150 mM NaCl, pH 8.0, 2 mM DTT 
His6-TNKS2 ARC1-5 HisTrap Excel 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 2 mM DTT 
50 mM Tris-HCl pH 8.0, 
300 mM NaCl, 500 mM 
imidazole, 2 mM DTT 
 Size-exclusion  50 mM Tris-HCl, 150 mM 
NaCl, pH 8.0, 2 mM DTT 
GST-1TBP-CTPR4-
SolvH 
Glutathione 50 mM Tris·HCl pH 8.0, 
300 mM NaCl 
50 mM Tris·HCl pH 8.0, 
300 mM NaCl 
 Size-exclusion  50 mM Tris·HCl pH 8.0, 
150 mM NaCl 
GST-TNKS2 ARC4 Glutathione 50 mM Tris·HCl pH 8.0, 
300 mM NaCl, 2 mM DTT 
50 mM Tris·HCl pH 8.0, 
300 mM NaCl, 2 mM DTT 
 Size-exclusion  50 mM Tris·HCl pH 8.0, 
150 mM NaCl, 2 mM DTT 
Table 2.4: Buffer system used for the purification of the listed proteins. 
 
2.4.4 Protein concentration, purity and molecular weight determination 
Following protein purification, proteins were concentrated using a Vivaspin® centrifugal 
concentrator of the appropriate size and membrane molecular weight cut-off value. Proteins 
were flash-frozen and stored at -80ºC until further use. The final purity and identity of all the 
proteins were determined by SDS-PAGE and mass spectrometry using matrix-assisted laser 
desorption/ionisation (MALDI, Department of Biochemistry, Cambridge, UK) or liquid 
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chromatography-mass spectrometry electrospray ionisation (LCMS ESI, Department of 
Chemistry, Cambridge, UK). MS spectra are provided in Appendix C. Protein absorbance at 
280 nm was measured using the NanoDrop 2000 (Thermo Scientific). Protein concentration 
was calculated according to the Beer-Lambert law, using the theoretical extinction coefficient 
obtained from the primary amino acid sequence (ExPaSy ProtParam tool)151 of each protein 
(Table 2.5).  
 
Protein Molecular weight (Da) ε (M-1 cm-1) 
His6-1TBP-CTPR2 11308.23 28880 
His6-2TBP-CTPR4 20677.32 57760 
His6-3TBP-CTPR6 30046,40 86640 
His6-4TBP-CTPR8 39415,48 115520 
His6-1TBP-CTPR2-foldon(*) 49368.17 112080 
His6-2TBP-CTPR4-foldon(*) 77475.42 198720 
His6-3TBP-CTPR6-foldon(*) 105582.67 285360 
His6-4TBP-CTPR8-foldon(*) 133689.92 372000 
His6-CTPR6 26193.75 86640 
His6-CTPR6-foldon(*) 94024.71 285360 
His6-TNKS2 ARC1-3 54853.46 27390 
His6-TNKS2 ARC1-5 88086.00 51800 
GST-1TBP-CTPR4-Solv H 45402.22 / 19122.60 100620 / 57760 
GST-TNKS2 ARC4 43988.59 / 17708.97 55810 / 12950  
Table 2.5: Molecular weights and theoretical extinction coefficient of the listed proteins. Extinction 
coefficient calculated assuming all Cysteine residues being reduced. For GST-tagged constructs, values 
of molecular weight and ε for each construct before and after Thrombin cleavage are provided. (*) 
Values of molecular weight and ε for the trimeric construct are indicated. 
 
2.5 SEC-MALS 
Purified protein samples (100 μL, protein concentration >1.7 mg/mL) were subjected to SEC-
MALS, performed on a SEC Superdex 200 Increase 10/300 GL column (Cytiva) 
preequilibrated in the corresponding Elution Buffer, in line with a multiangle light scattering 
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module (DAWN-8+; Wyatt Technologies) and a differential refractometer (Optilab T-rEX; 
Wyatt Technologies). The light scattering and protein concentration at each point across the 
peaks in the chromatograph were used to determine the absolute molecular mass from the 
intercept of the Debye plot using Zimm’s model as implemented in the ASTRA v7.3.0.11 
software (Wyatt Technologies). To determine interdetector delay volumes, band-broadening 
constants and detector intensity normalisation constants for the instrument, Bovine Serum 
Albumin (BSA, Thermo Fisher Scientific) was used as a standard prior-to sample 
measurement. Data were plotted with the program PRISM (GraphPad Software Inc.). SEC-
MALS was performed at the MRC-Laboratory of Molecular Biology (Cambridge, UK) by Dr. 
Stephen McLaughlin. 
 
2.6 Far-UV Circular Dichroism (CD) spectroscopy and thermal denaturation 
All nTBP-CTPR2n protein samples to be analysed by CD were buffer exchanged into 10 mM 
sodium phosphate buffer pH 7.4, 150 mM NaCl, using a PD-10 Desalting column (Cytiva) and 
diluted to a final concentration of 20 µM. CD measurements were performed on a Chirascan 
CD spectrophotometer (Applied Photophysics) at 20°C in a 1 mm pathlength Precision Cell 
(110-QS, Hellma Analytics). Measurements were acquired at wavelengths between 200 nm 
and 280 nm using a 1 nm bandwidth at a scan speed of 120 nm per minute. Readings were 




𝐶 ∙ 𝑙 Eq. 2.1 
where θ is the ellipticity in millidegrees (mdeg), C the sample concentration in molarity (M = 
mol/L = mol/1000 cm3), and l the pathlength in centimeters. The value of [θ] has to be divided 




𝑐𝑚 ∙ 𝑀 =
𝑚𝑑𝑒𝑔 ∙ 1000 ∙ 𝑐𝑚!





#$ ∙ 	𝑑𝑒𝑔 ∙ 𝑐𝑚" ∙ 𝑑𝑚𝑜𝑙#$ 
 
2.7 Thermal denaturation monitored by CD 
The same protein samples used for far-UV CD (Section 2.6) were also analysed by thermal 
denaturation monitored by CD, using the same instrument and cuvette as above. Temperature 
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ramp was induced by increasing the temperature of the protein samples from 20ºC to 92ºC in 
1ºC steps, and the ellipticity at 222 nm was monitored as a function of temperature. The α-
helical content of the sample was followed by plotting the molar ellipticity against temperature. 
Readings were repeated five times and averaged. Since the heat capacity of the CTPR proteins 
under measurement is unknown, the molar ellipticity with respect to temperature was fitted to 
a sigmoidal Boltzmann equation including a sloping baseline term to extract the apparent 
melting temperature, Tm: 
 𝑌 = 𝜃! +
𝜃" − 𝜃!
1 + exp(𝑇# − 𝑇𝑛 )
 Eq. 2.2 
where θN and θU are the ellipticity of the native and denatured states, respectively, and n is the 
slope of the transition. In a sloping sigmoidal transition, θN and θU are corrected as 
 𝜃! = 𝛼N + 𝛽NT 
Eq. 2.3 
 𝜃" = 𝛼U + 𝛽UT 
Eq. 2.4 
where αN and αU are the state signal at the lowest and highest temperature, respectively, βN and 
βU are the slopes of the native and unfolded state baseline, respectively. 
Following thermal denaturation, the samples were allowed to cool back to 20ºC and the 
CD spectrum was re-acquired to evaluate the refolding capability of each CTPR protein.  
 
2.8 Equilibrium denaturation monitored by fluorescence spectroscopy 
Equilibrium denaturation experiments were performed according to a high-throughput method 
established in the Itzhaki laboratory.153 All protein samples were buffer exchanged into 50 mM 
sodium phosphate buffer, 150 mM NaCl, pH 6.8. A fixed volume (15 μL) of protein sample 
(at a concentration around 6-10 μM) were dispensed into 96-well, half-area, black polystyrene 
plates (Corning) using a Microlab ML510B dispenser (Hamilton). Each well contained 
increasing concentrations of guanidinium hydrochloride (GdmHCl) between 0 M and 6 M in 
increments of 0.1 M per well. Buffer was added into each well to reach a final volume of 150 
µL per well. Plates were incubated at 25ºC for 1 h, covered with 96-well Microplate Aluminium 
Sealing Tape (Corning) to avoid evaporation. Plate measurements were carried out on a 
CLARIOstar Plate Reader (BMG LABTECH) with a tryptophan-detection filter set consisting 
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of an excitation filter (275-285 nm), a dichroic PL325 nm, and an emission filter (350-370 nm) 
at 25ºC. Each measurement was performed in triplicate. 
The plots of fluorescence intensity versus denaturant concentration were fitted to a two-
state model, in which only two states are populated during unfolding (the native [N] and fully 
unfolded [U] states). The change in Gibbs free energy that describes the reversible equilibrium 
[N] ! [U] can be defined as 
 
 
Δ𝐺!$" = −𝑅𝑇𝑙𝑛𝐾%& = −𝑅𝑇𝑙𝑛
[𝑈]
[𝑁] Eq. 2.5 
 
where R is the gas constant and T is the temperature in Kelvin. Keq can be expressed as signal 






 Eq. 2.6 
where SN is the signal at the native state, SU is the signal at the unfolded state and S is the signal 






 Eq. 2.7 
And can be rearranged to obtain 
 
𝑆 =
𝑆! + 𝑆" ∙ exp ?−
Δ𝐺!$"
𝑅𝑇 @
1 + exp?−Δ𝐺!$"𝑅𝑇 @
 Eq. 2.8 
 
A linear extrapolation method is commonly used to describe the linear dependence of 
Δ𝐺%#&	on the concentration of denaturant. 
 Δ𝐺!$" = Δ𝐺'$"()* −𝑚[𝐷] 
Eq. 2.9 
where Δ𝐺%#&'"(  is the free energy change in the absence of denaturant, [D] is the concentration 
of denaturant and m is a constant proportional to the change in solvent accessible surface area 
upon denaturation. 
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We know from Eq. 2.5 that when [U]=[N], Δ𝐺%#& equals zero. Therefore, 
 Δ𝐺'$"()* = 𝑚[𝐷+,%] 
Eq. 2.10 
where D50% is the denaturant concentration at the midpoint of the unfolding transition. 
Therefore, 
 Δ𝐺!$" = 𝑚[𝐷+,%] − 𝑚[𝐷] = 𝑚([𝐷+,%] − [𝐷]) 
Eq. 2.11 




𝑆! + 𝑆" ∙ exp =−
𝑚([𝐷+,%] − [𝐷])
𝑅𝑇 >
1 + exp =−𝑚([𝐷+,%] − [𝐷])𝑅𝑇 >
 Eq. 2.12 
 
This equation describes an idealised signal trace. The measured signal intensity, however, 
varies linearly with the concentration of denaturant, independently of any state transition, and 
this is visualised as sloping baselines. The correction introduces denaturant dependent linear 




𝛼N + 𝛽N[𝐷] + (𝛼U + 	𝛽U[𝐷]) ∙ exp =−𝑚(
[𝐷+,%] − [𝐷])
𝑅𝑇 >
1 + exp =−𝑚([𝐷+,%] − [𝐷])𝑅𝑇 >
 Eq. 2.13 
 
where 𝛼N and 𝛼U are the state signal at the lowest and highest concentration of denaturant, 
respectively, and 𝛽N	and 𝛽U are the slopes of the native state and unfolded state baseline, 
respectively. 
Assuming that the protein is fully folded in the absence of denaturant and fully unfolded at the 
highest concentration of denaturant, the signal can be converted into fraction folded, λ, or 
fraction unfolded, 1-λ, using 
 𝑆 = (𝛼N + 𝛽N[𝐷])𝜆 + (𝛼U + 	𝛽U[𝐷])(1 − 𝜆) Eq. 2.14 
which can be rearranged into 
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 𝜆 =
𝑆 − 𝛼U − 𝛽U[𝐷]
𝛼N − 𝛼U	+ [𝐷](𝛽N − 	𝛽U)
 Eq. 2.15 
or 
 1 − 𝜆 = 1 −
𝑆 − 𝛼U − 𝛽U[𝐷]
𝛼N − 𝛼U	+ [𝐷](𝛽N − 	𝛽U)
=
−𝑆 + 𝛼N + 𝛽N[𝐷]
𝛼N − 𝛼U	+ [𝐷](𝛽N − 	𝛽U)
 Eq. 2.16 
 
2.9 Isothermal titration calorimetry (ITC) 
ITC was performed at 25°C using a MicroCal VP-ITC (Malvern Panalytical). Proteins were 
dialysed into ITC Buffer (500 mL of 10 mM sodium phosphate buffer, 150 mM NaCl, 0.5 mM 
TCEP, pH 7.4) for a total of 3 h. TNKS2 ARC4 was titrated into the sample cell containing 
one of the nTBP-CTPR2n or control proteins. Injections of TNKS2 ARC4 into the cell were 
initiated with one injection of 5 µL over 6 seconds, followed by 29 injections of 10 µL over 12 
seconds. Raw data were first subjected to baseline determination using NITPIC software155 and 
were fitted using the OneSite model within Origin 7.0 software to a non-linear regression. The 
values of -TΔS were obtained multiplying the change in entropy (ΔS, directly measured by the 
instrument) by the temperature (T, in Kelvin). The values of Gibbs free energy (ΔG) were then 
calculated using  
 ΔG = ΔH − TΔS Eq. 2.17 
where ΔH is the change in enthalpy, directly measured by the instrument.  
 
2.10 Tissue culture 
HEK293T cells were cultured in 15 mL of cell growth medium consisting of Dulbecco’s 
Modified Eagles Medium (DMEM), high glucose, pyruvate, (Thermo Fisher Scientific) 
supplemented with 10% Fetal Bovine Serum (Sigma-Aldrich) and 1X Penicillin/Streptomycin 
(Gibco) in adherence in a T75 flask (Sarstedt). Cells were incubated at 37°C, 5% CO2 and upon 
reaching confluency, cells were subcultured at a 1:6 ratio. For splitting, cells were washed with 
1X PBS (Thermo Fisher Scientific), detached from the surface using trypsin-EDTA (Gibco) 
and diluted in growth medium. 
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2.11 HiBiT-qIP 
2.5x106 HEK293T cells were seeded in a 10 cm dish and allowed to adhere overnight. The 
following day, cells were transfected with 3.5 μg of pcDNA3.1(-) vector encoding HiBiT-
tagged full-length TNKS2 and 3.5 μg of pcDNA3.1(-) vector encoding HA-tagged 3TBP-
CTPR6, CTPR6 or empty vector. Transfection was performed using Lipofectamine 2000 
transfection reagent according to the manufacturer’s protocol (Thermo Fisher Scientific). 
Following 48 h from transfection, cells were washed twice in 1X PBS and lysed for 30 minutes 
in 1 mL cold lysis buffer (50 mM Tris-HCl, 225 mM KCl, 1% NP-40, pH 7.5) including 
protease inhibitor cocktail (Sigma-Aldrich), 10 mM NaF, 1 mM Na3VO4, 1 mM PMSF. Cell 
debris was removed by centrifugation at 16000 xg for 20 minutes. The supernatant was 
incubated with 20 μL monoclonal anti-HA Agarose (Sigma-Aldrich), preequilibrated in lysis 
buffer, with gentle rotation for 4 h. Anti-HA agarose resin was washed 4 times with 500 μL 
lysis buffer. Elution was performed by adding 20 μL 2X Loading dye containing SDS to the 
settled resin. All steps following cell washing were performed at 4°C. The presence of HiBiT-
tagged TNKS2 throughout the IP process was detected by mixing 5 μL of each sample with 
the Nano-Glo HiBiT Lytic Detection System according to the manufacturer’s instructions 
(Promega). The amount of HiBiT-tagged TNKS2 bound to the resin before elution was instead 
quantified by mixing 5 μL of 50% anti-HA Agarose resin slurry with the Nano-Glo HiBiT 
Lytic Detection System. Data were obtained from two biological replicates. 
 
2.12 Western Blot and HiBiT Blot on HiBiT-qIP samples 
HiBiT-qIP samples to be analysed by Western Blot were run on a 10% polyacrylamide gel and 
transferred into a nitrocellulose membrane (pore size 0.20 μm, Pharmacia Biotech) by semi-
dry transfer in a three-buffer system156 comprising Anode I buffer (0.3M Tris pH 10.4, 10% 
methanol), Anode II buffer (25mM Tris pH 10.4, 10% methanol) and Cathode buffer (25mM 
Tris pH9.4, 192mM 6-amino-n-caproic acid, 10% methanol). Transfer was performed on a 
PierceTM Power Blot Cassette (Thermo Scientific) with voltage set at 15 V and current at 2.5 
A for 25 minutes. The membrane was cut into three parts to allow multiple detections on the 
same samples. HiBiT-tagged TNKS2 was visualised using the Nano-Glo HiBiT Blotting 
System according to the manufacturer’s instructions (Promega), which does not require 
membrane blocking. The other parts of the membrane were blocked in 5% milk (Marvel), 
shaking at room temperature for 1 h. HA-tagged 3TBP-CTPR6 and CTPR6 were detected using 
anti-HA-Tag (C29F4, 1:1000 dilution) rabbit monoclonal antibody (Cell Signaling 
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Technology). Tubulin was identified using anti-alpha Tubulin antibody (ab7291, 1:10000 
dilution) mouse monoclonal antibody (Abcam). HRP-conjugated goat anti-mouse (P0447, 
1:10000 dilution) and swine anti-rabbit (P0399, 1:10000 dilution) were used as secondary 
antibodies (Dako). The membrane was developed using Amersham ECL Western Blotting 
Detection Reagent and ECL Select Western Blotting Detection Reagent (Cytiva) on a LI-COR 
Odyssey Fc Imaging System. 
 
2.13 Co-precipitation assay 
20 μL of 10 μM TNKS2 ARC1-3 was mixed with an equal volume of 1TBP-CTPR2, 3TBP-
CTPR6, 3TBP-CTPR6-foldon or CTPR6 at the indicated concentration in co-precipitation 
buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5 mM TCEP, pH 7.3). Samples were incubated at 
room temperature for 1 h and centrifuged at 20000 xg for 30 minutes. The supernatant was 
collected and the pellet resuspended in an equal volume of co-precipitation buffer. Gel samples 
were prepared by adding the adequate amount of 4X Loading Dye and run on a 12% or 16% 
polyacrylamide gel. Gels were imaged using the Li-COR Odyssey Fc Imaging System and 
protein band densities were analysed using the Image Studio Lite 5.2 software. 
 
2.14 Transmission Electron Microscopy (TEM) 
Purified TNKS2 ARC1-3 was mixed with an equal volume and molar concentration (5 μM) of 
1TBP-CTPR2, 3TBP-CTPR6, 3TBP-CTPR6-foldon, CTPR6 or co-precipitation buffer. 
Samples were incubated at room temperature for 1 h. Few μL were then dispensed on carbon 
support film, 400 mesh, 3 mm nickel grids (EM Resolutions Ltd., Saffron Walden, UK) and 
stained with 2% uranyl acetate (w/v). The samples were imaged on a FEI Tecnai G2 
transmission electron microscope in the Cambridge Advanced Imaging Centre (CAIC, 
University of Cambridge, Cambridge, UK). Images were analysed using the SIS Megaview II 
Image Capture system. Grid preparation and imaging was performed by Dr. Janet R. Kumita. 
 
2.15 Fluorescence microscopy and FRAP 
1x105 HEK293T cells per well were seeded overnight in 700 μL of cell growth medium in a 
μ-Slide chamber (Ibidi). The following day, cells were transfected with 400 ng of m-Cherry 
tagged 1TBP-CTPR2, 3TBP-CTPR6, 3TBP-CTPR6-foldon or CTPR6 in combination with 
600 ng of eGFP-tagged TNKS2 ARC1-5 or 100 ng of TNKS2 ARC1, using 1.75 µL 
Lipofectamine 2000 transfection reagent according to the manufacturer’s protocol (Thermo 
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Fisher Scientific). Following 48 h from transfection, cells were imaged on a Leica TCS SP5 
confocal microscope with a 100X oil-immersion objective lens (1.4 numerical aperture). 
Excitation and filters were as follows: eGFP, excitation at 488 nm, emission from 500-540 nm; 
mCherry, excitation at 543 nm, emission from 600-630 nm. For FRAP, individual circular 
regions of interest (ROI) similar in size were selected within the fluorescent agglomerates and 
bleached using the 488 nm laser at 100% power for 5 seconds. Fluorescence intensity changes 
were recorded comparing 5 pre-bleaching frames with 60 post-bleaching frames (1.3 
seconds/frame). Data were analysed using Leica LAS AF suite software and data were 
normalised. 
 
2.16 TopFlash dual-luciferase reporter assay 
2.16.1 Wnt conditioned medium preparation 
Wnt pathway activity was induced by treating cells with conditioned medium obtained from 
L-cells expressing Wnt3A (ATCC CRL-2647) for 8 days, according to ATCC guidelines. L-
cells were kindly provided by Dr Marc de la Roche. Briefly, confluent L-cells were subcultured 
1:5 in a T75 flask with 10 mL of cell growth medium. After five days, the medium was 
collected and sterilised using a 0.22 µm filter. Cells were supplemented with 10 mL of fresh 
cell growth medium and allowed to grow for another three days, at the end of which the 
medium was collected, sterilised and combined with the previous batch. Wnt conditioned 
medium was aliquoted, snap frozen and stored at -80°C for future use. 
 
2.16.2 TopFlash assay  
For the TopFlash assay, 1x105 HEK293T cells per well in 24-well plates (NUNC) were 
transfected with 100 ng of a modified pGL3 vector (TCF/LEF-firefly), 10 ng of pRL-CMV 
vector (CMV-Renilla) and 100 ng of pcDNA3.1(-) or HiBiT-pcDNA3.1(-) plasmid encoding 
nTBP-CTPR2n, nTBP-CTPR2n-foldon or the control CTPR constructs using 0.5 µL 
Lipofectamine 2000 transfection reagent according to the manufacturer’s protocol (Thermo 
Fisher Scientific). pGL3 and pRL-CMV vectors were kindly provided by Dr Marc de la Roche. 
Transfected cells were allowed to recover in cell growth medium for 8 h and were then treated 
with Wnt-conditioned medium in a 1:1 ratio for a further 16 h. After washing the wells, the 
cells were imaged on an EVOS Floid Cell Imaging Station. TopFlash assay was then completed 
using the Dual-Luciferase® Reporter Assay System (Promega), as previously described.157 The 
luminescence activities of firefly and Renilla luciferases were measured sequentially from the 
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same sample, using the CLARIOstar microplate reader (BMG Labtech). Relative luciferase 
values were obtained dividing the averaged firefly luminescence value by the averaged Renilla 
luminescence values for each sample. Data were obtained from three biological replicates. 
When cells were transfected with HiBiT-pcDNA3.1(-) plasmids, the luminescence 
intensity of each HiBiT-tagged protein was also measured, by mixing 20 μL of the same cell 
lysate with the Nano-Glo HiBiT Lytic Detection System according to the manufacturer’s 
instructions (Promega). Luminescence was measured at the CLARIOstar microplate reader 
(BMG Labtech) with emission filter from 380-540 nm, gain set at 2200 and focal height at 
10.5. 
 
2.16.3 Western Blot on TopFlash samples 
TopFlash cell lysates to be analysed by Western Blot were run on a 12% or 15% 
polyacrylamide gels and transferred into a Immobilon-P PVDF membrane (pore size 0.45 μm, 
Merck Millipore) by semi-dry transfer using Tris/Glycine Transfer Buffer (National 
Diagnostic) on a PierceTM Power Blot Cassette (Thermo Scientific) with voltage set at 15 V 
and current at 2.5 A for 30 minutes. The membrane was cut into two parts to allow multiple 
detections on the same samples. Membranes were blocked in 5% milk (Marvel), shaking at 
room temperature for 1 h. HA-tagged CTPR proteins were detected using anti-HA-Tag (sc-
7392, 1:1000 dilution) mouse monoclonal antibody (Santa Cruz Biotechnology). Tubulin was 
identified using anti-alpha Tubulin antibody (ab7291, 1:10000 dilution) mouse monoclonal 
antibody (Abcam). HRP-conjugated goat anti-mouse (P0447, 1:10000 dilution) was used as 
secondary antibody (Dako). The membrane was developed using Amersham ECL Western 
Blotting Detection Reagent and ECL Select Western Blotting Detection Reagent (Cytiva) on a 
Fuji Medical X-Ray film (FujiFilm). The film was then developed in the dark room. 
 
2.17 Proteasomal-induced degradation assay  
1.5x104 HEK293T cells per well were seeded in a 96-well plate and transfected the following 
day in duplicates with 30 ng of HiBiT-pcDNA3.1(-) vector encoding a CTPR construct using 
0.15 μL of Lipofectamine 2000 transfection reagent according to the manufacturer’s protocol 
(Thermo Fisher Scientific). Following 19 h incubation, cells were treated or not with 10 µM 
MG132 (Calbiochem) and incubated for an additional 5 h. The number of viable cells was 
measured using the CellTiter-Fluor Cell Viability Assay (Promega) according to the 
manufacturer’s instructions. HiBiT-tagged proteins were quantified using the Nano-Glo HiBiT 
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Lytic Detection System (Promega) as above. HiBiT values obtained from three independent 
replicates were normalised using the corresponding cell viability measurements and the ratio 
+MG132/-MG132 for each replicate was calculated and plotted with standard deviation. Each 
plate also included a cell titration, to convert the CellTiter-Fluor fluorescence values into cell 
number. 
 
2.18 Liposomal delivery of nTBP-CTPR2n proteins  
2.18.1 Liposomal formulation of 3TBP-CTPR6 
Fusogenic Liposomes (FL) containing 3TBP-CTPR6 (FL-3TBP-CTPR6) were prepared using 
a previously reported method.158 In a typical procedure, 250 µg of 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), 250 µg of 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), and 25 µg of 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindotricarbocyanine iodide (DiR) (Avanti Polar lipids) were dissolved in 250 µL of 
chloroform (Merck). The solution was dried overnight inside a vacuum desiccator and the 
resulting lipid film was hydrated with 125 µL of 25 µM 3TBP-CTPR6 (in 10 mM HEPES, pH 
7.4). This dispersion was first vortexed for 2 minutes and then ultrasonicated for 20 minutes at 
room temperature. Control FL were prepared similarly, by hydrating the lipid film with 125 
µL of 10 mM HEPES, pH 7.4 with no protein. The liposomes were stored at 4°C until further 
use. The zeta potential and hydrodynamic size of the FL were measured at 25°C using a 
Zetasizer Nano ZS (Malvern Instruments). Liposomes preparation and characterisation were 
performed by Dr. Piyush K. Chaturbedy. 
 
2.18.2 Cell viability upon liposomal delivery 
4x104 HEK293T cells per well were seeded in 100 µL of cell growth medium in a 96-well plate 
and incubated for 24 h. Medium was replaced with 100 µL cell growth medium without FBS, 
containing different volumes (1-12 µL) of FL or FL-3TBP-CTPR6 and incubated for 15 
minutes at 37°C. After washing the wells with 1X PBS twice, 100 µL of CellTiter-Glo Reagent 
(Promega) was added, and luminescence was measured using a CLARIOstar microplate reader 
(BMG Labtech) according to the manufacture’s protocol. Untreated cells were used as control. 
Experiments were performed in triplicates, and the standard deviations were calculated from 
two independent experiments. This assay was performed by Dr. Piyush K. Chaturbedy. 
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2.18.3 Intracellular delivery of 3TBP-CTPR6 
To visualise the liposome-mediated intracellular protein delivery, 3TBP-CTPR6 was labelled 
with rhodamine B isothiocyanate (RITC) (Sigma). In a typical procedure, 50 µL of RITC (1 
mg/mL in DMSO) was slowly added to a 1 mL solution of 3TBP-CTPR6 (2 mg/mL) in 0.1 M 
sodium carbonate buffer pH 9.0, with stirring. The solution was stirred at 4°C for 8 h. 
Ammonium chloride (Sigma) was then added to a final concentration of 50 mM and stirring 
was continued for a further 2 h. RITC labelled 3TBP-CTPR6 (3TBP-CTPR6-RITC) was 
isolated from unreacted RITC using a PD10 desalting column (Cytiva). Liposomal formulation 
of 3TBP-CTPR6-RITC (FL-3TBP-CTPR6-RITC) was performed as described above. 1.4x105 
HEK293T cells per well were seeded overnight in 700 µL of cell growth medium in a µ-Slide 
chamber (Ibidi). The following day, medium was replaced with 700 µL cell growth medium 
without FBS and containing 28 µL of FL-3TBP-CTPR6-RITC. Samples were incubated for 15 
minutes at 37°C and then washed twice with 1X PBS. Confocal images were acquired using a 
Leica TCS SP5 confocal microscope. This assay was performed by Dr. Piyush K. Chaturbedy. 
 
2.18.4 Cellular activity of liposome-encapsulated 3TBP-CTPR6 protein in the TopFlash 
assay 
HEK293T cells were seeded in 24-well plates as described above. Cells were transfected with 
100 ng of a modified pGL3 vector (TCF/LEF-firefly), 10 ng of pRL-CMV vector (CMV-
Renilla) per well using 0.25 µL of Lipofectamine 2000 transfection reagent according to the 
manufacturer’s protocol (Thermo Fisher Scientific). Transfected cells were allowed to recover 
in cell growth medium for 8 h and were then treated with Wnt3A-conditioned medium, as 
above. 16 h post Wnt pathway activation, cells were treated with cell growth medium without 
FBS, containing 20 µL of liposomes and incubated for 15 minutes at 37°C. Following one 
wash in 1X PBS, Wnt3A conditioned medium was added and cells were incubated for 6 h. The 
TopFlash assay was performed, as described above, in triplicate in two independent 
experiments. 
For the dose-dependence analysis, the volume of liposome added was kept constant (20 
µL), while the protein concentration was varied. The FL-3TBP-CTPR6 samples were prepared 
in the following way: lipid cakes were hydrated with 10 mM HEPES pH 7.4 and 3.125 µM, 
6.25 µM, 12.5 µM, and 25 µM 3TBP-CTPR6. 20 µL of these liposomes in 500 µL cell growth 
medium resulted in 3TBP-CTPR6 concentrations of 0.125 µM, 0.25 µM, 0.5 µM and 1 µM, 
respectively. Samples of the liposome-encapsulated CTPR6 control protein, referred to as FL-
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CTPR6, were prepared by hydrating lipid cake with 25 µM CTPR6 in 10 mM HEPES pH 7.4. 
This assay was performed in collaboration with Dr. Piyush K. Chaturbedy. 
 
2.18.5 TopFlash assay using small molecule TNKSi 
HEK293T cells were seeded in 24-well plates as described above. Cells were transfected with 
100 ng of a modified pGL3 vector (TCF/LEF-firefly), 10 ng of pRL-CMV vector (CMV-
Renilla) per well using 0.25 µL Lipofectamine 2000 transfection reagent according to the 
manufacturer’s protocol (Thermo Fisher Scientific). The activity of the small molecule TNKS 
inhibitors XAV939, IWR-1 and G007 was tested prophylactically or interventionally, and the 
TopFlash assay was performed with small alterations, accordingly. When tested 
prophylactically, inhibitors were mixed with Wnt-conditioned medium and added to the well 
for 16 h. When tested interventionally, instead, inhibitors were added after the overnight 
treatment with Wnt-conditioned medium and incubated for another 6 h in Wnt-conditioned 
medium. All small molecule TNKS inhibitors were used at a final concentration of 1 µM in 
0.5% DMSO. The TopFlash assay was then completed as described above. 
 
2.19 TNKS2 degradation mediated by single- and hetero-bifunctional CTPR 
proteins  
1.5x104 HEK293T cells per well in 96-well plates were co-transfected with 20 ng of HiBiT-
pcDNA3.1(-) vector encoding full-length HiBiT-TNKS2 and 100 ng of vector encoding a 
single- or hetero-bifunctional CTPR construct, with or without the HiBiT tag, using 0.25 μL of 
Lipofectamine 2000 transfection reagent according to the manufacturer’s protocol (Thermo 
Fisher Scientific). Following a 24 h incubation, the number of viable cells was measured using 
the CellTiter-Fluor Cell Viability Assay (Promega) according to the manufacturer’s 
instructions. HiBiT-tagged proteins were quantified using the Nano-Glo HiBiT Lytic Detection 
System (Promega) as above. HiBiT values obtained from three independent replicates were 











Different modalities of peptide grafting onto the CTPR scaffold 
 
3.1 Introduction 
The relationship between protein structure and function has been a cornerstone of biology for 
decades. The tertiary structure allows a protein to perform its function by mediating the 
interaction with other proteins or small molecules. Protein-protein interactions (PPI) affect 
most biological processes and are themselves tightly regulated by factors such as sequence 
specificity, affinity, post-translational modifications and cellular localisation. Extensive efforts 
have been put into understanding biological protein interactions, and in particular the structural 
motifs involved in homo- and heterodimeric protein-protein interfaces. A secondary structure-
based analysis has identified and classified the different binding motifs within these two 
interface categories.159 Importantly, not only regular secondary structure elements (α-helices 
and β-strands) are involved in binding interfaces, but also non-regular structures, such as turns 
and loops, contribute to PPI. In particular, the study demonstrates that the former are more 
abundant in homo-dimer interfaces, whereas the latter frequently mediate heterodimeric 
interactions.159 Among all different protein’s structural motifs, this chapter focuses on 
unstructured and α-helical binding motifs. 
 
3.1.1 The world of short linear binding motifs 
In recent years, the unstructured or intrinsically disordered regions of the eukaryotic proteome 
have gained increasing interest, and disordered segments have been identified in ~44% of the 
human protein-coding genes.160 Firstly, protein folding studies have revealed that a broad range 
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of intermediate folding states exist between intrinsically disordered proteins (IDPs) and folded 
proteins. The versatility of protein folding entails that the majority of proteins include some 
structured domains as well as some intrinsically disordered regions (IDRs).161 Secondly, it is 
now well understood that polypeptide chains that do not fold into a defined three-dimensional 
structure can also be functional.161 This concept has disrupted the traditional structure-function 
paradigm, according to which protein function is critically dependent on the folded structure 
of the protein and unstructured segments are passive segments that link structured domains.162 
Further investigations revealed that IDRs can include protein binding sequences, promoting 
protein-protein interactions or higher-order protein complexes assembly, and are frequently 
subject to post-translational modifications (PTMs), further expanding their functional features. 
IDRs can also function as entropic chains, such as flexible linkers, which allow movement 
between domains, or spacers, that regulate the distance between them.161 
Despite lacking a persistent secondary structure, the conformational ensembles of IDPs 
are extremely heterogeneous. Their amino acid sequences dictate the fold of the IDP. 
According to Pappu’s molecular dynamics simulations, the overall conformation of an IDP 
depends on the fraction of positively, f+, and negatively charged residues, f-, and falls within 
one of the five conformational regions (R1-R5) (Figure 3.1a).163 Region 1 corresponds to either 
weak polyampholytes1 or weak polyelectrolytes2 that fold into globule or tadpole-like 
conformations. Region 3 corresponds to strong polyampholytes that form non-globular 
conformations. The boundary region 2 represents a continuum of conformational possibilities 
between those adopted in regions 1 and 3. Regions 4 and 5 correspond to strong 
polyelectrolytes with one charge prevailing over the other, that are expected to fold into coil-
like conformations. It is not only the frequency but also the distribution of charged residues 
over the IDR that have an impact on the conformation. For this reason, Das and Pappu 
introduced the parameter κ to describe the patterning of opposite charges in strong 
polyampholites.163 When opposite charges are all evenly distributed, κ approaches zero, as 
interchain electrostatic repulsions and attractions are counterbalanced. When opposite charges 
are segregates, instead, κ is closer to one. With low κ the IDRs form swollen coils; with high 
κ they fold into hairpin-like conformations with long-range interactions between the two ends 
being formed by the electrostatic attraction of opposite charges (Figure 3.1a, b). According to 
 
1 Polyampholyte: molecule containing both positive and negative charges 
2 Polyelectrolyte: molecule with prevailing positives or negative charges 
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the same study, in nature most IDPs are strong polyampholytes (class R3) with low values of 
κ, further driving their random coil conformation.163 
 
 
Figure 3.1: Das-Pappu conformational ensembles of IDPs. (a) Das-Pappu diagram of states with 
representative examples for each of the five conformational regions. (b) Schematic representation of a 
series of peptides having the same amount of positive (blue) and negative (red) residues, but different 
values of κ. Figure obtained from Holehouse et al.164 
 
Moreover, IDRs often lack bulky hydrophobic amino acids, explaining why they are unable to 
fold into a hydrophobic core that characterises a structured domain. IDRs, instead, are rich in 
uncompensated charged groups (often negative), leading to a large net charge at neutral pH.165  
The rising interest in IDRs is due in part to the concentration in these regions of short 
independently functioning binding motifs known as MoRFs (molecular recognition features) 
or SLiMs (short linear motifs). These motifs are short peptides of about 3-10 amino acids, and 
it has been estimated that there are over 100,000 such SLiMs in the human proteome.166 
According to their sequence specificity, they allow protein-protein as well as protein-nucleic 
acid interactions, generally with relatively low affinities (with dissociation constants in the 1-
10 µM range) due to the limited number of residues involved in the binding.167 Apart from 
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mediating interactions, SLiMs facilitate a variety of other functions, for example by acting as 
recognition sites for post-translational modifications or proteolytic cleavage, or by altering the 
protein’s specific subcellular locations or its context-dependent activity.167 SLiMs 
preferentially occur in disordered regions and are themselves unstructured but often acquire a 
secondary structure upon binding to their interaction partner.168 
As PPI are disrupted in a significant number of diseases, IDRs have recently been 
explored in drug discovery, mostly as potential inhibitors of disease-associated targets. One 
approach to exploit these motifs is to chemically synthesise them while trying to mimic their 
bioactive conformation. For this purpose, peptides are often combined with modifications such 
as cross-linking and macrocyclisation in order to improve their affinity, half-life and cell 
penetration.169 Alternatively, rational design can be used to graft SLiMs as solvent-exposed 
loops onto stable protein scaffolds, as discussed in Section 1.1.3. 
 
3.1.2 Grafting loops onto CTPRs 
Despite the fact that hetero-dimeric protein-protein interfaces containing loops are frequent in 
nature and loops frequently mediate biological interactions,159 loop grafting has been 
challenging for the following reasons: loop conformations can be hard to predict 
computationally and experimentally, loop flexibility comes with an entropic penalty upon 
binding and an appropriate protein scaffold is required.170  
In the past few years, the Itzhaki group has explored the possibility of functionalising 
the CTPR repeats by grafting non-helical SLiMs onto a CTPR loop using a simple “cut-and-
paste” design. Studies from previous members of the Itzhaki group demonstrated that the CTPR 
scaffold can tolerate the extension of the existing 4-residue loop connecting adjacent repeats 
(DPNN/DPRS), to form a longer, solvent-exposed loop without compromising the correct 
folding of the CTPR scaffold (Figure 3.2).80 The scaffold can accept the grafting of a single or 
multiple non-helical sequences up to 25 residues in length onto individual loops, with a small 
loss in stability.80 More recently, even longer sequences (up to 50 residues in length) have been 
grafted as solvent-exposed loops in the Itzhaki lab, without disrupting the overall fold.81 For 
the stability of the protein, however, a minimum of two CTPR repeats is required. An additional 
study performed in the Itzhaki group explored the effect of extending multiple loops within the 
same CTPR protein, with variable length, frequency and localisation.146 The authors 
demonstrated how multiple loop extension leads to an increased dynamics of the internal 
repeats, compared the unmodified CTPR scaffold.146 




Figure 3.2: Loop grafting onto the CTPR scaffold. The residues forming the loop (DPRS) connecting 
adjacent repeats (indicated with n) are coloured in red. Peptide grafting within this loop forms an 
extended, solvent-exposed loop, schematically represented by a red dashed line, variably extended 
depending on the number of residues being introduced. (PDB: 2FO7) Image of the CTPR2 protein was 
generated using the software UCSF Chimera. 
 
Additionally, it was shown that functionalising the CTPR scaffold by loop grafting was 
possible, as exemplified by introducing a short binding peptide derived from Nrf2 (Nuclear 
factor erythroid-2-related factor 2). This sequence, with known binding specificity for the E3 
ubiquitin ligase Keap1 (Kelch-like ECH-associated protein 1), is an appropriate candidate, 
given its turn-like native conformation.82 The authors demonstrated the ability of the 
functionalised scaffold to bind the target in vitro, confirming that the peptide maintains its 
binding properties when grafted onto the scaffold, opening the possibility for designing target-
specific binders using the CTPR scaffold.82 
Here, the same approach was adopted to design TNKS-specific inhibitors by grafting 
the consensus sequence recognised by the ARC subdomains of TNKS (referred to subsequently 
as the tankyrase-binding peptide or TBP)46 onto the loop between consecutive repeats. Previous 
studies in the Itzhaki laboratory have also shown that the macrocyclic TBP peptide is able to 
bind TNKS with a slightly enhanced affinity than the unstapled sequence, can compete with 
Axin for the binding to TNKS and inhibit Wnt signalling in the cell.85 
 
3.1.3 α-helices as structured binding motifs 
Apart from unstructured loops, α-helices also mediate many protein-protein interactions. 
Helices are key building blocks in protein folding171 and are characterised by a specific pattern 
of 3.6 residues per helical turn.172 A common motif within α-helices is called the heptad repeat 
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and consists of seven residues folded into two helical turns.172 Helices can vary in length and 
are stabilised by hydrogen bonds formed between every backbone N-H group and the backbone 
C=O group of the amino acid located three or four residues earlier along the helix. In nature, 
α-helices within tertiary structures often exhibit two “faces” and are therefore called 
amphipathic: hydrophobic and polar residues are segregated on opposite faces, each 
responsible for specific functions. While the former are oriented towards the interior of the 
protein and contribute to stabilising hydrophobic interactions and folding, the latter are solvent 
exposed. These features can be easily visualised on a helical wheel plot, a representation that 
illustrates the orientation of each residue along the helical axis. The same amphipathic nature 
is also observed in the helices of the CTPR repeats.61 
Due to their involvement in many PPIs, α-helices are attractive therapeutic tools as 
inhibitors of disease-related interactions. Binding helices have therefore been extrapolated 
from their folded protein and used as peptide inhibitors. However, they come with major 
limitations: peptides are generally unstable in the cell and subject to proteolysis; they are not 
cell permeable and they mostly remain unfolded without the remaining parts of the protein and 
hence have low binding affinities. To overcome these issues, helices have been stabilised by 
helix stapling or helix grafting, both of which provide a solution to the problems mentioned 
above. 
For helix stapling, or cyclization, peptides are chemically synthesised incorporating 
two unnatural amino acids at a distance of one (i, i+4) or two (i, i+7) or three helical turns (i, 
i+11), so that their side chain are on the same side of the helix. Moreover, unnatural residues 
are placed on the opposite face than binding residues, to avoid disrupting the binding interface. 
Helix stapling is then performed by covalently linking the two unnatural amino acid side chains 
according to various macrocyclisation chemistries. Upon stapling, the population of unfolded 
conformations decreases, constraining the peptide into a helical fold. The entropic penalty for 
binding is therefore decreased.173 Apart from inducing the binding-competent helical 
conformation, stapling has also been shown to increase the stability and the plasma half-life of 
the peptide, as well as its cell penetration ability, leading to improved pharmacokinetic as well 
as pharmacodynamic properties.174 
 Helix grafting, instead, is performed by resurfacing a helical domain within a 
structured, stable protein scaffold with the key contact residues involved in PPI of a different 
helix. As all helices share the same heptad conformation, helix grafting is performed by 
replacing some residues of the “host” helix with the corresponding amino acid of the “guest” 
binding helix, located in the same heptad position.83,84,175–177 Initially, the two helices are 
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compared to identify the residues in the same heptad position. This allows residues to still be 
displayed in the same conformation after the transfer of a residue from one helix to the other. 
Secondly, residues interacting with the target need to be identified and located within the 
“guest” helix, whereas residues necessary for the stability of the protein scaffold need to the 
identified on the other. The transfer of the first set of residues into the second while maintaining 
the same heptad position generates the grafted helix. In this way, a helical recognition epitope 
is transferred from its native α-helical context onto the helix of a stable protein scaffold (Figure 
3.3).176 
 
3.1.4 Grafting α-helices onto CTPRs 
Given the high α-helical content of the CTPR protein, the Itzhaki lab has also explored the 
possibility of grafting helical sequences onto this scaffold. The group has attempted grafting 
of binding helices at both termini of the CTPR scaffold (unpublished data). These studies have 
demonstrated how the CTPRs can tolerate the grafting of α-helical motifs at either end without 
affecting the overall stability and folding of the scaffold. The procedure adopted for helix 
grafting is detailed in the Results section of this Chapter. 
Here, helix grafting was exploited to introduce the coiled-coil foldon (CC-foldon) motif 
at the C-terminal end of each of the TNKS-binding CTPR constructs (Figure 3.3). Rather than 
a new binding functionality, the grafted foldon domain induces the CTPR protein to form a 
trimer, thereby increasing the valency. 
 
 
Figure 3.3: Helical wheel representation of a CTPR Helix A (Left) and the coiled-coil (CC) helix of 
the foldon motif (Right). For helix A, the residues involved in interactions with the preceding repeat 
are highlighted and need to be maintained. All the other residues are replaced with those of the CC-
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foldon helix, located at the corresponding heptad position. Polar residues are shown as boxes, nonpolar 
residues as circles. Figures were obtained from the web-based application NetWheels.62 
 
3.1.5 The foldon domain  
The foldon is a trimerisation motif and corresponds to the C-terminal residues of fibritin, a 
viral protein encoded by the bacteriophage T4.178 Fibritin is the main component of the 
filaments protruding from the “neck” of the virion and it plays essential roles in virus assembly 
and as environment-sensing device. Its structure consists of a N-terminal domain responsible 
for attachment to the phage particle; a long, coiled-coil central region divided into 13 helical 
segments, and a C-terminal domain containing the foldon motif. The foldon motif is essential 
for the correct trimerisation of fibritin, leading to coiled-coil formation.179 The three-
dimensional structure of the foldon domain was firstly solved by Tao et al. in 1997, when the 
final, C-terminal 119 residues of fibritin (residues 368-487) were crystallised in a trimer 
configuration (Figure 3.4C).178 The structure reveals the conformation of the last three 
segments of the coiled-coil region (residues 368-457), continuing into the 11-amino acid foldon 
motif (residues 458-487) (Figure 3.4B). The foldon domain folds into a β-hairpin motif and an 
extended loop connects the β-hairpin to the end of the last α-helical coiled-coil segment (Figure 
3.4A). The foldon is rich in hydrophobic residues, forming stabilising hydrogen bonds within 
the same chain (Figure 3.4A). Foldon trimerisation is mediated by two additional hydrogen 
bonds formed between each pair of neighboring β-hairpins. 
The structure of the foldon domain was also confirmed by Boudko et al. in 2004.180 
The authors obtained the structure of a designed fibritin fragment referred to as ‘NCCF’ 
containing the N-terminal region, the first coiled-coil segment and the foldon motif. 180 In the 
same year, a 27-amino acid peptide corresponding to the foldon motif was proven to fold into 
a trimer independently of the structural context of fibritin, making it the ideal candidate for 
protein engineering efforts.181 The authors also concluded that the foldon is evolutionarily 
optimised for rapid folding and trimeric fibritin assembly.181 Given its intrinsic stability and 
fast folding, the foldon domain has already been used as self-assembling building blocks for 
nanomaterials or as scaffold of trimeric peptide and protein structures.182–187 
 
 




Figure 3.4: Crystal structure of fibritin. (A) Ribbon representation of the C-terminal foldon domain, 
with the sidechains of the hydrophobic residues involved in stabilising intra-molecule and inter-
molecules hydrogen bonds shown and coloured by heteroatom. Hydrogen bonds are represented with 
light blue lines (PDB 1AA0). (B and C) Ribbon representation of the C-terminal end of fibritin, 
consisting of three coiled-coil segments followed by the foldon domain. The monomer (B) and the 




3.2.1 Protein design and grafted peptide sequence 
The CTPR sequence was developed by Main and co-workers in 2003 using a statistical 
approach.61 In 2005, Kajander et al. mutated the CTPR sequence to facilitate the cloning 
method, generating a new CTPR variant named CTPRa. The CTPRa sequence was obtained 
by replacing the two final residues of the DPNN loop (two asparagine amino acids at positions 
33 and 34 in the TPR repeat, connecting helix B and helix A of the following repeat) with a 
DPRS loop.149 This difference arose from the need for a simple cloning strategy that could 
allow the concatemerisation of tandem repeats at the DNA level. The final residues RS, indeed, 
correspond to the BglII restriction site where the ligation between consecutive CTPR units 
occurs, as explained in the method Section 2.3.3.149 
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Based on previous studies and in-house results, the Itzhaki group has adopted the alterations 
listed below, generating the CTPR sequences described in this study.  
1. For all the constructs made, the N-terminal capping sequence was not included.  
2. Except for one construct, the CTPR proteins in this study do not have the extra C-
terminal solvating helix that has been used by some groups to improve 
solubility.41,61,188,189 The Solvating helix was introduced only in one construct, named 
1TBP-CTPR4-Solvating Helix, that was designed for crystallographic studies. In all the 
other constructs, the CTPR scaffold consists of the 34 amino acid residues denoted with 
n (Figure 3.5). 
3. The original residues at position 18 and 19, aspartic acid (D18) and glutamic acid (E19), 
were mutated to glutamine (Q) and lysine (K), respectively,67,190 to further enhance the 
intrinsic stability of the CTPR scaffold by introducing novel charge-charge interactions. 
Q at position 18 corresponds to the amino acid with the third highest global propensity 
value, while K is the second most frequent residue at position 19.61 
4. To facilitate the concatemerisation of tandem 1TBP-CTPR2 units, the two final resides 
within the DPNN loop were replaced by DPRS residues, containing the BglII 
recognition site at the DNA level.149 Due to this cloning strategy, two CTPR sequences 
were therefore generated in the nTBP-CTPR2n array, one preceding (1) and one 
following (2) the grafted loop (Figure 3.5). The DPNN-to-DPRS mutation, however, 
causes a stability loss, as shown in previous studies.80,191 
 
 
Figure 3.5: CTPR sequence development. Sequences of the CTPR and CTPRa motifs designed by the 
Regan laboratory are shown.61,149 (1) and (2) denote the CTPR sequences used for this study, with the 
first preceding the loop, and the second following it. Single point mutations are indicated with 
individual arrows. Secondary structural elements are shown at the top of the figure. Helices are 
represented as rods. 
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The CTPR scaffold used in this study, therefore, consists of alternating sequence (1) and 
sequence (2), provided in Figure 3.5. This scaffold was functionalised by grafting an 8-residue 
TNKS-binding peptide (TBP), REAGDGEE, onto the loop between two adjacent repeats, to 
form an extended, solvent-exposed loop. The TBP was identified by Guettler et al. from a 
mutational analysis of the TNKS binding sequences of 3BP2, RSPPDGQS (Kd 4.9 ± 0.4 μM), 
and is known to bind more tightly to TNKS2 ARC4 (Kd 0.6 ± 0.04 μM).46 According to the 
crystal structure of ARC4 in complex with the 3BP2 binding peptide, the peptide binds ARC4 
in an extended conformation. The TBP peptide is also expected to be unstructured: a 
prerequisite for successfully grafting it into a solvent-exposed loop. 
The TBP was inserted immediately after the DPNN loop of the first CTPR repeat. A 
DPRS sequence was also introduced at the C-terminus of the TBP sequence, to terminate the 
extended loop and induce the correct folding of the following repeat. The flanking DPXX 
sequences also place the TBP sequence in the middle of the loop, at an equal distance between 
the two adjacent repeats. Moreover, the presence of a proline residue in each flanking DPXX 
sequence ensures a conformational turn, maintaining helices A and B correctly folded and the 
SLiM unstructured. Therefore, the final loop sequence is N’-DPNNREAGDGEEDPRS- C’. 
An analysis using the CIDER software was performed to predict the physical properties 
of the DPNN-TBP-DPRS sequence.164 CIDER calculates various sequence parameters, mostly 
related to the number and distribution of charged amino acids, across a disordered protein 
sequence, and plots a Das-Pappu phase diagram with the fraction of positively (x-axis) and 
negatively charged residues (y-axis). The sequence lies in the strong polyampholyte region, as 
it contains both positive and negative charges in similar proportions, and strong 
polyampholytes are expected to fold into nonglobular conformations that are coil-like, hairpin-
like or chimeras (Figure 3.6). The CIDER software also revealed that the κ value for the DPNN-
TBP-DPRS loop is equal to 0.34, in accordance with the finding that naturally occurring strong 
polyampholytes have low values of κ.192 
 




Figure 3.6: CIDER calculations on the DPNN-TBP-DPRS sequence (16 residues). (A) Das-Pappu 
phase diagram of the TBP loop in the context of the CTPR scaffold. (B) Linear Hydropathy diagram 
using a sliding window (blob) of five residues, with values scaled to lie between 0 (hydrophilic) and 1 
(hydropathy). It indicates that the A and G residues in the central region are the most hydrophobic ones. 
(C) NCPR (net charge per residue) diagram using a sliding window (blob) of five residues. Values are 
calculated as f+ - f-, where f+ and f- denote the fraction of positive and negative charges within the five-
residue window. (D) Linear fraction of charged residues diagram using a sliding window (blob) of five-
residues. Values are calculated as f+ + f-, with f measured within the five-residue window. C and D 
indicate that charged residues are more frequent on the second half of the DPNN-TBP-DPRS sequence. 
Diagrams obtained using the web-software CIDER.192 
The construct generated by loop grafting was named 1TBP-CTPR2, as it consists of one TBP 
loop between two CTPR motifs (Figure 3.7). By grafting the TBP into an inter-repeat loop, the 
TBP is expected to be solvent-exposed and, therefore, able to bind the target. 




Figure 3.7: Top: Domain architecture of TNKS1 and TNKS2, comprising a histidine, proline, serine-
rich (HPS) domain, a substrate-binding ankyrin-repeat (ANK) domain consisting of five ankyrin-repeat 
clusters (ARC), a sterile alpha motif (SAM) and the catalytic PARP domain. Semi-circles indicate TBP-
binding sites within ARC1, ARC2, ARC4 and ARC5. Bottom: Schematic representation of the 1TBP-
CTPR2 construct, showing the TNKS-binding peptide (TBP, coloured in red, sequence REAGDGEE) 
grafted onto the loop between adjacent CTPR repeats (PDB 2HYZ).  
 
3.2.2 nTBP-CTPR2n: a multivalent linear array  
Taking advantage of the repetitive nature of the CTPR scaffold, as well as the presence of 
multiple ARC subdomains within TNKS, a series of multivalent constructs were generated to 
study the effect of multivalency on the binding to TNKS. To this aim, the minimal TNKS-
binding unit was tandemly repeated and joined together at the DNA level by concatemerisation, 
to generate a series of multivalent, linear CTPR molecules with increasing valency and 
molecular weight. The constructs were named nTBP-CTPR2n, with n between one and four, 
according to the number of TBP loops and CTPR repeats present in each. Using this method, 
CTPR constructs with identical sequence repeats at both the DNA and protein level were 
generated. As a control, a CTPR6 construct with no loops was used. A schematic representation 
of the linear array is shown in Figure 3.8. 
 This approach resulted in the formation of multivalent constructs having TBP loops 
located in alternating inter-repeat interfaces. As loop grafting causes a stability loss at the 
interface in which it is located,80 this design allows to maintain a stabilising interface in 
between two TBP loops. 
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According to the crystal structure of CTPR8 and CTPR20 proteins, long arrays of 
CTPR repeats adopt a rigid, superhelical conformation, with eight repeats required to complete 
a superhelical turn.64 Thus, in the nTBP-CTPR2n multivalent proteins, the TBP loops are 
expected to point towards different directions and be offset from each other by approximately 
90° (Figure 3.9), as loop grafting did not affect the overall folding of the proteins previously 
tested.80,82,146 However, it remains difficult to judge the effect of spacing and orientation of the 
TBP loops within these multivalent TBP-CTPR constructs on the binding with TNKS. 
Moreover, due to the absence of the crystal structure of the full-length ANK domain of 
TNKS and its dynamic nature,89 a structure-based design approach could not be applied to 
drive the development of multivalent TBP-CTPR binders, further explaining the rationale 




Figure 3.8: Schematic representation of the nTBP-CTPR2n and control constructs of the linear array. 
Each CTPR is shown as a yellow rectangle, and the TBP grafted onto the inter-repeat loops are in red. 
The amino acid sequence of the generated constructs is provided in Appendix B. 
 
 




Figure 3.9: The superhelix conformation affects the orientation of the TBP loops in the linear array. 
Left: schematic representation of 4TBP-CTPR8 (chosen as representative), with arrows indicating the 
loop orientation within the construct. Right: crystal structure of CTPR8 (PDB 2HYZ) viewed along the 
superhelical axis. CTPR helices are in yellow and the inter-repeats loops, onto which the TBP sequence 
is grafted, are in red. The image was generated using the software UCSF Chimera. 
 
3.2.3 Linear protein array expression and purification 
All His6 tagged nTBP-CTPR2n were recombinantly expressed in the C41 E. coli strain as 
described in Section 2.4. A small aliquot of the overnight culture was used to perform a 
solubilisation test using BugBuster® Master Mix, which confirmed that all proteins were 
expressed as soluble proteins in solution. All nTBP-CTPR2n constructs could be purified in high 
yields (~20 mg per litre of culture). All proteins were purified by affinity chromatography first, 
followed by size exclusion chromatography. Affinity chromatography relies on the presence 
of an affinity tag, such as the His6, whereas size-exclusion chromatography separates molecules 
depending on their size and 3D conformation. nTBP-CTPR2n could elute from the HisTrap 
affinity chromatography column as highly pure proteins and at high concentration. Higher 
order constructs, in particular 4TBP-CTPR8, showed the presence of lower and higher 
molecular weight contaminants, probably corresponding to recombination products generated 
at the DNA or the protein level. To further improve their purity, proteins were run on a 
Superdex 75 16/600 size-exclusion chromatography column (Figure 3.10A, left). As expected, 
the retention volume of the nTBP-CTPR2n proteins lowers with their increasing molecular 
weight. All chromatograms share a similar shape, characterised by an asymmetric peak with a 
long trailing tail that follows the maximum. This tail is recognizable on the size-exclusion 
chromatograms of all the CTPR proteins tested in the Itzhaki lab (with variable length, number 
of loops and loop sequences) and we believe is most likely due to their non-specific binding of 
the CTPR repeats to the column matrix. It is also worth noting the presence of a second peak 
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in the chromatogram of most proteins, that elutes after one column volume (120 mL). It was 
however observed that the 1:5 dilution of the same 2TBP-CTPR4 protein sample run under 
identical experimental conditions abolished the second elution peak (Figure 3.10A, right). 
Therefore, I speculate that the combination of high protein concentration and non-specific 
binding to the column matrix might slow down a fraction of the protein sample, resulting in 
the observed second peak. When comparing the molecular weights of the purified samples with 
their size-exclusion chromatography traces, one can see that the CTPR6 protein elutes earlier 
than expected and with a broad peak, probably indicating the existence of fast-exchanging 
oligomerisation species (further evidence are provided in Chapter 4). SDS-PAGE 
electrophoresis confirmed the high purity of all purified samples (Figure 3.10B). Only in the 
4TBP-CTPR8 sample, some contaminants were still present even after size-exclusion 
chromatography. Finally, mass spectrometry confirmed the correct identity of the purified 
proteins (Appendix C).  
 
Figure 3.10: protein purification. (A) Superdex 75 16/600 size-exclusion chromatography traces of the 
indicated proteins. On the right, the traces obtained with highly concentrated and 1:5 diluted 2TBP-
CTPR4 sample are compared. (B) SDS-PAGE gels with lanes corresponding to the purified sample of 
the indicated proteins. 
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3.2.4 nTBP-CTPR2n-foldon: a multivalent trimeric array 
An additional, trimeric array of nTBP-CTPR2n constructs was generated alongside the linear 
one. Trimerisation of the nTBP-CTPR2n proteins was achieved by grafting the ‘foldon’ motif 
at one end of each linear construct (now referred to as nTBP-CTPR2n-foldon), generating their 
homo-trimeric counterparts having three, six, nine or twelve TBP loops. The rationale for 
making the trimeric nTBP-CTPR2n-foldon proteins was to further extend their multivalent 
capabilities and to produce additional and more complex display geometries beyond what is 
possible with the linearly arrayed nTBP-CTPR2n format. 
The foldon motif was grafted at the C-terminus of each nTBP-CTPR2n construct as 
described in Sections 3.1.3 and 3.1.4. More precisely, helical grafting onto the C-terminal end 
of the CTPR scaffold requires the introduction of an additional helix A following helix B of 
the last repeat. This helix A corresponds to the “host” helix on which we grafted a portion of 
the coiled-coil that precedes the foldon motif, continuing into the foldon motif itself. When 
grafting a helical region onto the final CTPR helix, the residues at the interface between 
consecutive CTPR repeats need to be preserved in order to maintain the stability of the CTPR 
scaffold. The residues were identified in alanine 3 (A3), asparagine (N6), leucine 7 (L7), and 
alanine 10 (A10). These residues are located on the same face of the helix, as represented in 
Figure 3.3, and their side chains are involved in the CTPR inter-repeat interactions, therefore 
they need to be conserved. Residue A1 was also maintained to provide stability on the helical 
conformation at a position immediately after the loop connecting adjacent repeats. Residues 
asparagine 9 (N9) and lysine 13 (K13) of helix A were also maintained, as they match the CC 
residues at the same heptad position. The remaining residues of the terminal helix A were 
substituted with those of the fibritin NCCF coiled-coil construct180 (residues 65 to 77) at the 
corresponding heptad position. These were followed by the remaining helical residues (NCCF 
residues 78 to 82) and the foldon motif (NCCF residues 83 to 109) (Figure 3.11A). The 
resulting constructs are referred to as nTBP-CTPR2n-foldon, and their protein sequence is given 
in Appendix B. A model of the trimeric CTPR2-foldon protein is shown in Figure 3.11B, with 
the loops onto which the TBP is grafted highlighted in red. Apart from increasing the number 
of TBP loops, this trimeric configuration is expected to display the loops in a different 
geometry, being offset from each other by 120°, rather than 90° as for the monomeric 
constructs. 
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3.2.5 Trimeric protein array expression and purification  
The nTBP-CTPR2n-foldon constructs were expressed as soluble proteins and were purified 
using Ni-NTA affinity resin. In this batch purification method, beads agglomeration was 
observed, possibly caused by the fact that for each trimer there are three His6 tags, therefore 
causing a cross-linking effect between beads. As this effect has never been observed with any 
other His6 tagged-CTPR protein in the Itzhaki lab, this evidence represents a first indication 
that the grafted foldon causes trimerisation of the CTPR constructs in solution. Cross-linking 
did not affect the efficiency of elution and purification. Trimeric nTBP-CTPR2n-foldon proteins 
could be further purified by size-exclusion chromatography. 
 
 
Figure 3.11: Foldon motif. (A) Sequence alignment between CTPR helix A (residues 1 to 15), the 
grafted CTPR-foldon construct, and fibritin NCCF (residues 65 to 109). Rods represent α helices, 
arrows represent β strands, thin lines indicate unstructured regions. (B) Left: schematic representation 
of CTPR2-foldon. Each CTPR is shown as a yellow rectangle and the foldon domain as a purple 
triangle, as indicated in the legend. Middle and Right: Different views of the modelled structure of 
CTPR2-foldon. The model was generated by grafting the foldon helix (PDB: 1OX3) onto the CTPR 
helix (PDB: 2HYZ) using the software UCSF Chimera. CTPR helices are shown in yellow, the inter-
repeats loops, onto which the TBP is grafted, are in red. 
 
Trimerisation of the nTBP-CTPR2n-foldon constructs was first verified by native gel 
electrophoresis. Trimeric nTBP-CTPR2n-foldon proteins were run alongside their linear 
counterparts for comparison (Figure 3.12). The series lacking the foldon domain (1TBP-
CTPR2, 2TBP-CTPR4, 4TBP-CTPR8, calculated molecular weights 11.3 kDa, 20.6 kDa and 
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39.4 kDa, respectively) run at increasing molecular weights between the 20 kDa and 66 kDa 
molecular weight markers. In contrast, those including the foldon domain (1TBP-CTPR2-
foldon, 2TBP-CTPR4-foldon, 4TBP-CTPR8-foldon, calculated molecular weights as trimers 
49.2 kDa, 77.4 kDa and 133.5 kDa, respectively) run at higher molecular weights between the 
66 kDa and 146 kDa markers. Native gel electrophoresis, therefore, indicates that all the nTBP-
CTPR2n-foldon proteins tested run as trimers. 
 
 
Figure 3.12: Native gel electrophoresis analysis. Each lane corresponds to the indicated nTBP-CTPR2n 
or nTBP-CTPR2n-foldon protein. A polyacrylamide gel not containing SDS and NativeMarkTM Protein 




In this chapter, the potential of the CTPR as a protein scaffold, as well as the different grafting 
methods that can be applied to it, has been explored and exemplified. 
One way of functionalising the CTPR scaffold is by grafting a target-binding SLiM 
onto the loop connecting consecutive repeats, forming an extended, solvent-exposed loop. This 
method can be potentially applied to a great variety of non-helical SLiMs. Here, loop grafting 
was applied to introduce the TNKS binding sequence, named TBP, onto the scaffold. The 
specific reasons for choosing this target are: first, TNKS is an important therapeutic target 
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involved in several diseases, against which an effective and specific inhibitor is still lacking, 
and second, the interaction between TNKS and the TBP peptide has been well studied by the 
Guettler laboratory, and further investigation has been performed by our group using 
chemically constrained TNKS-binding peptides.85 
Another way of functionalising the CTPR scaffold is by helical grafting at either termini 
of the CTPR scaffold, by adding an additional “host” helix (helix A if added at the C-terminal 
end or helix B if added at the N-terminal end) onto which to graft the residues of a “guest” 
helix. The method has been performed here to introduce the trimerisation foldon and generate 
trimers of the nTBP-CTPR2n constructs. Helical grafting on the CTPR scaffold is particularly 
convenient, as helices are stacked in a linear array and only few residues have to be conserved 
within the “host” helix, leaving many heptad positions available for grafting. Moreover, there 
is no residue clashing on any of the free heptad positions of the “host” helix, therefore any 
amino acid can be accommodated. 
The CTPR unit has many other favourable properties. It is very stable, it can be 
expressed in E. coli as soluble protein, in high yields and can be easily engineered for different 
purposes. The repeating nature of CTPRs also allowed us to create a multivalent system by 
simply combining consecutive TNKS-binding units. Unlike other artificial binding proteins 
such as bi-specific antibodies and DARPins9,53,193 where multivalency is generated by 
connecting multiple repeat units like “beads-on-a-string” through flexible linkers, multivalency 
in CTPRs is induced by simply introducing more CTPR binding units in the same DNA open 
reading frame, therefore producing an extended, higher-molecular weight protein. Moreover, 
given the superhelical conformation of CTPR repeats, the geometric arrangement with which 
the multiple functions are displayed in the CTPR scaffold is intrinsic to its repeating 
architecture and can be pre-programmed in a precise and predictable way. By grafting the TBP 
loop in alternating inter-repeat interfaces, the extended loops are expected to be displayed 
offset from each other by 90º, therefore avoiding steric hindrance between them. 
Multivalent nTBP-CTPR2n constructs were obtained by concatemerisation of the 1TBP-
CTPR2 unit at the DNA level. This corresponds to the simplest and most efficient way to 
generate higher order tandem-repeat constructs, mostly because it is not possible to order DNA 
fragments with a highly repetitive sequence. By concatemerisation, therefore, repeats having 
identical DNA and protein sequences are therefore repeated in tandem as desired. Having a 
long nTBP-CTPR2n construct encoded by the same repeating DNA sequence can, however, be 
a downside. As observed in Figure 3.10B, 4TBP-CTPR8 was purified together with lower and 
higher molecular weight contaminants, probably corresponding to recombination products. 
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This observation led us to the conclusion that any further CTPR construct designed 
subsequently should be encoded by a maximally diversified DNA sequence, with all repeats 
being different, where possible (as in Chapter 5). By grafting the foldon domain, the number 
of TBP loops was further increased by trimer formation rather than extending the linear nTBP-
CTPR2n constructs with additional TNKS-binding units. In this way, not only further 
concatemerisation is avoided, but also the downsides connected to it are circumvented. 
Loop and helical grafting can be applied on the same CTPR construct with endless 
combinations. When different binding sequences are grafted on the same protein, hetero-
bifunctional constructs are generated. Hetero-bifunctional proteins can be exploited for several 
applications, further expanding the potentiality of the CTPR scaffold. An example of hetero-
bifunctional nTBP-CTPR2n constructs is provided in Chapter 9. 
For simplicity, from now onwards the CTPR constructs generated in this study will be 
named nTBP-CTPR2n when referring to the linear array, nTBP-CTPR2n-foldon when referring 
to the trimeric array, CTPRn when referring to the control constructs with no binding loops or 












Biophysical characterisation of the CTPR constructs 
 
4.1 Introduction 
Early characterisation and development of protein biotherapeutics rely on the analysis of their 
biophysical properties, such as solubility, folding, target-binding specificity and 
monodispersity in solution to prevent the formation of protein aggregates. Continuous efforts 
in the biopharmaceutical industry are indeed spent to improve the protein’s stability, as it has 
an effect on its efficacy, manufacturing, formulation and potentially safety too. The methods 
and techniques adopted in this chapter aim to evaluate the biophysical properties of the nTBP-
CTPR2n proteins of the linear array. 
 
4.1.1 Biophysical properties for the development of biotherapeutics  
Arrays of CTPR modules generate highly stable proteins.61 The formation of the hydrophobic 
core at the interface between adjacent repeats guarantees high protein stability and drives the 
overall folding of the repeat protein.61,65 
In this Chapter, particular attention is therefore put on the effect of inter-repeat loop 
extension on the native structure of the CTPR array and the overall thermodynamic stability. 
Previous studies performed in the Itzhaki lab have highlighted how the extension of a single or 
multiple loops within the same CTPR construct does not alter the secondary structure of the 
native state.80,82,146 However, loop grafting in the CTPR scaffold is expected to cause a context-
dependent stability loss due to the entropic penalty of closing the loop. This behaviour has been 
previously described by the Fersht and Regan labs, whereby increasing the length of an 
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unstructured loop in a globular protein led to reduced protein stability.194,195 Moreover, a 
correlation between longer loop length and decreased protein stability was observed.195 In 
agreement with these studies, evidence from our own lab also indicate that loop extension 
destabilises the CTPR constructs through both the entropic cost of loop closure and the 
consequent weakened interactions at the inter-repeat interface.80 The effect of loop length (10 
to 25 amino acids) on the stability loss was however variable, depending on the total number 
of repeats in the CTPR array.80 Moreover, a subsequent study concluded that the frequency of 
loops also affects the stability, as loops extended at each inter-repeat interface cause adjacent 
repeats to be only weakly coupled.146 This extreme configuration was therefore avoided in the 
nTBP-CTPR2n constructs design, where loops were extended only at alternating inter-repeat 
interfaces and the other native, stabilising interfaces were maintained. 
 
4.2 Results 
Biophysical characterisation of the linear nTBP-CTPR2n constructs was performed using a 
number of different methods. Far-UV circular dichroism (CD) was used to evaluate the correct 
folding of the nTBP-CTPR2n proteins. Denaturation studies induced by temperature ramp or 
increasing concentrations of a chemical denaturant were performed to investigate the stability 
of the proteins. The TBP was introduced into the inter-repeat loops to functionalise the CTPR 
scaffold and provide TNKS-binding specificity. The nTBP-CTPR2n constructs’ ability to bind 
the target of interest was therefore investigated using isothermal titration calorimetry (ITC), 
which represents the “gold-standard” method for the analysis of thermodynamics of binding in 
solution. The dispersity of the samples was tested by size-exclusion chromatography coupled 
with multi-angle light scattering (SEC-MALS), which is a relatively straightforward and 
sensitive technique. Finally, we attempted X-ray crystallography to determine the structures of 
the TBP-grafted CTPR proteins. 
 
4.2.1 Effect of TBP insertions on CTPR folding and stability measured by far-UV 
circular dichroism 
We first investigated the effects of the TBP grafting on protein folding using far-UV circular 
dichroism (CD). CD refers to the differential absorption of left and right circularly polarized 
light (LCP and RCP, respectively) by optically active chiral molecules and provides an 
indication of the secondary structure content of a protein in solution. In particular, proteins 
with high α-helical content, such as CTPRs, generate CD spectra with double minima at 208 
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nm and 222 nm.61,188,189 All nTBP-CTPR2n constructs showed the expected spectrum for CTPR 
repeats, confirming that all nTBP-CTPR2n proteins are correctly folded (Figure 4.1A). A similar 
CD profile was previously observed in the Itzhaki lab for CTPR proteins with different grafted 
loops, confirming that loop extension does not radically alter the secondary structure of the 
CTPR repeats.80,82,146 In all the CD spectra of CTPR proteins previously published, including 
those shown here, the minimum at 208 nm is not pronounced and might represent a 
characteristic feature of this protein system.61,80,82,146,188,189 Of note is the linear increase in the 
molar ellipticity at 222 nm observed with increasing number of the CTPR repeats, which 
further proves that the proteins are natively folded (Figure 4.1B). 
 
 
Figure 4.1: CD spectroscopy of nTBP-CTPR2n proteins. (A) Far-UV CD spectra of 1TBP-CTPR2, 
2TBP-CTPR4, 3TBP-CTPR6 and 4TBP-CTPR8. Protein concentration was 20 μM in 10 mM sodium 
phosphate pH 7.4, 150 mM NaCl at 20°C. On the right, the figure legend with a schematic 
representation for each construct. (B) Plot of molar ellipticity at 222 nm, obtained from the experiment 
in A, against the number of CTPRs in the protein. 
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Next, thermal denaturation was performed to investigate the stability and folding of the nTBP-
CTPR2n constructs. As ellipticity at 222 nm is a good measure of the α-helical content, this 
wavelength was chosen to follow the denaturation of the protein.196 According to the classical 
cooperative folding model, protein denaturation is visualised as a two-state transition from the 
folded to the unfolded state without stable intermediate states. When a complete two-state 
transition is recorded, it is possible to measure the apparent midpoint of the unfolding 
transition, indicated with Tm, which corresponds to the temperature at which the folded and 
unfolded populations are equal.196 The value of Tm is a simple way to compare the stability of 
different constructs. 
All nTBP-CTPR2n proteins were found to be extremely thermostable, with only the 
smallest protein, 1TBP-CTPR2, undergoing complete denaturation. The larger nTBP-CTPR2n 
proteins remained partly folded even at the highest temperature. The apparent midpoint of the 
unfolding transition is therefore provided only for 1TBP-CTPR2 and corresponds to 75°C 
(Figure 4.2). This result is in agreement with previous thermostability studies using CTPR 
proteins of various lengths, which concluded that the stability increases with increasing number 
of repeats,61 but the apparent Tm value was not measured beyond CTPR3. Previous members 
of the Itzhaki group also investigated the apparent Tm values of various CTPR2 constructs, 
with and without loop extension.82 
It is possible that for the larger proteins approximately two repeats undergo unfolding 
at the highest temperatures, since the molar ellipticity of nTBP-CTPR2n at these temperatures 
is similar to the molar ellipticity measured for n-1TBP-CTPR2n-2 at 20°C. These are most likely 
to be the terminal repeats, as they have only one neighbouring repeat to form stabilising inter-
repeat interactions and are therefore less stable than the internal repeats.65,197 
 




Figure 4.2: Thermal denaturation curves of the samples in Figure 4.1, monitored by CD. On the right, 
the figure legend with a schematic representation for each construct. 
 
Following thermal denaturation, the samples were allowed to return to 20°C, and the CD 
spectrum of each construct was re-measured to evaluate the reversibility of the unfolding 
reaction. For all of the proteins, there was no significant difference between the CD spectrum 




Figure 4.3: CD spectra of the proteins before and after thermal denaturation. Far-UV CD spectra of 
1TBP-CTPR2, 2TBP-CTPR4, 3TBP-CTPR6 and 4TBP-CTPR8. All proteins were at 20 μM 
concentration in 10 mM sodium phosphate pH 7.4, 150 mM NaCl, and measurements were made at 
20°C, before (light colour) and after (darker colour) thermal denaturation (TD). 
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4.2.3 Effect of TBP insertions on CTPR folding and stability measured by chemical 
denaturation 
Protein stability was also assessed by chemical-induced denaturation. The aim was to 
investigate the destabilising effect of loop extension and provide a comparison with the CTPR 
counterpart without loops. Although loops have been extended in alternating rather than in all 
inter-repeat interfaces, a smaller, but still measurable destabilising effect is expected, as 
demonstrated in a previous study.146 On the other hand, this assay should also confirm the 
improved stability with increasing numbers of repeats, as observed in the thermal unfolding 
experiment. Chemical-induced denaturation is achieved by incubating proteins with increasing 
concentrations of guanidinium hydrochloride (GdmHCl). GdmHCl is a chaotropic agent and 
one of the strongest protein denaturants, although its mechanism of action is still not fully 
understood. A high-throughput method developed by a previous member of the Itzhaki lab was 
used, which relies on the fast and accurate monitoring of the fluorescence emitted by the 
tryptophan residues (one per repeat) using a microplate reader.153 Tryptophan is an intrinsic 
fluorophore due to its aromatic nature, and its fluorescence emission spectrum is highly 
affected by changes in the microenvironment induced by chemical denaturation. Given its 
simplicity, chemical denaturation is widely used as a highly sensitive technique to assess 
protein stability and thereby to optimise the appropriate formulation conditions for biologics.198 
This method has also been used extensively to investigate the stability of CTPR arrays of 
different lengths.80,146,191 
Similar to the thermal denaturation studies, a single transition between the folded and 
unfolded states was observed for all of the constructs, both the CTPR series and the nTBP-
CTPR2n series. This observation is in agreement with previous chemical denaturation studies 
on CTPR constructs of increasing length.80,146,191 The data were fitted to a two-state model with 
sloping baselines to obtain the midpoints of unfolding (D50%), the slope of the transition (𝑚 
value, a parameter related to the change in solvent-exposure upon unfolding) and the free 
energy of unfolding (Δ𝐺%#&'"( ) (Figure 4.4 and Table 4.1). First, the nTBP-CTPR2n showed an 
expected decrease in the stability compared with their respective counterparts without the TBP 
loops. As shown previously,80 loop insertion has a destabilising effect through both the entropic 
cost of loop closure and a consequent weakened coupling of adjacent repeats. Second, there is 
a significant increase in D50%, m value and Δ𝐺%#&'"(  with increasing number of CTPR units. The 
largest increase in stability is between 1TBP-CTPR2 and 2TBP-CTPR4, whereas for all the 
other nTBP-CTPR2n constructs the increases are much smaller. We do not see the incremental 
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stability increase that characterises the CTPR2, CTPR3, CTPR4 and CTPR6 series. The 
explanation is that 1TBP-CTPR2 has no native inter-repeat interface and the three larger 
proteins have a native CTPR2 interface alternating with the loop-inserted interface and 
therefore the stability does not build up. 
 
 
Figure 4.4: Equilibrium denaturation curves of CTPR and nTBP-CTPR2n proteins monitored by 
fluorescence. Protein concentration was 6-10 μM in 50 mM sodium phosphate pH 6.8, 150 mM NaCl 
at 25ºC. The CTPR proteins with no extended loops were purified and analysed by Dr. Albert Perez-





(kcal mol-1 M-1) 
𝚫𝑮𝑵#𝑼𝑯𝟐𝑶  
(kcal mol-1) 
1TBP-CTPR2 2.57 ± 0.01 1.94 ± 0.05 -4.98 ± 0.13 
2TBP-CTPR4 3.46 ± 0.01 2.33 ± 0.09 -8.06 ± 0.31 
3TBP-CTPR6 3.60 ± 0.01 2.49 ± 0.06 -8.96 ± 0.22 
4TBP-CTPR8 3.65 ± 0.01 2.55 ± 0.07 -9.31 ± 0.26 
CTPR2 2.89 ± 0.02 2.42 ± 0.12 -6.99 ± 0.35 
CTPR3 3.60 ± 0.01 3.06 ± 0.15 -11.02 ± 0.54 
CTPR4 3.90 ± 0.01 3.37 ± 0.13 -13.14 ± 0.51 
CTPR6 4.22 ± 0.01 3.54 ± 0.15 -14.94 ± 0.63 
Table 4.1: Values of D50%, m and Δ𝐺#$%&'(  obtained from a two-state fit with sloping baselines of the 
equilibrium denaturation data. All measurements were performed in triplicate, and the errors listed are 
the SE of the mean. 
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4.2.4 Binding studies between nTBP-CTPR2n constructs and TNKS2 ARC4 measured 
by isothermal titration calorimetry (ITC) 
The TBP loop sequence is a consensus TNKS-binding motif identified by Guettler et al. using 
a peptide library screen.46 The binding affinity of the TBP to TNKS2 ARC4 was measured by 
the same authors and was reported to be 0.6 ± 0.04 μM, and it is expected to bind to the other 
ARC subdomains with a similar affinity.46 The crystal structures of TNKS2 ARC4 in complex 
with diverse TNKS-binding motifs, including 3BP2, show how they all employ an identical 
ARC4:peptide binding mode (Figure 4.5A).46 The same extended and unstructured 
conformation characterises all TNKS-binding peptides, when bound to ARC4 or other TNKS 
ARC subdomains.89,144 
A previous Itzhaki lab member generated a series of macrocyclic variants of the TBP 
peptide using a number of different chemical cross-linkers.85 Macrocyclisation serves to 
constrain the peptide in its bioactive conformation and to make it protease-resistant, for use as 
an inhibitor in the cell. The crystal structure of a macrocyclic peptide, cp4n2m3, in complex 
with TNKS2 ARC4 shows that the peptide does assume an elongated conformation and 
interacts with TNKS2 ARC4 in a similar way to that of the natural peptides (Figure 4.5B).85 
Here we took the same TBP sequence identified by Guettler et al. and grafted onto the 
loop between consecutive CTPR repeats with DPXX linker residues on each side (DPNN 
preceding and DPRS following the TBP loop). To investigate whether the TBP sequence 
constrained in this way is able to maintain its binding properties to TNKS, we wanted to 
measure the binding affinity of each nTBP-CTPR2n construct for TNKS and establish whether 
all of the TBP loops in the multivalent constructs are accessible for binding. To simplify the 
analysis, the binding of each nTBP-CTPR2n construct was measured in the presence of TNKS2 
ARC4 (the fourth ankyrin-repeat cluster of TNKS2), which contains a single binding site for 
the TBP (Figure 4.6A). 
The analysis required first the recombinantly expression and purification of the TNKS2 
ARC4 construct, following a protocol previously established in the lab and described in Section 
2.4.3. The TNKS2 ARC4 construct was expressed as a fusion protein to a N-terminal 
glutathione S-transferase (GST) tag immediately followed by a thrombin cleavage site. The 
GST tag is a quite bulky affinity tag of 211 amino acids (26 kDa) that often promotes greater 
expression and higher solubility of recombinant proteins than expression without a tag. 
Moreover, when adopted as an affinity tag, it enables to reach higher purity rates from affinity 
chromatography compared to less specific tags, such as the His6 tag. 
 




Figure 4.5: Crystal structures of TNKS2 ARC4 binding moieties. (A) Ribbon representation of TNKS2 
ARC4 binding the 3BP2 peptide, with the peptide’s side chains shown in stick representation (PDB: 
3TWR). The five ANK repeats of TNKS2 ARC4 are coloured in shades of red, while the 3BP2 peptide 
is in purple with the side chains coloured by heteroatoms (oxygen in red, nitrogen in blue) and the eight 
residues that constitute the TNKS-binding motif (RSPPDGQS) are labelled. (B) Ribbon representation 
of TNKS2 ARC4 binding the cp4n2m3 macrocyclic peptide, with the peptide’s side chains shown in 
stick representation (PDB: 5BXO). The five ANK repeats of TNKS2 ARC4 are coloured in shades of 
red, and the peptide is in purple with the side chains coloured by heteroatoms (oxygen in red, nitrogen 
in blue) and the eight resides that constitute the TNKS-binding motif (REXGDGXE) are labelled. 
UAA3 and UAA7 correspond to unnatural amino acids required for the cross-linking click reaction. 
Images were created using the software UCSF Chimera. 
 
Batch purification of GST-tagged TNKS2 ARC4 was performed using the Glutathione 
Sepharose 4B resin (Cytiva). This method also allows on beads cleavage of the GST tagged 
protein in the presence of bovine thrombin. Following overnight cleavage, highly pure and 
untagged TNKS2 ARC4 protein could be eluted from the beads, while the GST tag remained 
bound to the Glutathione resin (Figure 4.6B). Experimental evidence from the Itzhaki lab 
showed that the same approach cannot be applied to Ni-NTA beads, further validating the 
choice of the GST tag over the His6 tag for the purification of TNKS2 ARC4. Following affinity 
purification, the protein was further purified by size-exclusion chromatography, with the 
resulting highly purity protein shown in Figure 4.6C. 
 




Figure 4.6: GST-tagged TNKS2 ARC4 purification. (A) Schematic representation of the GST-tagged 
TNKS2 ARC4 construct. The molecular weight of the construct before and after Thrombin cleavage is 
provided. (B) SDS-PAGE gels with lanes corresponding to the fractions collected during affinity 
chromatography (SN: supernatant, FT: flow-through, W: wash, E: elution) (C) Top: gel filtration 
chromatogram obtained when running the sample eluted in A on a HiLoad 16/600 Superdex 75 pg 
column (Cytiva). Bottom: SDS-PAGE gels with lanes corresponding to the eluted fractions of the main 
peak observed in the chromatogram above. 
 
The binding between nTBP-CTPR2n constructs and TNKS2 ARC4 was studied by ITC. This 
technique provides the thermodynamic parameters of interaction in solution, as well as details 
on the stoichiometry of binding, an important consideration in our analysis.199 Depending on 
the nature of the interaction, the instrument measures the amount of heat generated or taken up 
following each injection of ligand into the sample cell containing the binding partner. For these 
experiments, TNKS2 ARC4 was titrated into the cell, containing either one of the nTBP-
CTPR2n constructs or a control (CTPR6 or ITC buffer). A representative dataset obtained by 
ITC is shown in Figure 4.7. 
All nTBP-CTPR2n constructs showed similar low-micromolar affinities (average Kd of 
14 µM), confirming that the binding of the TBP for the target protein is maintained also when 
grafted in the CTPR scaffold. Importantly, the stoichiometry of binding, indicated with N, was 
found to increase in proportion to the number of TBP loops, from one to three, confirming that 
all sites are solvent-exposed and available for binding (Table 4.2). We speculate that the 
stoichiometry for 4TBP-CTPR8 is lower than 4, possibly due to steric hindrance effects 
between multiple TNKS2 ARC4 molecules binding to the same 4TBP-CTPR8 molecule. The 
presence of impurities in the 4TBP-CTPR8 sample might also cause a shift in the value of N, 
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due to the impossibility of accurately measuring the protein concentration. No binding could 
be detected for the control samples, where TNKS2 ARC4 was titrated into the sample cell 
containing the CTPR6 protein with no TBP loops, or simply ITC Buffer. 
 
 
Figure 4.7: ITC measurement, with TNKS2 ARC4 titrated into the main cell containing the indicated 
CTPR constructs or ITC Buffer. Top from left to right: TNKS2 ARC4 (500 µM) into 1TBP-CTPR2 (50 
µM), TNKS2 ARC4 (500 µM) into 2TBP-CTPR4 (25 µM), TNKS2 ARC4 (500 µM) into 3TBP-
CTPR6 (16.6 µM), TNKS2 ARC4 (500 µM) into 4TBP-CTPR8 (12.5 µM). The concentration of nTBP-
CTPR2n was calculated as 50/n, so that the molar ratio between the number of TBP loops and TNKS2 
ARC4 remains constant across the runs. Bottom from left to right: control runs where TNKS2 ARC4 
(500 µM) was titrated into CTPR6 (16.6 µM) or ITC buffer. All experiments were performed at 25ºC. 
A representative ITC dataset is shown. 
 
 
The values of ∆G (Gibbs free energy change), ∆H (enthalpy change) and -T∆S (entropy 
change) obtained for the four nTBP-CTPR2n proteins are listed in Table 4.3 and plotted on the 
right of it. The results show that in all cases the interaction is exothermic (negative ∆H) and 
the negative ∆G is indicative of a spontaneous process, enthalpically driven. It is also possible 
to notice a slight tendency for both the enthalpic gain and entropic cost of binding to increase 
Biophysical characterisation of the CTPR constructs 
 
 85 
with increasing number of TNKS2-binding loops. The increase in enthalpy with increasing 
number of binding loops is to be expected, as having multiple binding sites in close proximity 
should make it more likely for the protein to bind a target again after dissociation. The greater 
entropic cost of ordering a greater number of loops upon binding is also as expected, as they 
are all available for binding. The greater entropic cost is offset by the greater enthalpic gain, 
and hence the value of ∆G is similar for all four nTBP-CTPR2n proteins. 
 
Protein Stoichiometry (N) Kd (µM) 
1TBP-CTPR2 
 
1.01 ± 0.03 
0.90 ± 0.02 
14.68 ± 0.99 
12.80 ± 1.10 
2TBP-CTPR4 
 
2.18 ± 0.02 
2.05 ± 0.01 
11.89 ± 0.26 
18.59 ± 0.39 
3TBP-CTPR6 
 
2.72 ± 0.03 
2.77 ± 0.02 
5.62 ± 0.21 
20.12 ± 0.39 
4TBP-CTPR8 
 
3.38 ± 0.01 
2.91 ± 0.03 
13.61 ± 0.19 
15.48 ± 0.43 
Table 4.2: Stoichiometry (N) and dissociation constant (Kd) obtained by ITC measurements, 
characterising the binding between nTBP-CTPR2n proteins and TNKS2 ARC4. For each protein, the 
values from two independent experiments are listed. 
 






1TBP-CTPR2 -6.60 -6.69 
-15.81 ± 0.73 
-24.87 ± 0.87 
9.21 
18.18 
2TBP-CTPR4 -6.73 -6.47 
-18.35 ± 0.26 
-34.12 ± 0.32 
11.62 
27.65 
3TBP-CTPR6 -7.18 -6.44 
-12.39 ± 0.21 
-35.85 ± 0.37 
5.21 
29.41 
4TBP-CTPR8 -6.65 -6.59 
-25.04 ± 0.21 
-31.44 ± 0.48 
18.39 
24.85 
Table 4.3: Values of the changes in Gibbs free energy (ΔG), enthalpy (ΔH) and entropy (–TΔS) for the 
interactions of the nTBP-CTPR2n proteins with TNKS2 ARC4 obtained by ITC. The values listed are 
from two independent experiments. For each parameter, the average from two independent experiments 
is plotted on the right. 
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4.2.5 Assessment of the oligomerisation states of the CTPR proteins 
The oligomerisation state of some representative CTPR proteins was analysed by size-
exclusion chromatography coupled with multi-angle light scattering (SEC-MALS). SEC-
MALS relies on the separation of proteins according to their size through SEC, followed by 
the oligomerisation analysis of the eluted fractions according to their light scattering potential. 
This method also allowed us to further confirm the protein trimerisation mediated by the foldon 
domain. The analysis was performed on two sets of proteins: 3TBP-CTPR6 and 3TBP-CTPR6-
foldon, CTPR6 and CTPR6-foldon. The four proteins were purified by His affinity 
chromatography, followed by size-exclusion on a Superdex 200 10/300 column. The retention 
volume for each eluted protein on the size-exclusion column can already provide insights into 
the monomeric versus trimeric conformations, due to the difference in molecular weight. Given 
their smaller size, the monomeric 3TBP-CTPR6 and CTPR6 eluted at much higher retention 
volumes than their trimeric counterparts, confirming the trimerisation of their counterparts 
containing the foldon motif. The elution volume of the trimeric CTPR6-foldon remains 
questionable, as it elutes earlier than 3TBP-CTPR6-foldon, despite its smaller molecular 
weight (Figure 4.8). 
 
 
Figure 4.8: Size-exclusion chromatograms. 3TBP-CTPR6 (orange), 3TBP-CTPR6-foldon (green), 
CTPR6 (light blue) and CTPR6-foldon (dark blue) were separately purified by size-exclusion 
chromatography on a S200 10/300 column. 
 
The purified proteins were run over SEC-MALS with the help of Dr. Stephen McLaughlin 
(MRC, LMB, Cambridge). SEC was performed on the same S200 10/300 column and proteins 
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eluted with a similar profile. The column was connected to a MALS detector for direct analysis 
of each eluted fraction. The SEC-MALS results demonstrate that 3TBP-CTPR6 and 3TBP-
CTPR6-foldon are monodispersed in solution (Figure 4.9 top). The mass for 3TBP-CTPR6 
(30.0 kDa calculated molecular weight) is 40.2 kDa at the beginning of the peak, with the 
trailing edge having a mass of 31.6 kDa, resulting in a peak average molecular weight of 38.4 
kDa, consistent with the protein being monomeric. The vast majority of the 3TBP-CTPR6-
foldon sample (105.6 kDa calculated molecular weight as a trimer) elutes at an average 
molecular weight of 130.6 kDa, consistent with it forming a trimer with some less-populated 
oligomerisation species at lower and higher molecular weight also present (99.3, 203.5 and 
320.8 kDa, respectively). The results for CTPR6 and CTPR6-foldon constructs, instead, 
indicate dimerisation for both proteins under the same experimental conditions (Figure 4.9 
bottom). The molecular weight observed for CTPR6 (expected molecular weight 26.2 kDa) at 
the beginning of the peak is 49.6 kDa and 30.7 kDa at the trailing edge, leading to an average 
molecular weight of 44.3 kDa. The result might indicate a fast-exchanging equilibrium between 
the monomer and the dimer form under these experimental conditions. The vast majority of the 
CTPR6-foldon sample (94.0 kDa calculated molecular weight as a trimer) elutes at an average 
molecular weight of 370.2 kDa, corresponding to the mass of four CTPR6-foldon trimers (94.0 
x 4 = 376.0 kDa). This oligomerisation product is achievable when each CTPR6 of a trimer 
molecule interacts with a CTPR6 of another trimer, consistent with the monomeric CTPR6 
being instead mostly dimeric. Less-populated oligomerisation species for the CTPR6-foldon 
sample elute with a mass of 543.0, 234.8 and 132.8 kDa. The gel filtration was repeated at a 
10-fold lower concentration of CTPR6-foldon, and the distribution of masses was found to be 
the same (Figure 4.9 bottom). 
 




Figure 4.9: SEC-MALS analysis of 3TBP-CTPR6, CTPR6 and their trimeric counterparts. The total 
protein concentration was 2.2 mg/mL for 3TBP-CTPR6, 1.7 mg/mL for 3TBP-CTPR6-foldon, 2.3 
mg/mL for CTPR6 and 6.6 mg/mL for CTPR6-foldon. A schematic representation of the constructs 
used is provided below the corresponding graph. 
 
4.2.6 X-ray crystallography studies 
Interest in determining the structure of a representative nTBP-CTPR2n construct led us to 
investigate the possibility of crystallising these constructs. X-ray crystallography is a powerful 
technique that allows protein structure determination at high resolution. Protein crystallisation 
remains a challenging method, as not all proteins can form crystals, and it is impossible to 
predict whether or not a protein will crystallise and the crystallisation conditions required. If 
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successful, the 3D structure of a nTBP-CTPR2n protein, on its own or in complex with TNKS2 
ARC4, would provide insights into the conformation and orientation of the TBP loop under the 
two sample conditions. Moreover, it would allow us to identify any conformational changes in 
the inter-repeat interface induced by the loop extension. The feasibility of x-ray crystallography 
for this project was supported by the fact that multiple crystal structures of CTPR molecules 
have already been published, as well as those of the TNKS2 ARC4 subdomain in complex with 
the TBP peptide, including the one obtained by our lab.46,61,64,66,85 Moreover, the high 
expression levels and high purity obtained for the nTBP-CTPR2n proteins and TNKS2 ARC4 
are ideal starting points for crystallography. However, the presence of an unstructured loop 
might represent an element of instability for the initiation of crystal packing, thereby preventing 
crystallisation. Initial unsuccessful attempts at crystallisation using His-tagged 2TBP-CTPR4 
in the presence or absence of TNKS2 ARC4 led us to re-evaluate the optimal construct design 
for crystallisation.  
Several factors were considered with the aim of maximising the chances of success: 
1. Given the loss in stability observed due to the grafted loop, as well as its unstructured 
nature, the number of TBP loops was reduced to one. 
2. Stability can be enhanced by adding more CTPRs, with a big increase observed when 
the number of repeats is increased from two to four, and the single TBP loop should be 
introduced at an inter-repeats interface located in the middle of the CTPR protein rather 
than at a terminal repeat. 
3. Protein tags need to be removed. 
4. Most of the previously crystallised CTPR constructs include a C-terminal “solvating” 
helix.61,64 The solvating helix is a variant of helix A, with four solvent-exposed 
hydrophobic residues mutated into polar or charged amino acids (two lysine and two 
glutamine residues), and it has been shown to enhance the solubility of the CTPR 
proteins (Figure 4.10).61 
5. The TBP loop represents a flexible element that consequently might not be visible in 
the crystal structure. In complex with TNKS2 ARC4, the TBP loop is likely to become 
more rigid and would be resolved, and therefore it was decided to attempt 
crystallography of a TBP-CTPR protein in complex with TNKS2 ARC4. 
6. High protein purity and high protein concentration are required. To minimise the 
formation of recombination products during cloning and protein expression, the DNA 
sequence encoding each repeat was maximally differentiated, where possible. 




Figure 4.10: Solvating helix. (A) Protein sequence alignment between a CTPR helix A and the 
solvating helix. Each mutated residue is indicated by an arrow and numbered. (B) Ribbon structure of 
the CTPR2-Solvating Helix protein obtained by Main et al.61 The CTPR repeats are coloured in pale 
yellow, the solvating helix is in goldrod. The side chains of the mutated residues are shown and labelled 
(PDB: 1NA3). The image was generated using the software UCSF Chimera. 
 
With these considerations in mind, a new protein construct was designed to fulfil the 
requirements detailed above and was named 1TBP-CTPR4-SolvH (protein sequence available 
in the Appendix B). It consists of four CTPRs (with identical amino acid sequence, but 
diversified at the DNA level), a TBP loop located in the central inter-repeat interface and a C-
terminal solvating helix, as graphically represented in Figure 4.11A. The construct was fused 
to a N-terminal GST tag followed by a thrombin recognition sequence to allow on-beads 
cleavage of the protein and achieve a higher sample purity by GST affinity purification 
compared to His affinity chromatography (Figure 4.11A). GST-tagged 1TBP-CTPR4-SolvH 
was purified by affinity chromatography on GST beads and eluted by O/N thrombin cleavage 
on beads (Figure 4.11B). Despite the abundance of uncleaved product still bound to the resin, 
the amount of untagged, cleaved protein collected in the eluted fractions was sufficient to 
proceed with the purification. The protein was therefore further purified by gel filtration on a 
Superdex 75 16/600 column, which successfully separated the protein from all the higher 
molecular weight contaminants (Figure 4.11C). Figure 4.11C also provides a comparison 
between the chromatograms of 1TBP-CTPR4-SolvH and 2TBP-CTPR4, a CTPR construct of 
similar size (therefore eluting at a similar retention volume). It is worth noting how the peak 
shape differs in the two chromatograms: the presence of the solvating helix improves the 
elution profile of the protein, probably by preventing unspecific binding to the column. The 
elution peak of 1TBP-CTPR4-SolvH is indeed more symmetrical and does not show the 
trailing tail that instead characterises the 2TBP-CTPR4 chromatogram. 




Figure 4.11: 1TBP-CTPR4-Solvating Helix purification. (A) Schematic representation of the GST-
tagged 1TBP-CTPR4-SolvH construct. The molecular weight of the construct before and after 
Thrombin cleavage is provided. (B) SDS-PAGE protein gel with lanes corresponding to different 
fractions collected throughout the GST affinity chromatography (Total: total lysate, SN: supernatant, 
FT: flowthrough, W: wash, E: elution, Beads: bead sample after O/N thrombin cleavage). (C) Size-
exclusion chromatogram of the untagged 1TBP-CTPR4-SolvH (blue) over a Superdex 75 16/600 
column and SDS-PAGE protein gel with lanes corresponding to fractions of the eluted peaks. A 
comparison with the size-exclusion chromatogram of 2TBP-CTPR4 diluted 1:5 (orange, same as in 
Figure 3.9A) is provided. 
 
The protein was concentrated to 35.7 mg/mL, and crystal screening was performed at the 
Crystallographic X-ray Facility (Department of Biochemistry, University of Cambridge). 
Protein sample was dispensed at 1:1 and 2:1 protein:buffer dilutions onto a variety of 
crystallisation plates covering a broad range of buffers and precipitants. Despite the very high 
protein concentration, the high solubility of the CTPR scaffold, further enhanced by the 
presence of the TBP loop and the solvating helix, might have prevented crystal formation, as 
all drops look clear with no evidence of precipitation even after months. 
In order to determine the crystal structure of the protein complex, the latter was induced 
by incubating 1TBP-CTPR4-SolvH in the presence of a molar excess of untagged TNKS2 
ARC4 (1:3). The sample was run on a Superdex 75 gel filtration column, which successfully 
separated the complex (corresponding to the first eluted peak, pink chromatogram) from the 
TNKS2 ARC4 molecules in excess (corresponding to the second peak, pink chromatogram 
Figure 4.12). The protein complex, given its higher molecular weight, eluted earlier than the 
single components (Figure 4.12 top). It is worth noting how, despite the weak binding affinity 
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between the TBP loop and TNKS2 ARC4 (Kd of 14 μM), the complex remained intact through 
the gel filtration column without the need of chemical cross-linking. 
 
 
Figure 4.12: TNKS2 ARC4:1TBP-CTPR4-SolvH complex purification. (Top) Comparison between 
the size-exclusion chromatogram traces of TNKS2 ARC4 (blue), 1TBP-CTPR4-SolvH (orange) and 
the protein complex formed between the two (purple) run over a Superdex 75 16/600 column. (Bottom) 
SDS-PAGE protein gel with lanes corresponding to the peak fractions eluted from the protein complex 
run. While the fractions from the first peak contain both proteins (left-hand side of the protein gel), the 
fractions from the second peak comprise the TNKS2 ARC4 in excess (right-hand side of the protein 
gel). 
 
The complex was concentrated to 28.0 mg/mL and crystal screening was performed by 
dispensing the protein sample at 1:1 and 2:1 protein:buffer dilutions on the same set of 
crystallisation plates as before. Compared to the 1TBP-CTPR4-SolvH crystal plates, a higher 
rate of precipitation was observed in these wells; however no crystals could be detected. 
 
4.3 Discussion 
In this Chapter, the biophysical properties of the engineered CTPR proteins were characterised. 
As previously observed with other grafted loop peptides,80,146 the grafted TBP did not affect 
the overall fold of the CTPR repeats, and by increasing the number of repeats a stabilising 
effect was obtained. To assess their binding properties, ITC experiments were performed. To 
simplify the analysis, a TNKS2 construct with only one binding site for TBP was used (TNKS2 
ARC4). The study had indeed the purpose to evaluate the binding capacity of the grafted loop, 
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when present in one or more copies. The results obtained from the ITC studies confirmed our 
hypothesis that grafting the TNKS-binding sequence between consecutive repeats with 
sufficient flanking “linker” residues enables this peptide to maintain its binding-competent 
conformation. This is a noteworthy result, considering that the TBP loop binds to the ARC4 
subdomain in an extended conformation,85 and loop grafting might impose a structural 
constriction on the TBP that would weaken its binding affinity. This constriction, however, 
might explain the lower affinity of binding observed for the grafted TBP, compared to its 
peptide counterpart, to the same target. Altogether, this result consolidates our confidence in 
the broad applicability of this grafting approach, as we believe it can be applied to display a 
great variety of non-helical SLiMs in very different binding conformations. Thus, the Keap1-
binding peptide from Nrf2 adopts a turn-like conformation that appears ideal for grafting onto 
the CTPR inter-repeat loop,82 but peptides binding in an extended conformation, such as the 
TBP, can also be successfully grafted. 
The ITC studies in the presence of a multivalent nTBP-CTPR2n construct where n>1 
showed that all the TBP loops are accessible for binding to TNKS2 ARC4. This result lays the 
foundation for the development of multivalent or multispecific CTPR arrays. This result has 
important implications: not only can multivalency be achieved by displaying multiple copies 
of a binding peptide for the same target molecule, but also different targets could potentially 
be recruited on a hetero-bifunctional CTPR construct displaying different binding peptides 
(Chapter 9). A deeper insight into the binding properties of the TBP-CTPR constructs is 
therefore explored in Chapters 5, 6 and 9. 
Lastly, we aimed to determine the structures at atomic resolution using X-ray 
crystallography. Unfortunately, no crystals were formed. As it has been observed in the crystal 
lattice of previously crystallised CTPR constructs, crystal formation requires the tight packing 
of CTPR superhelices in all directions.64,66 The presence of the TBP loop might disrupt the 












Intracellular interaction between nTBP-CTPR2n and TNKS2 
 
5.1 Introduction 
The ITC experiments described in Chapter 4 confirmed the binding interaction between the 
nTBP-CTPR2n constructs and TNKS2 ARC4. The first step towards functional cellular-based 
assay is to determine whether this interaction is maintained in a cellular environment, where 
many other factors, such as the presence of TNKS substrates with which the grafted loop needs 
to effectively compete, TNKS distribution in the cell and different microenvironments come 
into play. To answer this question, a cell-based assay was established, as described in this 
Chapter. 
 
5.1.1 Experimental design 
The simplest and fastest method to verify intracellular protein-protein interactions is by 
immunoprecipitation (IP) under native conditions. IP relies on the isolation of an antigen (here 
TNKS) from the cellular lysate through its binding to a protein bait (nTBP-CTPR2n), itself 
bound to an affinity resin. In our system, the nTBP-CTPR2n bait is expressed with a C-terminal 
HA tag, which allows sedimentation of the protein-protein complex of interest upon 
recognition by an anti-HA antibody coupled to a matrix. Following a series of sample washes 
to reduce unspecific protein-protein interactions, the composition of the protein complex on 
the surface of the matrix can be analysed by SDS-PAGE electrophoresis or, more specifically, 
by Western Blot using antibodies recognising the bait and the target of interest. 
A series of considerations were assessed in order to apply this assay to our system. 
First, the method requires the presence of both the protein bait (HA-tagged nTBP-CTPR2n) and 
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its substrate (TNKS1 and TNKS2) within a cellular environment. Following cell lysis, the 
protein complex can be pulled-down by binding to the anti-HA resin. HA-tagged nTBP-CTPR2n 
can be expressed in the cell by transfection of the mammalian expression vector. Given the 
high transfection efficiency of HEK293T cells and their greater ease of in vitro culturing 
compared with other cell lines, these cells were selected for this experiment. Moreover, as the 
amount of endogenous, intracellular, soluble TNKS within HEK293T cells is unknown and 
might be insufficient for detection by Western Blot, a plasmid encoding the full-length TNKS2 
was also transfected to enhance the intracellular TNKS2 protein levels and thereby facilitate 
its detection. To further facilitate TNKS2 detection following pull-down, the TNKS2 protein 
was expressed as a fusion protein with a different tag than the HA tag, which is already used 
for the bait protein. The need of a tag for TNKS2 is further motivated by the lack of highly 
specific anti-TNKS antibodies, as proven by our early attempts at Western Blot using a number 
of different commercial primary antibodies that failed to detect TNKS1/2 specifically (data not 
shown). To overcome this problem, the full-length TNKS2 gene was cloned in frame with an 
N-terminal HiBiT-tag in the pcDNA3.1(-) mammalian expression vector, for specific 
recognition. 
 
5.1.2 The HiBiT tag 
The HiBiT tag is an innovative, proprietary reporter tag developed by Promega. In 2012, the 
company published the development of a novel luciferase, named NanoLuc, smaller in size (19 
kDa), more stable, ATP independent and >150-times brighter than traditional firefly and 
Renilla luciferases, the two most frequently adopted luciferases, among others. NanoLuc was 
derived from the catalytic domain of a deep-sea shrimp Oplophorus gracilirostris luciferase 
and engineered by structural optimisation with three mutagenesis rounds.200,201 The NanoLuc 
substrate, coelenterazine, was also optimised into an improved analogue, called furimazine, 
which is more stable and generates a higher and longer-lasting luminescent signal.200 As a 
result of these favourable properties, NanoLuc has become quickly the preferred tool in several 
luminescent-based biomedical research applications.201 
The structure of NanoLuc consists of a 10-stranded ß-barrel and a “lid” domain 
composed of three α-helices (PDB 5IBO, Figure 5.1). Taking advantage of its small size, 
Promega proceeded with the development of the NanoLuc® Binary Technology (NanoBiT), a 
structural complementation reporter system relying on the split of the NanoLuc luciferase 
between the 9th and 10th strand of the ß-barrel. NanoLuc is therefore split into a larger (LgBiT) 
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and a smaller (SmBiT) fragment, that bind to each other with very low binding affinity.202 The 
two complementing fragments were further evolved for improved solubility, function and 
binding affinity. HiBiT corresponds to the evolved, smaller fragment that binds the larger 
LgBiT with much higher affinity (Kd = 0.7 x 10-9 M) than the natural peptide (Kd = 0.9 x 10-6 
M).203 Upon binding to LgBiT, HiBiT complements the ß-barrel to reconstitute the full-length 
and functional luciferase (Figure 5.1). 
 
 
Figure 5.1: Schematic representation of the NanoLuc enzymatic reaction. NanoLuc converts 
furimazine in the presence of O2 into furimamide and releases CO2 and light. The structure of the 
NanoLuc enzyme is shown (PDB 5IBO), with the light blue ß-strand corresponding to the HiBiT 
sequence. The NanoLuc image was generated using the software UCSF Chimera. 
 
The HiBiT tag can therefore be used as a small, 11-amino acid (VSGWRLFKKIS) peptide tag, 
that is unstructured in solution. Given its small size, the risk of its interference with a protein’s 
normal function and structure is minimised, unlike for other bulky reporter tags. For the same 
reason, the HiBiT tag is the ideal candidate for CRISPR/Cas9 genome editing of endogenous 
proteins, as it can provide a higher insertion rate than other larger reporters.203 When HiBiT, 
the large LgBiT subunit and the furimazine substrate are present, the reconstituted NanoLuc 
emits a luminescence signal proportional to its protein amount.203 The HiBiT tag, therefore, 
provides an unambiguous and quantitative method of correlating the luminescent signal with 
the concentration of the HiBiT fusion. Moreover, bioluminescence is more sensitive than 
fluorophore-based methods, therefore allowing the detection of extremely low protein levels 
(up to 1 amol).203 Therefore, the split-NanoLuc luciferase technology represents an easy and 
sensitive alternative to detect and quantify the amount of HiBiT-tagged protein.203 Once the 
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NanoLuc is reconstituted, the luminescence readout can be measured using a microplate 
luminometer (under the appropriate settings) or by HiBiT blotting. The microplate reader 
allows extremely fast, quantitative and high-throughput measurements, as multiple samples 
can be processed within a few minutes. HiBiT blotting is, instead, an innovative Promega 
technology similar to Western Blot, where the large NanoLuc subunit replaces the primary and 
the secondary antibodies for the HiBiT tag recognition on a transfer membrane and generates 
a luminescent signal once bound to it. 
 
5.1.3 HiBiT-qIP method 
By combining the IP method with the split-NanoLuc technology, I developed a new method, 
named “HiBiT-based quantitative immunoprecipitation (HiBiT-qIP)”, which allows a fast, 
high-throughput, quantitative (q) and highly specific detection of any HiBiT-tagged protein of 
interest throughout each stage of the IP protocol, without the need of antibodies and laborious 
Western Blot procedures. Here, the method allowed the real-time detection of the HiBiT-
tagged TNKS2 construct throughout each step of the IP. As shown in Section 5.2.3, the HiBiT-
tagged protein could be detected in the cell lysate, in the unbound and washes samples, as well 
as onto the resin, therefore circumventing the need of eluting the protein complex from the 
beads. A schematic representation of the constructs designed for this assay and the HiBiT-qIP 
method is provided in Figure 5.2A and B, respectively. A similar HiBiT-qIP method has been 
also developed by Ranawakage et al., but for a different application, as it is used for antibody 
affinity determination in the presence of purified, HiBiT-tagged epitope.204 




Figure 5.2: Schematic representation of the HiBiT-qIP method. (A) Schematic representation of the 
two constructs transfected into HEK293T cells, N-terminal HiBiT-tagged TNKS2 and C-terminal HA-
tagged 3TBP-CTPR6. (B) In the HiBiT-qIP method, the HEK293T cell lysate is incubated with anti-
HA resin to immunoprecipitate the HA-tagged bait. Washes allow the clearance of all the other proteins 
not binding to the resin. The presence of HiBiT-tagged TNKS2 is detected directly on beads by 
measuring the luminescence generated by the reconstituted NanoLuc luciferase. 
 




5.2.1 Molecular biology using the pcDNA3.1(-) vector 
The immunoprecipitation method described above requires transfection into HEK293T cells 
of a mammalian expression vector encoding for the protein baits of interest fused with the 
appropriate epitope tag. For this purpose, the in-house variant of the commercially available 
pcDNA3.1(-) vector (Thermo Fisher) was chosen, which allows C-terminal HA tagging of 
recombinant proteins. For the immunoprecipitation assay, the 3TBP-CTPR6 and CTPR6 
constructs were subcloned into this vector. 
5.2.2 Molecular biology using the HiBiT-pcDNA3.1(-) vector 
A variant of the mammalian expression vector pcDNA3.1(-) including a N-terminal HiBiT tag, 
named HiBiT-pcDNA3.1(-), was initially generated to facilitate the production of HiBiT-
tagged TNKS2 gene constructs. Round-the-Horn site-directed mutagenesis (as described in 
Section 2.3.4) was, therefore, applied to insert the HiBiT encoding DNA sequence immediately 
downstream the ATG start codon. Moreover, as recommended in the Promega Nano-Glo 
HiBiT Lytic Detection System Technical Manual,145 the N-terminal HiBiT tag was designed 
to be followed by a 6-amino acid linker region (GSSGGS), providing flexibility and distance 
between the HiBiT tag and the protein of interest, to facilitate accessibility and recognition 
between HiBiT and LgBiT. The newly generated vector was named HiBiT-pcDNA3.1(-). As 
for the parental pcDNA3.1(-) vector, conventional restriction digestion and ligation was 
adopted using the unique restriction sites BamHI and EcoRI. Due to the size of the full-length 
TNKS2-encoding gene (3507 bp) and the presence of additional EcoRI sites within the DNA 
sequence, cloning was particularly challenging. After few attempts, the TNKS2-encoding gene 
was successfully fused in frame with the HiBiT tag and the linker region. Finally, as the HiBiT-
pcDNA3.1(-) vector also induces C-terminal HA tagging, an additional Round-the-Horn site-
directed mutagenesis step was required to introduce a stop codon immediately upstream of the 
HA tag sequence. The presence of the HA tag on TNKS2 would otherwise compromise the 
correct outcome of the immunoprecipitation procedure, which relies on the HA-tagged bait for 
pull-down. 
 
5.2.3 nTBP-CTPR2n proteins and TNKS2 interact in the cell 
Intracellular complex formation between HiBiT-tagged TNKS2 and nTBP-CTPR2n was 
confirmed using the HiBiT-qIP method described above. HA-tagged 3TBP-CTPR6 (chosen as 
representative of the linear nTBP-CTPR2n array) was used as bait to pull-down the HiBiT-
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tagged TNKS2 using an Anti-HA resin. In the control samples, CTPR6 or the empty 
pcDNA3.1(-) vector (expressing the HA tag only) were used instead. HEK293T cells were co-
transfected with two plasmids, encoding the HiBiT-tagged TNKS2 and one of the bait proteins. 
After 48 h incubation, the presence of HiBiT-tagged TNKS2 was followed and quantified 
throughout the IP process, by measuring the luminescence signal generated by the reconstituted 
NanoLuc luciferase. At each stage of the IP protocol, a small aliquot was saved for 
measurement on the microplate reader, allowing the real-time detection of the pulled-down 
target. With a conventional IP method, in contrast, the user has to wait until the Western Blot 
membrane is developed (1-2 days) before knowing the outcome of the assay. The split-
NanoLuc technology, therefore, not only simplifies the analysis process, but also allows a faster 
and more quantitative measurement than Western Blot. 
Similar levels of HiBiT-tagged TNKS2 were observed in the cell lysate, as well as in 
the unbound fraction of all the three samples. The amount of HiBiT-tagged TNKS2 then 
progressively reduced at each washing step and a luminesce value corresponding to 
background noise could be measured in wash 4 and wash 5, confirming that the resin had been 
thoroughly washed. Elution of the HA-tagged bait from the resin failed after incubation with 
the HA peptide. As an alternative, a small amount of resin was incubated with the Nano-Glo 
HiBiT Lytic Detection System buffer containing LgBiT and the substrate. By doing so, the 
measured luminesce readout is generated by the HiBiT-tagged TNKS2 still bound to the resin 
through the bait. The luminescent signal obtained from the resin samples confirmed that HiBiT-
tagged TNKS2 was pulled-down only by 3TBP-CTPR6, and not by the control CTPR6 
construct and the HA peptide expressed by the empty vector. This evidence is in agreement 
with the previous ITC binding studies and, moreover, it confirms that the grafted TBP loop 
mediates the binding to full-length TNKS2 within the cellular environment (Figure 5.3). 
Moreover, non-specific binding of HiBiT-tagged TNKS2 to the Anti-HA Agarose resin was 
not detectable, as the luminesce readout of the resin for the two control samples is comparable 
to background noise (Figure 5.3). This result confirms that the pulled-down protein complex 
can be detected directly onto the resin when using the new HiBiT-qIP method. 
 




Figure 5.3: HiBiT-tagged full-length TNKS2 protein levels measured by luminescence intensity 
throughout each step of the HiBiT-qIP method. IP was performed in the presence of HA-tagged 3TBP-
CTPR6, CTPR6 or an empty vector expressing the HA tag only. Averaged values and error bars 
corresponding to the standard deviation from two independent biological replicates are shown.  
 
Elution of the proteins bound to the resin was then achieved by adding loading dye containing 
SDS. The HiBiT-qIP results were further validated by Western Blot and Nano-Glo HiBiT 
blotting (Figure 5.4). The transfer membrane was cut into three parts to evaluate the presence 
of tubulin and HA-tagged baits by traditional Western Blot and HiBiT-tagged TNKS2 by 
Nano-Glo HiBiT blotting. The detection of tubulin was used to confirm that the initial cellular 
content (SN of the cell lysate) is comparable between the treatments. Unexpectedly, tubulin 
was also present in the elution samples, suggesting that it binds non-specifically to the resin, 
and mostly to the one incubated with “Empty vector” cell lysate having no bait protein 
occupying the surface. An anti-HA primary antibody was instead used to verify the correct 
expression of the bait protein and its binding to the Anti-HA resin. The anti-HA blot shows 
that the recombinant protein amounts of HA-tagged 3TBP-CTPR6 are much higher than those 
of the HA-tagged CTPR6 construct (consistent with other results shown in Chapter 7). Upon 
binding to the resin, both proteins get concentrated on its surface, explaining the higher 
intensity of the two bands in the “Elution” samples. Finally, Nano-Glo HiBiT blotting proved 
that HiBiT-tagged TNKS2 was correctly expressed as a fusion protein of 129 kDa in size. It 
was also expressed in similar amounts in all the samples tested, less in 3TBP-CTPR6 as 
observed also in Figure 5.3. Nano-Glo HiBiT blotting further confirmed that HiBiT-tagged 
TNKS2 was pulled-down only when 3TBP-CTPR6 was used as bait (Figure 5.4). 





Figure 5.4: Complementary HiBiT-qIP analysis performed by Nano-Glo HiBiT blotting and 
conventional Western Blot on the samples in Figure 5.3. For each treatment, the supernatant (SN), the 
final wash (Wash5) and the Elution samples are shown. All blots were obtained from the same transfer 
membrane, divided into three parts as indicated. 
 
5.3 Discussion 
In this Chapter, the development of an innovative and antibody-free HiBiT-qIP method was 
described. The method combines for the first time the IP process with the HiBiT split-NanoLuc 
technology. This technique is particularly useful to detect any protein target for which a 
specific antibody is still unavailable, as is the case for TNKS1 and TNKS2. The only 
requirement is the addition of a HiBiT tag at one or the other end of the protein of interest, 
through conventional molecular biology applications or by CRISPR/Cas9. In the latter, the 
endogenous protein is tagged, to achieve a more accurate measurement and preventing 
transfection in difficult-to-work cell lines. The HiBiT-qIP technique allowed the real-time 
tracking of the HiBiT-tagged TNKS2 construct throughout the IP process, when it was present 
in solution, as well as bound to the Anti-HA resin. The method confirmed that the TBP loop 
within the CTPR scaffold can bind to full-length TNKS2 in the cellular environment. Until 
now and in the literature, the binding of the TBP peptide to TNKS proteins had only been 
assessed using purified proteins and with a small fragment of TNKS2 (TNKS2 ARC4).46,85 The 
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results obtained here, therefore, extend the TBP binding properties to the full-length TNKS 
and in a cellular environment. Moreover, given the high sequence homology between TNKS1 
and TNKS2, it is reasonable to assume that the nTBP-CTPR2n constructs can interact with both 
TNKS homologue proteins. 
Western Blot and Nano-Glo HiBiT-blotting were also performed in support of the 
HiBiT-qIP results. The Nano-Glo HiBiT-blotting allows the sensitive detection of HiBiT-
tagged proteins separated according to their molecular weight. It therefore confirmed that the 
complex was formed between 3TBP-CTPR6 and full-length HiBiT-tagged TNKS2, and that 
no TNKS2 degradation products are present. Despite transfecting cells with identical amounts 
of plasmid DNA, different levels of 3TBP-CTPR6 and CTPR6 protein were observed in the 
samples, according to the anti-HA blot. The same variability was also observed in other 
experiments described in Chapter 7, and a potential explanation for this observation is 
provided. 
To conclude, the results obtained by HiBiT-qIP set the basis for investigating in greater 
detail the binding of the engineered TBP-CTPR proteins to TNKS in the cell (Chapter 6), as 
well as the functional effects of the TBP-CTPR proteins on endogenous TNKS activity in the 
















In biology, multivalency plays a great role in diverse processes: from extracellular 
carbohydrate-lectin and antibody-receptor binding, to various intracellular signalling event, 
RNA metabolism and chromatin organisation, multivalency orchestrate the formation of 
complexes with specific properties and functional outcomes.4 Multivalency has been mostly 
studied in the contest of extracellular ligands. More recently, the effects of multivalency on 
intracellular proteins has been explored, where interacting systems are often characterised by 
modest affinity but high valency, with binding sites connected by long and flexible linkers to 
facilitate the interaction. Of particular interest in recent years has been the role of multivalent 
interactions in the formation of cross-linked networks and liquid-liquid phase separation, as 
observed in so-called membraneless organelles or biomolecular condensates.205–207 TNKS is 
itself a multivalent protein due to its multiple substrate-binding sites (the ARC domains) and 
indeed one of its substrates, Axin, engages with TNKS through two TNKS-binding peptides 
connected by a flexible linker.144 
Looking more closely into the mechanism of binding, when two multivalent protein 
binders, both having more than one binding site, interact with each other in solution, they have 
the potential to engage according to the two modalities shown schematically in Figure 6.1. 
Scenario A represents avidity of binding, which can be achieved when multiple binding events 
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occur between the same two protein molecules. Avidity requires complementarity in terms of 
spacing and orientation of the multiple binding sites in the two interacting molecules. This 
binding mechanism is what characterises the 1:1 interaction between TNKS and Axin189 and 
in nature, as well as in drug development, is what allows to convert a low-affinity ligand into 
a high-avidity one. Scenario B represents the formation of a macromolecular complex being 
generated when both proteins interact with more than one binding partner and are both present 
in high concentration, leading to the formation of an extended, clustered network of molecules. 
This scenario has been found to be extremely frequent among biological interactions, in 
particular those involving multivalent proteins with intrinsically disordered regions.208,209 
These macromolecular structures have also been shown to undergo a collapse transition, where 
the interacting partners precipitate into a globule and convert into a membraneless organelle. 
This process is also known as liquid-liquid phase separation and can occur under specific 
conditions and concentrations.210,211 This type of high-order assembly formation is not an 
undesired consequence of the failure to form 1:1 interactions as in Scenario A, but rather it 
enables proper functioning by cellular sub-compartmentalisation. New examples of functional 
liquid-liquid phase separations are discovered every year, but the problem of how to drug them 
remains unsolved. 
 
6.1.1 Multivalent interactions between the CTPR constructs and TNKS 
In our system, the linear and trimeric TNKS-binding CTPR constructs, as well as the target, 
are both multivalent (except for 1TBP-CTPR2) and they have the possibility to engage 
according to the two modalities of binding described above (Figure 6.1). 
 
 
Figure 6.1: Different modalities of multivalent binding between full-length, multivalent TNKS2 and 
3TBP-CTPR6 (chosen as representative construct of our multivalent array). (A) Schematic 
representation of avidity, with multiple binding events (dashed lines) occurring between the same two 
molecules (B) Schematic representation of a macromolecular complex being formed by the two proteins 
engaging simultaneously with multiple partner molecules. 
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The multivalent linear and trimeric CTPR constructs studied here were not designed to 
accurately match the multiple substrate-binding sites present on the ARC1-5 subdomains of 
TNKS. This is due to the fact that there is no high-resolution structure of the entire ARC1-5 
domain of TNKS1 or TNKS2 to guide a structure-based design of a matching multivalent 
CTPR construct. Moreover, the conformation of the entire ARC1-5 domain is likely to be quite 
flexible, as proven by the SAXS data89 and the impossibility of forming protein crystals. For 
this reason, the multivalent array described here was designed by simply joining multiple TBP-
CTPR units to each other, rather than spacing the TBP loops according to the distance between 
TNKS ARC subdomains. Overall, it was thought as an initial proof-of-concept study for the 
design of multivalent CTPR constructs against a target that is itself multivalent. Although 
avidity of binding remains a possibility especially in the TBP-CTPR-foldon constructs, where 
several binding combinations are possible, we believe that the multivalent constructs are more 
likely to interact according to scenario in Figure 6.1B. We tested this hypothesis by using a 
number of different approaches, applied both in the test tube and in cell-based assays, and 
compared the behaviour of single- and multivalent CTPR constructs in the presence of 
multivalent TNKS constructs. 
 
6.2 Results 
6.2.1 Multivalent TNKS2 construct design and purification 
The ITC experiments described in Chapter 4 confirmed the binding interaction between the 
nTBP-CTPR2n constructs and the single-valent TNKS2 ARC4 subdomain. However, to study 
the effect of multivalency on the complex formation, a TNKS2 construct comprising more than 
one ARC subdomain had to be generated. For this purpose, two TNKS2 ARC1-5 constructs 
comprising all five consecutive ARC subdomains (residues 2-797) were cloned, with either a 
GST tag or a His6 tag to aid protein purification. A His6-tagged TNKS2 ARC1-5 construct has 
been successfully purified previously by Eisemann et al.89 According to the large-scale protein 
expression test and in agreement with previous findings,89 the His6-tagged TNKS2 ARC1-5 
construct was expressed in higher amounts compared to the GST-tagged counterpart (Figure 
6.2). It was therefore decided to proceed with the purification of the His-tagged TNKS2 ARC1-
5 construct, which has four binding interfaces (ARC1, ARC2, ARC4 and ARC5) for TBP 
(Figure 6.3A). 




Figure 6.2: Large scale expression test of the GST- and His-tagged TNKS2 ARC1-5 constructs. SDS-
PAGE protein gel with lanes corresponding to bacterial lysates before (-) and after (+) induction of 
protein expression by IPTG. The expression levels of the two indicated constructs are compared.  
 
 
The first step of purification by HisTrap chromatography did not effectively purify TNKS2 
ARC1-5, and many contaminants were still present in the eluted fractions (Figure 6.3B). 
Further purification steps by ion-exchange chromatography (unsuccessful, not shown) and gel 
filtration (Figure 6.3C) also failed to separate the protein of interest from the contaminants. In 
particular, two bands with a slightly lower molecular weight than His6-TNKS2 ARC1-5 (about 
55 kDa and 65 kDa) are visible throughout the purification steps and in the final samples eluted 
from gel filtration. Given the high band intensity of these proteins, it is likely that they 
correspond to degradation products of His6-TNKS2 ARC1-5. 
 




Figure 6.3: Purification of His6-tagged TNKS2 ARC1-5. (A) Schematic representation of the His6-
tagged TNKS2 ARC1-5 construct compared to the full-length TNKS2 protein. (B) SDS-PAGE protein 
gel with lanes corresponding to different fractions collected throughout the HisTrap affinity 
chromatography. Total: total lysate, SN: supernatant, FT: flow-through. (C) Size-exclusion 
chromatogram of the His6-tagged TNKS2 ARC1-5 over a Superdex 200 16/600 column and SDS-
PAGE protein gel with lanes corresponding to fractions of the two eluted peaks.  
 
To improve the purity and stability of the TNKS2 protein sample, a new multivalent TNKS2 
protein construct was generated, corresponding to the first three ARC (ARC1-3) subdomains 
of TNKS2 (residues 2-485, 54.8 kDa) (Figure 6.4A). Although this construct has only two TBP 
binding interfaces (ARC1 and ARC2), which risks reducing the effect of multivalency in the 
complex formation, TNKS2 ARC1-3 has a more rigid overall structure than TNKS2 ARC1-5, 
as shown in the crystal structure and may be therefore less prone to proteolysis.89 The higher 
flexibility of the ARC4-5 subdomains might explain why TNSK2 ARC1-5 appeared to be 
susceptible to proteolytic degradation resulting in the formation of degradation products, one 
of them with a molecular weight of about 55 kDa (Figure 6.3C) that is approximately the size 
of the ARC1-3 subdomain. The TNKS2 ARC1-3 construct was cloned with a N-terminal His6 
tag and purified by HisTrap chromatography and gel filtration (Figure 6.4B, C). The construct 
was expressed at a much higher yield than TNKS2 ARC1-5 and, at the end of the purification, 
pure protein was obtained, with only a lower-molecular weight contaminant present in some 
of the fractions. A multivalent TNKS2 protein construct was therefore successfully generated, 
allowing us to proceed with the binding analysis. 
 




Figure 6.4: Purification of His6-tagged TNKS2 ARC1-3. (A) Schematic representation of the His6-
tagged TNKS2 ARC1-3 construct compared to the full-length TNKS2 protein. (B) SDS-PAGE protein 
gel with lanes corresponding to different fractions collected throughout the HisTrap affinity 
chromatography. Total: total lysate, SN: supernatant, FT: flow-through. (C) Size-exclusion 
chromatogram of the His6-tagged TNKS2 ARC1-3 over a Superdex 75 16/600 column and SDS-PAGE 
protein gel with lanes corresponding to fractions of the eluted peak. 
 
6.2.2 Multivalent 3TBP-CTPR6 and 3TB-CTPR6-foldon induce the formation of large 
macromolecular complexes, studied by co-precipitation 
To study the effect of multivalency on our protein system and verify whether the scenario in 
Figure 6.1B is favoured, a co-precipitation assay was established. The assay adopts a simple 
and straightforward method, relying on the co-precipitation induced by high gravitational force 
of the protein complex formed by the two interacting proteins. For this assay, the multivalent 
3TBP-CTPR6 and 3TBP-CTPR6-foldon constructs, chosen as representatives of the linear and 
trimeric arrays, respectively, were incubated in the presence of TNKS2 ARC1-3. 1TBP-CTPR2 
and CTPR6 were chosen as single-valent and non-binding controls for this assay. Following a 
1 h incubation, samples were centrifuged at 20000 xg for 30 minutes using a tabletop 
centrifuge. Although much higher speeds are often applied by ultracentrifugation and analytical 
ultracentrifugation, a pellet was visibly formed using our experimental settings, avoiding the 
need of more sophisticated devices. The supernatant (S) and pellet (P) of each sample were 
then collected and run on a polyacrylamide gel to verify their composition (Figure 6.5). 
Whereas all the CTPR constructs remained in the supernatant when incubated with co-
precipitation buffer only, 3TBP-CTPR6 and 3TBP-CTPR6-foldon precipitated when mixed 
with TNKS2 ARC1-3 (Figure 6.5 top). Despite TNKS2 ARC1-3 self-precipitated to some 
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extent (about 50-70% of the total protein precipitates in buffer), the amount of precipitant 
increases in the presence of the multivalent 3TBP-CTPR6 and 3TBP-CTPR6-foldon, as the 
protein band intensity indicates. This result is the first evidence of macromolecular complex 
formation in solution mediated by multivalency. In contrast, the mono-valent 1TBP-CTPR2 
construct and the control CTPR6 construct remained in the supernatant even when incubated 
with TNKS2 ARC1-3 (Figure 6.5 bottom and top, respectively), confirming that the 
multivalency of the TBP loops is required for the formation of a large supramolecular complex 
with multivalent TNKS2. It is also worth noting that, despite 3TBP-CTPR6 and 3TBP-CTPR6-
foldon being incubated at the same TBP molar concentration, the trimeric 3TBP-CTPR6-
foldon construct precipitated to a higher extent and led to an increased precipitation rate of 
TNKS2 ARC1-3, as the high protein band intensity in the pellet (P) of the 3TBP-CTPR6-
foldon+TNKS2 ARC1-3 sample indicates (Figure 6.5 top). 
Co-precipitation of 3TBP-CTPR6 was also observed in the presence of the higher-
valency construct TNKS2 ARC1-5, although the many degradation products of this construct 
ruined the quality of the gel (data not shown). 
Additionally, co-precipitation assay was also performed by titrating increasing 
concentrations of 3TBP-CTPR6 or 3TBP-CTPR6-foldon proteins (used at the same TBP molar 
concentration) into TNKS2 ARC1-3. This experiment showed that the extent of co-
precipitation was dependent on the molar ratio of the two interacting molecules, until saturation 
is reached. A quantitative analysis was performed by measuring the protein band intensities, 
which allowed to calculate the molar protein concentration of the species in each band. As the 
proteins in the pellet correspond to those forming the precipitated complex, the calculated 
molar protein concentration in the pellet provides an estimate of the molar composition of the 
macromolecular complex that has been first formed and then precipitated. For accurate 
analysis, the molar concentration of precipitated TNKS2 ARC1-3 was subtracted by the 
amount that self-precipitates. The values indicate a consistent 1:1 molar composition for the 
3TBP-CTPR6:TNKS2 ARC1-3 complex, and a composition of 1:2 for the 3TBP-CTPR6-
foldon:TNKS2 ARC1-3 complex, explaining why the trimeric 3TBP-CTPR6-foldon can 
induce a greater extent of TNKS2 ARC1-3 co-precipitation than the linear 3TBP-CTPR6 
(Figure 6.6 and Table 6.1). Overall, it is clear from this result that not all TBP loops are 
involved in binding, as the scenario in Figure 6.1B indicates. 
 




Figure 6.5: Multivalent interactions between TBP-CTPR proteins and TNKS2 ARC1-3 analysed by 
co-precipitation assay. After centrifugation, supernatant (S) and pellet (P) were separated and run on a 
12% (top) or 16% (bottom) SDS polyacrylamide gel. For co-precipitation, proteins were mixed in equal 
volumes at the following concentration: 10 μM 1TBP-CTP2 (10 μM TBP loop concentration), 10 μM 
3TBP-CTPR6 (30 μM TBP loop concentration), 3.3 μM 3TBP-CTPR6-foldon (30 μM TBP loop 
concentration), 10 μM CTPR6 and 10 μM TNKS2 ARC1-3 (20 μM TBP-binding sites). Gel images 
were obtained using Li-COR Odyssey Fc Imaging System. 
 




Figure 6.6: Co-precipitation experiments as a function of increasing CTPR protein concentration. 
Samples were prepared by mixing a constant amount of TNKS2 ARC1-3 (10 μM) with the indicated 
CTPR proteins at increasing concentrations (from 0 to 12.5 μM), in equal volumes. Therefore, the final 
protein concentration is halved. The trimeric 3TBP-CTPR6-foldon was prepared at a concentration 
three times lower the one of the linear 3TBP-CTPR6, for comparison purposes. After centrifugation, 
supernatants (S) and pellets (P) were separated and run on polyacrylamide gels. Gel band intensities 
were quantified and plotted on the left-hand side graphs. Knowing the initial protein concentration, the 
gel band intensities were converted into the corresponding protein concentration and plotted on the 
right-hand side graphs. Shown is a representative analysis of two independent experiments. 
 




Table 6.1: Estimated molar composition of the assemblies formed between the multivalent CTPR 
constructs and the multivalent TNKS2 ARC1-3 protein. As the TNKS2 ARC1-3 protein showed some 
precipitation itself, the molar concentration of TNKS2 ARC1-3 in the pellet was corrected accordingly. 
The values obtained thus correspond to the amount of TBP-induced TNKS2 ARC1-3 precipitation. The 
stoichiometry (ratio) is calculated by dividing the concentration of the CTPR protein by the 
concentration of the TNKS2 ARC1-3 protein. *Corrected for the self-precipitation of TNKS2 ARC1-
3. 
 
6.2.3 Macromolecular assemblies visualised by negative stain-EM 
Further characterisation of the macromolecular assemblies was performed by negative stain 
transmission electron microscopy (TEM). In agreement with the previous results, large 
assemblies, microns in size, could be observed only when both interacting partners are 
multivalent (TNKS ARC1-3 in combination with 3TBP-CTPR6 or 3TBP-CTPR6-foldon), and 
not in samples with 1TBP-CTPR2 or CTPR6 having no TNKS binding loops. Qualitatively, 
the clusters did not appear to have any particular structural organisation, but they display quite 
rounded edges. 3TBP-CTPR6 resulted in the formation of variable sized clusters throughout 
the TEM grid, ranging from small (1-2 μm clusters) to large networks many microns in size, 
whereas clusters formed by the trimeric 3TBP-CTPR6-foldon appeared to be predominantly 
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large, with smaller assemblies only occasionally visible. In contrast, samples of TNKS2 ARC1-
3 in combination with 1TBP-CTPR2, CTPR6 or alone showed only some small amorphous 
aggregates (Figure 6.7). 
 
 
Figure 6.7: Negative stain TEM. TNKS2 ARC1-3 was incubated with 3TBP-CTPR6, 3TBP-CTPR6-
foldon (Top), 1TBP-CTPR2, CTPR6 or buffer (Bottom) and imaged by negative stain TEM following 
a 1 h incubation. Proteins were mixed in equal volumes at the following concentrations: 5 μM 1TBP-
CTPR2 (5 μM TBP loop concentration), 5 μM 3TBP-CTPR6 (15 μM TBP loop concentration), 1.7 μM 
3TBP-CTPR6-foldon (15 μM TBP loop concentration), 5 μM CTPR6 and 5 μM TNKS2 ARC1-3 (10 
μM TBP-binding sites). Scale bars for all images are 500 nm. Grid preparation and imaging was 
performed by Dr Janet R. Kumita, a post-doc in the Itzhaki lab. 
 
6.2.4 Multivalent TBP-CTPR and TNKS constructs co-localise in the cell 
Once the formation of a macromolecular complex was confirmed, we then wanted to 
investigate the effect of multivalency inside the cell. Fluorescence microscopy was therefore 
applied in a co-localisation assay. To this end, single- and multi-valent eGFP-tagged TNKS2 
constructs were cloned in a mammalian expression vector, while the CTPR constructs were 
tagged with mCherry. These two fluorescent proteins have non-overlapping excitation and 
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emission spectra, allowing us to localise both signals without interference. For this assay, 
HEK293T cells were co-transfected with eGFP-tagged TNKS2 ARC1-5 in combination with 
a mCherry-tagged CTPR construct having one, multiple or no TNKS-binding loops. Although 
the eGFP-tagged full-length TNKS2 construct was also cloned, the TNKS2 ARC1-5 construct 
was chosen instead, as it was expressed in higher amounts, resulting in a brighter intracellular 
fluorescence signal (data not shown). After 48 h from transfection, the presence of large, 
polymeric species was visible in the cytoplasm of cells co-transfected with the multivalent 
TNKS2 ARC1-5 and the multivalent 3TBP-CTPR6 or 3TBP-CTPR6-foldon construct, where 
the fluorescent signal of eGFP and mCherry perfectly co-localised (Figure 6.8). In agreement 
with the previous results, formation of these large assemblies depends on the interaction 
between two high-valency molecules: when TNKS2 ARC1-5 was co-expressed with the mono-
valent 1TBP-CTPR2 or CTPR6 instead, no such assemblies were produced and observed 
(Figure 6.8). 
In addition, Figure 6.8 also indicates that 1TBP-CTPR2 and CTPR6 are present in the 
cytoplasm as well as in the nucleus of the cells, whereas 3TBP-CTPR6 and 3TBP-CTPR6-
foldon are retained in the cytoplasm. This might be a result of their larger molecular weight 
making them unable to translocate into the nucleus or, more likely, the effect of their 
recruitment into large macromolecular assemblies. 
Despite the large size of these macromolecular assemblies (up to 1-2 μm), any 
particular effect on the cell morphology and cell viability could be visibly observed under the 
microscope in cells containing the agglomerates. 
 




Figure 6.8: Fluorescence microscopy of HEK293T cells co-transfected with mCherry-tagged CTPR 
proteins and eGFP-tagged TNKS2 ARC1-5. Co-localisation in large macromolecular clusters is 
observed for eGFP-tagged TNKS2 ARC1-5 in combination with mCherry-tagged 3TBP-CTPR6 or 
with mCherry-tagged 3TBP-CTPR6-foldon. These clusters are not observed for the mono-valent 
mCherry-tagged 1TBP-CTPR2 protein or the control mCherry-tagged CTPR6 protein. Scale bars for 
all images are 10 μm. 
 
Likewise, when the same CTPR proteins were co-expressed with a monovalent TNKS2 
construct comprising only the first ARC domain (eGFP-TNKS2 ARC1), no polymeric species 
were visible in any of the combinations tested (Figure 6.9). With the macromolecular 
assemblies not being formed, 3TBP-CTPR6 was also localised inside the nucleus of the cells, 
similarly to 1TBP-CTPR2 and CTPR6. 3TBP-CTPR6-foldon was instead only present in the 
cytoplasm.  
 




Figure 6.9: Fluorescence microscopy of HEK293T cells co-transfected with mCherry-tagged CTPR 
proteins and eGFP-tagged TNKS2 ARC1. The monovalent nature of the TNKS2 ARC1 construct 
prevents the formation of large macromolecular assemblies. Scale bars for all images are 10 μm. 
 
 
6.2.5 Macromolecular assemblies have different internal dynamics 
Having observed the formation of large assemblies inside the cell, Fluorescence Recovery 
After Photobleaching (FRAP) was used to assess their internal dynamics. FRAP relies on the 
observation of the fluorescent signal over time, before, during and after photobleaching a small 
area. The extent of fluorescence recovery provides an indication on the kinetics of diffusion of 
fluorescent molecules in living cells, using fluorescent microscopy.212 FRAP was performed 
on those fluorescent macromolecular assemblies generated by eGFP-TNKS2 ARC1-5 in 
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complex with the mCherry-tagged linear 3TBP-CTPR6 or the trimeric 3TBP-CTPR6-foldon. 
For each sample, small Regions of Interest (ROI) were selected within the assemblies and in 
these the recovery rate of the eGFP signal was followed after its localised photobleaching 
(Figure 6.10). Macromolecular assemblies induced by the linear 3TBP-CTPR6 showed a rapid 
recovery rate, with signal reaching a plateau within 30 seconds after photobleaching. This 
evidence suggests that the proteins within this assembly are highly dynamic, with binding 
partners in rapid exchange. Fluctuations in the recovery rate were also observed due to the 
slight movement of the assembly around the selected ROI, providing further evidence of the 
dynamic nature of these assemblies over a short window of time. In contrast, the assemblies 
generated by the trimeric 3TBP-CTPR6-foldon did not show any sign of fluorescence recovery 
within the same experimental settings, even after one minute from photobleaching. In 
agreement with the co-precipitation assay and stoichiometry analysis, we believe that the 
trimeric conformation of the 3TBP-CTPR6-foldon molecule, together with its increased 
valency, allows this construct to engage with more target molecules and establish a more 
interconnected, rigid network which abolishes the internal dynamic of the complex. 
 
6.3 Discussion 
The TNKS-binding CTPR constructs developed here combine target specificity with 
multivalency, two features that have not yet been explored in previous drug development 
efforts against TNKS. Having previously confirmed the target-binding properties of the CTPR 
constructs, the effect of multivalency was then investigated using a variety of in-vitro and cell-
based assays. The presence of multiple binding sites in both the interacting partners, TNKS 
and the designed CTPR proteins, manifests in the formation of large, intracellular 
macromolecular assemblies, both in the cell and in the test tube. The co-precipitation assay 
provided the first evidence of macromolecular complex formation only when multivalent 
TNKS2 ARC1-3 was incubated with a multivalent TNKS-binding CTPR construct. The same 
protein assemblies were also observed by negative stain TEM. The results from both assays 
indicate the formation of larger assemblies when 3TBP-CTPR6-foldon is used, compared to 
those induced by the linear 3TBP-CTPR6 construct. 




Figure 6.10: FRAP analysis of the assemblies formed between TNKS2 ARC1-5 and the indicated 
CTPR proteins. (A) FRAP analysis was performed on seven individual Regions of Interest (ROI) 
selected within macromolecular assemblies induced by eGFP-tagged TNKS2 ARC1-5 in complex with 
3TBP-CTPR6 (orange) or 3TBP-CTPR6-foldon (green). HEK293T cells were bleached in the ROI and 
fluorescence recovery of eGFP-tagged TNKS2 ARC1-5 was monitored over 90 seconds. (B) 
Representative ROI selected within three independent macromolecular assemblies are shown before, 
during and post bleaching for both protein complexes. 
 
 
A co-localisation assay demonstrated the formation of these macromolecular assemblies also 
in a cellular environment. Moreover, these assemblies showed different internal dynamics 
depending on the configuration of the CTPR construct (i.e. monomeric versus trimeric). The 
FRAP assay demonstrated how the macromolecular assemblies induced by the 3TBP-CTPR6-
foldon construct are very rigid and interconnected, unlike those produced by the linear 3TBP-
CTPR6. Interestingly, all the assays shown in this Chapter, together with the stoichiometry 
evaluation, point to the same conclusion: the 3TBP-CTPR6-foldon, due to its increased valency 
compared to 3TBP-CTPR6, is able to engage with several TNKS molecules, resulting in the 
formation of a larger and more interconnected network of proteins. Although these assays were 
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performed in the presence of TNKS2 constructs that are shorter than the full-length protein, 
the results shown here should still be representative of the binding interaction between the 
TBP-CTPR constructs and the endogenous TNKS. One final caveat is that here we over-
expressed both the CTPR constructs and the TNKS construct. This will lead to higher protein 
levels that may enhance the formation of higher-order species. The functional effects that the 
macromolecular assemblies might have on TNKS activity should be further explored, and an 
initial investigation is provided in the following Chapter. It remains to be determined whether 
the observed intracellular macromolecular assemblies have undergone liquid-liquid phase 
separation and resemble biomolecular condensates. High valency and low binding affinities is 
what characterises most biomolecular condensates as well as the multivalent proteins under 
















Most biologics and small molecule drugs available in the market are able to inhibit a protein 
target by simply binding to it. In most cases, the target:drug binding causes the inhibition of 
the target’s catalytic activity or, less commonly, prevents the recognition of its natural 
substrate. As TNKS are clinically relevant targets, several small-molecule inhibitors of the 
TNKS PARP domain’s active site have been developed and tested in vitro and, in some cases, 
in xenografts and/or genetically engineered mouse models of cancer.135,138 Given the 
involvement of TNKS in the Wnt signalling pathway, one can measure the efficacy of TNKS 
inhibitors (TNKSi) by observing the alterations induced in this pathway. The most common 
method used to measure Wnt signalling is by TopFlash,157 a Wnt-responsive luciferase reporter 
assay. The same assay was extensively adopted to screen for Wnt inhibitors109,134–137 and to 
investigate the functional effect of small molecule TNKSi on this pathway.138 In the Itzhaki 
group, the inhibitory effects of a series of macrocyclic, cell-penetrating TBP peptides was 
demonstrated using the same assay.85 Inhibition of TNKS PARP activity leads to stabilisation 
of Axin. As Axin is a component of the β-catenin destruction complex, Axin stabilisation leads 
to the reduction of the cytoplasmic levels of β-catenin. This results in a reduced translocation 
of β-catenin into the nucleus and, therefore, in a decreased transcriptional activation of Wnt-
controlled genes. 
 
nTBP-CTPR2n and nTBP-CTPR2n-foldon proteins inhibit Wnt signalling 
 
 122 
7.1.1 The TopFlash dual-luciferase reporter assay 
The TopFlash assay relies on the luciferase activity of two different luciferases, expressed in 
cultured cells. Here, cells are co-transfected with a plasmid encoding luc+ firefly luciferase 
under the control of the TCF/LEF Wnt-dependent promoter and a second plasmid encoding the 
Renilla luciferase constitutively expressed from the CVM promoter. The luc+ gene encodes a 
modified firefly (Photinus pyralis) luciferase, that has been optimised for improved expression 
and monitoring in transfected eukaryotic cells. Renilla, instead, is the wild-type luciferase from 
Renilla reniformis and is used as internal control to allow more accurate results. Wnt signalling 
is enhanced by adding purified Wnt protein or Wnt conditioned medium to the cell growth 
medium. Wnt conditioned medium is obtained by culturing cells expressing and releasing Wnt 
protein into their growth medium. Upon binding of the Wnt molecule to the Wnt-Frizzled 
receptor on the cellular surface, the canonical Wnt signalling pathway is activated, resulting in 
the accumulation of β-catenin and its translocation into the nucleus, where it induces the 
transcription of Wnt-dependent genes. As a consequence, an increase in firefly luciferase 
expression is measured in the reporter assay, compared to the untreated negative control 
sample. The expression levels of the Renilla luciferase, instead, remain unaltered. The 
introduction of TNKS inhibitors in the form of small molecules or peptides, instead, has an 
inhibitory effect on the Wnt signalling pathway, measurable as a reduction in firefly luciferase 
expression and, therefore, reduced firefly luminescence signal. 
Here, given the high transfection efficacy of HEK293T cells and their greater ease of 
in vitro culturing compared to other cell lines, these cells were selected for the TopFlash 
experiments. Activation of Wnt signalling was achieved by culturing transfected HEK293T 
cells in the presence of the Wnt conditioned medium, previously produced by culturing L Wnt-
3A cells (ATCC), a cell line engineered to produce and secrete a non-tagged form of the 
biologically active Wnt3A glycoprotein in the medium.213 Small molecule TNKSi or a 
macrocyclic TBP peptide can then be simply added to the culturing medium, as they are cell 
permeable.85 In contrast, the nTBP-CTPR2n and the nTBP-CTPR2n-foldon proteins are unable 
to cross the plasma membrane on their own, due to their bulky size. Instead, a mammalian 
expression vector encoding the TBP-CTPR constructs was transfected into the cells, meaning 
that co-transfection of three plasmids was required for this TopFlash assay (Figure 7.1). As an 
alternative approach, purified TBP-CTPR protein can be encapsulated into fusogenic 
nanocarriers for their delivery into cells (and also for their protection against digestion by 
extracellular proteases). Both strategies were used and the results are described in Chapter 7 
and Chapter 8, respectively. A dual-luciferase reporter assay (DLR, Promega) was then 
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performed to provide the corresponding substrate to each luciferase and measure the 
luminescence levels generated by both (Figure 7.1). 
The stage in the experimental setting at which the TNKSi or CTPR constructs are 




Figure 7.1: Schematic representation of the transfected plasmids required for the dual-luciferase 
reporter assay. The expression levels of firefly and Renilla are indicative of the events listed on the 
right. A dashed arrow corresponds to the inhibitory effect that the TNKS-binding CTPR constructs can 
have on the firefly expression levels. 
 
7.1.2 Prophylactic vs interventional administration of drugs 
Depending on their mechanism of action, drugs can exploit their pharmacological function 
prophylactically or interventionally. Agents with a pharmacological prophylactic activity 
prevent a disease from occurring and need to be used before a potential issue might arise. Drugs 
administered interventionally, instead, act by interfering with the biological target and pathway 
causing the disease. To be of clinical use in the treatment of Wnt-dependent cancers, drugs 
need to be administered and be active interventionally (i.e. when Wnt signalling is already 
upregulated). Evidence from my own work and from our collaborator Dr Marc de la Roche has 
revealed the prophylactic effect of the small molecule TNKSi in preventing activation of the 
Wnt signalling. These TNKSi, however, are not as potent when used interventionally.139 To 
explore whether the linear nTBP-CTPR2n and trimeric nTBP-CTPR2n-foldon constructs have an 
inhibitory effect on the Wnt signalling pathway, and to what extent, the Topflash assay was 
performed and the results compared to three well-characterised small molecule TNKSi. When 
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used prophylactically (as shown in this Chapter), the TNKS inhibitors, in the form of small 
molecules or CTPR constructs, are introduced before or at the same time as the Wnt 
conditioned medium and their activity is to prevent the activation of the Wnt signalling 
pathway. When used interventionally (as shown in the following Chapter), instead, the TNKS 
inhibitors are introduced after the pathway has already been activated by the Wnt molecule and 
their activity is to reduce the Wnt signalling. 
 
7.2 Results 
7.2.1 Subcloning into pcDNA3.1(-) and HiBiT-pcDNA3.1(-) 
The TopFlash assay requires cell transfection with a mammalian expression vector encoding 
each of the linear nTBP-CTPR2n and trimeric nTBP-CTPR2n-foldon constructs, as well as the 
control constructs. As described in Chapter 2, all the linear and trimeric CTPR constructs were 
therefore subcloned into our lab’s variant of the commercially available pcDNA3.1(-) vector 
(Thermo Fisher), providing C-terminal HA tagging of the recombinant proteins. All the 
constructs were subsequently also cloned into the HiBiT-pcDNA3.1(-), an additional variant 
of the pcDNA3.1(-) vector that I generated, for the reasons mentioned below. Genes in this 
vector are fused to a N-terminal HiBiT tag and a C-terminal HA tag. 
 
7.2.2 TopFlash dual-luciferase reporter assay - Prophylactic 
The TopFlash reporter assay was used to evaluate the prophylactic inhibitory effect of the 
monomeric nTBP-CTPR2n and trimeric nTBP-CTPR2n-foldon constructs on Wnt signalling. As 
controls, an empty vector (causing maximum firefly luciferase expression, set at 100% for 
normalisation); CTPR2, CTPR6, CTPR6-foldon and a 3RL-CTPR6 construct containing a 
non-binding peptide named “Random Loop” (RL) were tested in parallel. The cells that were 
not treated with Wnt conditioned medium (No WNT), instead, maintain minimal levels of Wnt 
signalling. 
Several parameters of the TopFlash assay were initially optimised, such as the number 
of seeded cells, the quantity of plasmids to transfect, as well as the ratio among them, and the 
type of Wnt signalling activator (Wnt conditioned medium instead of LiCl). To test the 
prophylactic activity of the CTPR constructs, HEK293T cells were co-transfected with 
plasmids encoding the TCF/LEF-dependent firefly, CMV-dependent Renilla and a HA-tagged 
CTPR construct. Cells were allowed to recover for eight hours before activating the Wnt 
signalling pathway by adding the Wnt conditioned medium to the transfected cells. Following 
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a 16 h incubation, cells were observed under the microscope to identify any signs of toxicity 
induced by the Wnt activation, the transfection or the expression of the recombinant constructs. 
Figure 7.2 provides a representative comparison between cells transfected with an empty vector 
with and without the addition of Wnt conditioned medium, or the 3TBP-CTPR6 expression 
vector in the presence of Wnt conditioned medium. All wells were observed under the white 
light microscope before completing the assay, and no effects on cell viability induced by the 
Wnt conditioned medium or the expression of CTPR constructs could be observed. 
 
 
Figure 7.2: Living HEK293T cells imaged under bright field, using the EVOS Floid Cell Imaging 
Station, just before completion of the TopFlash assay. Representative figures are shown. Left: cells 
transfected with empty pcDNA3.1(-) vector; Middle: cells transfected with empty pcDNA3.1(-) vector 
and treated with Wnt conditioned medium; Right: cells transfected with pcDNA3.1(-) vector encoding 
3TBP-CTPR6 and treated with Wnt conditioned medium. 
 
 
The TopFlash assay was then completed using the Dual-Luciferase® Reporter Assay 
System that, following cell lysis, allows the consecutive measurement of the luminescent signal 
generated by firefly and Renilla on the same sample. To calculate the percentage luciferase 
activity, the firefly averaged luminescence signal was divided by the Renilla averaged 
luminescence signal in each sample and the ratio was normalised to the empty vector control 
sample set at 100%. The results indicate that treatment of HEK293T cells with all the nTBP-
CTPR2n and nTBP-CTPR2n-foldon constructs, with the exception of 1TBP-CTPR2, led to a 
significant reduction in Wnt pathway activity compared to the control samples having no TBP 
loop (Figure 7.3). The control constructs CTPR2, CTPR6, 3RL-CTPR6 (sequence provided in 
Appendix B) and CTPR6-foldon were unable to inhibit Wnt signalling, as expected. Notably, 
the resulting Wnt signalling inhibition observed here is an indirect measure of the effective 
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Figure 7.3: TopFlash reporter assay for HEK293T cells transfected with TCF-firefly, CMV-Renilla 
reporter gene vectors and an expression vector encoding the constructs listed. For each sample, firefly 
activity was normalised with the corresponding Renilla signal and the ratio was normalised to the 
control well transfected with the empty vector set at 100%. The monomeric constructs, trimeric 
constructs and controls are shown in different shades of orange, green and blue, respectively. F indicates 
the foldon motif. Standard deviation was calculated from six independent sample measurements. The 
significance of the difference between samples (ns: non-significant, p>0.05, *p≤0.05, **p≤0.01, 
***p≤0.001) was assessed using One-way ANOVA coupled with Dunnett’s Multiple Correction test. 
1TBP-CTPR2 and 1TBP-CTPR2-F were compared to CTPR2. Multivalent linear and trimeric 
constructs were compared to 1TBP-CTPR2 and 1TBP-CTPR2-F, respectively. 
 
To assess the levels of HA-tagged CTPR proteins present in each sample during the TopFlash 
assay, Western Blot was performed on the same cell lysates using an anti-HA primary antibody. 
Despite transfecting cells with an equal amount of pcDNA3.1(-) plasmid encoding the various 
constructs, it was surprising to see a noteworthy difference in protein levels after 24 h from 
transfection (Figure 7.4). According to the Western Blot bands intensity, the trimeric nTBP-
CTPR2n-foldon proteins appeared to be present at higher levels than their linear counterparts. 
Moreover, the membrane had to be overexposed in order to detect protein bands corresponding 
to shorter CTPR constructs, with 1TBP-CTPR2 still barely detectable. 




Figure 7.4: Western Blot analysis performed on some of the TopFlash cell lysate samples from Figure 
7.3. Membranes were probed for α-tubulin and HA-tagged CTPR constructs, as indicated. 
 
To address this problem, a more sensitive and quantitative technique than Western Blot was 
therefore necessary and was identified in the Nano-Glo HiBiT Lytic Detection System. As 
shown in Chapter 5, the Nano-Glo HiBiT technology allows the detection of proteins with high 
sensitivity directly on the cell lysate without the need of performing Western Blot. This 
technology, however, requires all of the CTPR constructs to be tagged with the HiBiT 
sequence. For this purpose, all CTPR-encoding genes were subcloned into the HiBiT-
pcDNA3.1(-) expression vector. The TopFlash assay was therefore repeated with the newly 
generated HiBiT-tagged constructs under the same experimental settings. Results consistent to 
those in Figure 7.3 were obtained, with the same extent of inhibition being observed for each 
protein construct (Figure 7.5A). 
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The cell lysates obtained by TopFlash were then incubated with the Nano-Glo HiBiT 
Lytic Detection System. Given the high sensitivity of the split-luciferase Nano-Glo technology, 
the intracellular protein level of each HiBiT-tagged CTPR construct could be successfully 
measured and quantified (Figure 7.5C). The measured values fall within the broad linearity 
range of luminescence generated by HiBiT, according to published and my own evidence (data 
not shown).203 The result confirmed that the trimeric TNKS-binding constructs were present in 
higher amounts than their linear counterparts, as observed previously by Western Blot. 
Moreover, in both the linear and the trimeric geometries, the protein levels generally increased 
with longer CTPR constructs, with the 3TBP-CTPR6 construct showing the highest protein 
amount. This trend, however, was not observed for the control constructs, that were all present 
in very low amounts, independently of their molecular weight. When comparing Figure 7.5A 
with Figure 7.5C, it is possible to detect a complementary trend, suggesting that a lower protein 
concentration might lead to a lower Wnt signalling inhibition. Therefore, the extent of Wnt 
inhibition appears to be proportional to the CTPR protein levels as quantified 24 h after 
transfection. 
Finally, the effects of the CTPR proteins were compared to those obtained using three 
well characterised small molecule TNKSi, tested prophylactically. Each of the three TNKSi 
was added with the Wnt conditioned medium and at a final concentration of 1 μM (Figure 
7.5B). The comparison shows that some of the nTBP-CTPR2n and nTBP-CTPR2n-foldon 
constructs can inhibit the Wnt signalling pathway to a similar extent as the small molecule 
TNKSi.  




Figure 7.5: Prophylactic activity of the CTPR constructs and TNKSi in inhibiting the Wnt signalling. 
(A) TopFlash reporter assay for HEK293T cells transfected with TCF-firefly, Renilla reporter gene 
vectors and an expression vector encoding the constructs listed. For each sample, firefly activities were 
normalised with the corresponding Renilla values and the ratio was expressed as relative luciferase 
activity to the control well transfected with the empty HiBiT vector set at 100%. The monomeric 
constructs, trimeric constructs and controls are shown in different shades of orange, green and blue, 
respectively. F indicates the foldon motif, H indicates the N-terminal HiBiT tag. Standard deviation 
was calculated from triplicate sample measurements. The significance of the difference between 
samples (ns: non-significant, p>0.05, *p≤0.05, **p≤0.01, ***p≤0.001) was assessed using One-way 
ANOVA coupled with Dunnett’s Multiple Correction test. 1TBP-CTPR2 and 1TBP-CTPR2-F were 
compared to CTPR2. Multivalent linear and trimeric constructs were compared to 1TBP-CTPR2 and 
1TBP-CTPR2-F, respectively. (B) Effect of small molecule TNKSi tested prophylactically in the 
TopFlash assay. Cells were treated with inhibitors and Wnt-conditioned medium simultaneously. Final 
concentration was 1 µM for all the small molecule TNKSi tested. Data were normalised by the untreated 
control well, set at 100% (not shown in the graph). Error bars were determined from two independent 
sample measurements. The statistical analysis was performed as in A, with samples compared to 
DMSO. (C) Luminescence readings corresponding to the intracellular HiBiT-tagged CTPR protein 
levels from samples in (A). Data were averaged and standard deviation was calculated from triplicate 
sample measurements. The significance of the difference between each sample and Empty HiBiT vector 
(ns: non-significant, p>0.05, *p≤0.05, **p≤0.01, ***p≤0.001) was assessed using One-way ANOVA 
coupled with Dunnett’s Multiple Correction test. 
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7.2.3 Proteasome-induced degradation assay 
Data in Figure 7.5C reveal that all the CTPR2 proteins, in the form of 1TBP-CTPR2, 1TBP-
CTPR2-foldon and CTPR2, are present at much lower levels than the larger proteins. 
Differences in protein amounts might arise from variable expression rates at the transcription 
and/or translation level or might be due to differential resistance to degradation. Due to their 
intrinsic lower stability (Chapter 4), we hypothesised that the smaller, less stable CTPR2 
constructs might undergo proteasome-induced degradation to a greater extent than the other 
CTPR constructs. To address this hypothesis, a proteasomal-induced degradation assay, in 
combination with the Nano-Glo HiBiT Lytic Detection System, was established. In this assay, 
wells transfected in duplicates with a HiBiT-tagged construct were incubated in the presence 
or absence of the proteasome inhibitor MG132 for 5 h. MG132 is a potent, cell-permeable and 
synthetic peptide aldehyde, able to inhibit multiple peptidase activities within the proteasome. 
MG132 and other proteasome inhibitors are known to be toxic to cells, leading to cell death 
when used at high concentrations or for prolonged incubation times. Therefore, MG132 
treatment needs to be complemented with a cell viability assay for normalisation. The 
appropriate cell viability assay has to fulfil the following requirements, in order to be 
multiplexed with the Nano-Glo luminescence assay: 
- Cell viability and HiBiT-mediated luminescence should be measured sequentially on 
the same cell sample and in this order, as the Nano-Glo System is lytic. The cell 
viability assay must, therefore, adopt a non-lytic reagent. 
- The cell viability measurement must not interfere with the consecutive HiBiT-mediated 
luminescence and must, therefore, exploit a physical property different than 
luminescence. 
The compatible cell viability assay was identified to be the CellTiter-Fluor Cell Viability Assay 
(Promega). The assay relies on a fluorogenic, cell-permeable peptide substrate (Gly-Phe-AFC), 
that produces a fluorescent signal upon cleavage by the conserved and constitutive live-cell 
protease activity. The live-cell protease activity is restricted to intact viable cells, providing a 
measurable signal proportional to the number of living cells. 
Following MG132 treatment for the indicated incubation time, cell viability was 
measured, and a significant decrease in the number of viable cells was observed in wells treated 
with MG132, further validating the need for a sensitive cell viability measurement to be 
multiplexed in this assay (Figure 7.6A). Cells were then analysed for their CTPR protein levels 
and the HiBiT-induced luminescence was measured. The luminescent signal was then 
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normalised by the corresponding cell viability to account for the variability in cell numbers 
between the two experimental conditions (+MG132 and -MG132). The ratio +MG132/-MG132 
was then calculated and plotted (Figure 7.6B). The experiment shows that, in the presence of 
MG132, there is an approximate 3-fold increase in protein levels of all the constructs, with the 
exception of the two smallest proteins 1TBP-CTPR2 and CTPR2, whose stability is more 
affected. In other words, the results indicate that 1TBP-CTPR2 and CTPR2 undergo 
proteasome-mediated degradation to a much greater extent than the other, larger protein 
constructs. Moreover, when comparing the linear with the trimeric constructs, the foldon 
domain appears to provide the CTPR2 construct with protection against proteasome-mediated 
degradation, whereas the foldon motif does not appear to provide protection to the larger CTPR 
constructs presumably because these proteins are already reasonably stable (Figure 7.6B). 
The cell viability measurement shown here provided additional evidence regarding the 
potential cytotoxicity effect induced by the recombinant CTPR constructs. In agreement with 
the microscopy images in Figure 7.2, the cell viability measurements in the absence of MG132 
are comparable across all the samples tested, confirming that none of the constructs showed 
cytotoxicity (Figure 7.6A). 
 
 
Figure 7.6: Proteasome-induced degradation assay. (A) Cell viability assay showing the viable cell 
number in the presence or absence of MG132, following transfection with the indicated constructs. (B) 
Fold increase in HiBiT-tagged CTPR protein levels in the presence of the proteasome inhibitor MG132. 
Data were averaged, and standard deviation was calculated from triplicate samples. 
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7.3 Discussion  
The results in this Chapter provide interesting insights into the inhibitory potential of the linear 
nTBP-CTPR2n and trimeric nTBP-CTPR2n-foldon constructs when tested prophylactically. To 
verify whether the proven intracellular interaction between the TBP loop and TNKS 
(demonstrated in Chapters 5 and 6) can lead to the desired Wnt signalling inhibition, the 
TopFlash assay was adopted. The TopFlash assay is a well-established and easy method to 
measure the effect of Wnt inhibitors on the Wnt signalling pathway. However, it requires cell 
transfection with at least two plasmids (Wnt-dependent firefly and a control luciferase reporter) 
and the activation of Wnt signalling. When small molecule Wnt-antagonists are tested with the 
TopFlash assay, they can be added directly into the culture medium as they are cell-permeable. 
In the TopFlash assay described here, instead, the CTPR proteins were introduced by 
transfecting cells with an additional plasmid encoding them, making a total of three plasmids 
to transfect. The same multi-plasmid transfection has been previously tested to compare the 
activity of transfected Wnt ligands or protein-based antagonists such as Dickkopf-related 
protein 1 (Dkk-1) and the Secreted Frizzled-related Proteins (SFRPs), validating the approach 
used here.214,215 The CTPR-encoding plasmid was transfected in combination with the firefly- 
and Renilla-expression vectors, eight hours before Wnt activation. By doing so, the CTPR 
constructs are tested for their prophylactic activity. However, CTPR expression under the CMV 
promoter within the pcDNA3.1(-) plasmid is expected to occur over a long period of time, 
causing a continuous TNKS inhibition both before and after the introduction of the Wnt 
conditioned medium. 
Significantly different CTPR protein levels were measured after 24 hours, making it 
difficult to compare the inhibitory effects of the different linear nTBP-CTPR2n and trimeric 
nTBP-CTPR2n-foldon constructs and establish their prophylactic activity. Differences in 
protein levels can be partially explained by their different stability and susceptibility to 
proteasome-mediated degradation. Shorter CTPR constructs, such as 1TBP-CTPR2 and 
CTPR2, undergo proteasome-mediated degradation to a greater extent than do the larger CTPR 
constructs. Their intrinsic lower stability might contribute to their enhanced degradation. As 
proteasomal degradation equally affects longer TNKS-binding and control CTPR constructs, 
we also propose that the multivalency-induced macromolecular assemblies (as described in 
Chapter 6) might help protect the multivalent TBP-CTPR constructs from degradation. This 
effect would explain why the levels of the multivalent TBP-CTPR proteins are much higher 
than those of 1TBP-CTPR2 and the non-binding control constructs. On a similar note, as Wnt 
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inhibition is observed in cells transfected with the multivalent TBP-CTPR constructs, it is also 
possible that Wnt inhibition is enhanced by clustering TNKS within these macromolecular 
structures. Unlike the previously observed macromolecular complexes formed by 
overexpressed eGFP-tagged TNKS2 (Chapter 6), the macromolecular complexes suggested 
here would contain the endogenous TNKS1 and TNKS2 proteins. Further investigation is 
required to validate these hypotheses. 
Three well-characterised small molecule TNKSi (XAV939, IWR-1 and G007) were 
also tested for comparison and, in agreement with previous studies,109,134,138 around 90% 
inhibition of Wnt pathway activity was observed for XAV939 and G007 when used 
prophylactically. It was noteworthy to see that some of the linear nTBP-CTPR2n and trimeric 
nTBP-CTPR2n-foldon constructs were able to induce a similar extent of Wnt signalling 
inhibition in this setting. Lastly, no cytotoxicity effects could be observed upon over-
expression of the CTPR constructs, a desired feature for any further development of these 
proteins as biotherapeutic molecules. Altogether, the Wnt inhibition observed here is an 
encouraging starting point from which to explore further the inhibitory potential of the TBP-
CTPR proteins. In particular, the possibility of using them interventionally needs to be tested 
for them to be of clinical use. To this end, the TopFlash assay was performed in a different 












Intracellular delivery of nTBP-CTPR2n proteins 
 
The results presented in this Chapter were obtained in collaboration with Dr Piyush K. 
Chaturbedy, a post-doc in the Itzhaki lab with experience in nanoparticle synthesis and their 
application as intracellular drug delivery methods.  
 
8.1 Introduction 
Intracellular delivery of biotherapeutics represents a major challenge today. To avoid this 
problem, the vast majority of biotherapeutics, such as antibody-based drugs and alternative 
scaffolds-based inhibitors, are developed to bind and inhibit extracellular epitopes, as their 
large molecular weight size impedes their diffusion through the plasma membrane. Delivery 
methods are required to reach an intracellular target with a pharmacological molecule that is 
unable to cross the plasma membrane on its own.216 Various delivery methods have been 
developed in recent years, and some are in clinical use.217 The results described in the previous 
Chapter showed the potential of the CTPR proteins in inhibiting TNKS using the TopFlash 
Wnt signalling assay. In those experiments, the cells were transfected with DNA to express the 
CTPR proteins; in this Chapter, instead, we attempted to mimic more closely what would be 
required for a drug, and used so-called “fusogenic liposomes” to deliver the proteins into the 
cell. 
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8.1.1 Fusogenic liposomes 
Fusogenic liposomes are a class of non-viral delivery systems consisting of lipid vesicles. They 
can encapsulate large water-soluble cargos, such as proteins, and can deliver them into the 
cellular cytoplasm by membrane fusion. They are easy to prepare, safe and can be optimised 
to the desired structure, size and surface charge by varying their physio-chemical properties. 
Additional pharmacological properties include their scarce immunogenicity and their easy 
manipulation. Moreover, they protect the cargo, preventing its premature degradation and its 
recognition by the immune system.218 Fusogenic liposomes based on cationic lipids have 
gained interest in biomedical applications. The lipid’s positive charge, indeed, allows 
encapsulation of large amounts of DNA used for gene therapy applications, and promotes the 
interaction with the plasma membrane, therefore favouring the fusion and uptake by the cell. 
Liposomes are generally produced by the combination of a cationic lipid with a helper lipid. 
The fusogenic liposomes used in this study are formed by a 10:10:1 mixture of 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR).158 
DOTAP is a widely used cationic lipid, known for its ability to generate stable and fluid 
bilayers. DOPE is a common helper lipid, which is used to improve structural stability and 
decrease toxicity. Both DOTAP and DOPE have unsaturated fatty acid lipid chains, and this 
characteristic provides higher flexibility to the vector surface and also allows a better 
incorporation of the cargo. DiR is a lipophilic dye used to trace the presence of the liposomes 
in an experimental setting. 
Preparation of liposomes is usually a three-step process: 
1. Lipids and helpers dissolved in volatile organic solvents are mixed and dried to form 
thin films named “lipid cakes”; 
2. Lipid cakes are rehydrated in the desired buffer containing the cargo to be encapsulated; 
3. Sonication with high-power ultrasounds generates unilamellar liposomes, bounded by 
a single bilayer of lipids. 
Liposomes are stable at room temperature and their surface positive charge attenuates their 
tendency to fuse to each other, as a result of charge repulsion among liposomes. Fusogenic 
liposomes have also been shown to merge with the cell membrane and deliver their cargo 
directly into the cell cytoplasm, bypassing endocytosis.158 
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8.1.2 Experimental design 
In this Chapter, we tested the possibility of delivering the CTPR proteins into the cell by 
encapsulating them using fusogenic liposomes. Among our set of linear and trimeric CTPR 
proteins, 3TBP-CTPR6 was chosen as representative of the linear array. As control, the 
construct of equivalent CTPR units but lacking the TBP loops, CTPR6, was used. As the 
overall aim of these experiments was to demonstrate intracellular delivery, only those two 
proteins were used. The negative charge of the CTPR proteins is a favourable property for their 
encapsulation into cationic fusogenic liposomes. CTPR constructs were loaded into fusogenic 
liposomes by rehydrating lipid cakes in the presence of the purified protein as described in the 
previous section. 
Encapsulated and empty liposomal formulations were first characterised in terms of 
their biophysical properties and for their potential cytotoxicity in a cell-based assay. Then, the 




Figure 8.1: Schematic representation of the dual-luciferase reporter assay, performed here by 
transfecting the firefly and Renilla plasmids and delivering the CTPR constructs using fusogenic 
liposomes. The lipid bilayer of the plasma membrane and the liposomes is represented as two 
continuous lines close to each other. 3TBP-CTPR6 was chosen as representative CTPR construct to be 
encapsulated into fusogenic liposomes. 




8.2.1 Liposome characterisation  
Fusogenic liposomes were prepared as mentioned above and initially characterised for their 
biophysical properties. The surface charge of fusogenic liposomes containing 3TBP-CTPR6 
(FL-3TBP-CTPR6) and control liposomes without protein (FL) was therefore measured. Given 
the positive charge of the lipids, both FL and FL-3TBP-CTPR6 had highly positive surface 
with zeta potential (ZP) values of +126 mV and +75.7 mV, respectively, at pH 7.4 (Figure 
8.2A, B). The lower ZP of FL-3TBP-CTPR6 is expected, due to encapsulation of the negatively 
charged 3TBP-CTPR6 (pI ~ 4.8) within the liposomes. The hydrodynamic sizes of FL and FL-
3TBP-CTPR6 were similar, at ~106 nm (Figure 8.2 C, D). 
 
 
Figure 8.2: Characterisation of fusogenic liposomes. Schematic representation of FL (left) and FL-
3TBP-CTPR6. The surface charge and the hydrodynamic size of FL (A, C) and FL-3TBP-CTPR6 (B, 
D) were measured. This experiment was performed by Dr. Piyush K. Chaturbedy. 
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We next wanted to assess the cytotoxicity potential of fusogenic liposomes when incubated 
with living cells. To this purpose, HEK293T cells were treated with increasing amounts of FL 
and FL-3TBP-CTPR6 for 15 minutes and the CellTiter-Glo viability assay was then performed. 
FL and FL-3TBP-CTPR6 did not show any significant cytotoxicity even for amounts higher 




Figure 8.3: Cell viability assays of empty liposomes (FL, black bars) and liposome-encapsulated 3TBP-
CTPR6 protein (FL-3TBP-CTPR6; grey bars). Untreated cells were taken as control for the experiment. 
Data were normalised relative to untreated cells set at 100% (not shown). Error bars were obtained from 
triplicate sample measurements from two independent experiments. This experiment was performed by 
Dr. Piyush K. Chaturbedy. 
 
We then sought to visualise the liposome-mediated intracellular protein delivery under the 
confocal microscope. To this aim, 3TBP-CTPR6 was fluorescently labelled with rhodamine B 
isothiocyanate (RITC), a fluorescent dye used as tracer. Liposomes were prepared in the 
presence of the labelled protein and the new formulation was named FL-3TBP-CTPR6-RITC. 
The liposome formulation includes DiR, a lipophilic dye which allows us to localise where the 
liposomes have fused to the plasma membrane. Confocal images of HEK293T cells treated 
with FL-3TBP-CTPR6-RITC (Figure 8.4) clearly indicate that liposomes have fused to the 
plasma membrane and the protein has been delivered inside the cells and is distributed 
throughout the cytoplasm. Cells treated with empty FL did not show any signal for 3TBP-
CTPR6-RITC, as expected (Figure 8.5). 
 




Figure 8.4: Confocal microscope images of HEK293T cells treated with liposome-encapsulated protein 
(FL-3TBP-CTPR6-RITC). DiR (λex = 633 nm, λem = 720-800 nm) stains the cellular membrane. 3TBP-
CTPR6-RITC (λex = 514 nm, λem = 530-650 nm) is distributed throughout cell cytoplasm. The merge 
of red and the green channel clearly shows that protein has been delivered inside the cells. This 
experiment was performed by Dr. Piyush K. Chaturbedy. 
 




Figure 8.5: Confocal microscopy of HEK293T cells treated with empty FL. DiR (λex = 633 nm, λem = 
720-800 nm) stains the cellular membrane. This experiment was performed by Dr. Piyush K. 
Chaturbedy. 
 
8.2.2 TopFlash dual-luciferase reporter assay – Interventional  
The effect of liposome-delivered 3TBP-CTPR6 on Wnt signalling was then tested using the 
TopFlash assay. For this assay, fusogenic liposomes containing the control construct CTPR6 
were also prepared, for comparison. Liposomal delivery of the CTPR proteins allows us to 
measure their inhibitory effect on the Wnt signalling pathway interventionally. Unlike DNA 
transfection, which induces constitutive protein expression throughout the incubation period, 
liposome-mediated delivery allows the dosage of the protein in a much more accurate way and 
with a specific timing. To test their interventional activity, cells were treated with liposome-
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encapsulated CTPR constructs 16 hours after Wnt signalling had been activated using Wnt 
conditioned medium. This experimental set-up more closely correlates to the clinical setting, 
as Wnt-dependent cancer cells have high activation of the Wnt signalling pathway at the time 
of pharmacological treatment, and the drug aims to reduce this elevated signalling.219 Wnt-
activated HEK293T cells were therefore treated with FL-3TBP-CTPR6 and FL-CTPR6 for six 
hours and the TopFlash assay was then completed as indicated in the previous Chapter. A 
decrease in Wnt signalling was observed in cells treated with FL-3TBP-CTPR6, with the 
percentage luciferase activity lowered by about 50% after this short incubation time (Figure 
8.6A). No effect on the luciferase levels was observed in cells treated with FL-CTPR6, as 
expected. The assay was also performed in the presence of fusogenic liposomes containing 
progressively lower concentrations of 3TBP-CTPR6. Importantly, we could observe a 
correlation between the TopFlash activity and the concentration of FL-3TBP-CTPR6 (Figure 
8.6A), indicating a dose-dependent inhibition of endogenous TNKS. As additional control, 
treatment with free 3TBP-CTPR6 did not affect the luciferase expression levels as the protein 
cannot enter cells on its own. Similarly, FL did not alter luciferase levels, indicating that 
membrane fusion of liposomes does not interfere with the Wnt signalling. Importantly, the 
TopFlash assay was also used to evaluate the interventional activity of the three small molecule 
TNKSi under identical experimental conditions and at the highest concentration of FL-3TBP-
CTPR6 (Figure 8.6B). It is noteworthy that FL-3TBP-CTPR6 resulted in a greater extent of 
Wnt signalling inhibition compared to all three small molecule TNKSi, further underlying the 
potential of our molecules for future applications. 




Figure 8.6: TopFlash assay with CTPR constructs and TNKSi tested interventionally. (A) Inhibition of 
Wnt signalling in HEK293T cells by fusogenic liposome-encapsulated 3TBP-CTPR6. Each treatment 
was with 20 µL of liposomes. In brackets are the concentrations of the proteins used. For each run, data 
were normalised by the untreated control well, set at 100%. Bars with diagonal stripes correspond to 
samples treated with liposomes. No Wnt: cells without Wnt pathway activation and not treated with 
liposomes. Untreated cell: cells not treated with liposomes. FL: empty liposomes. Error bars were 
obtained from triplicate sample measurements from two independent experiments. The significance of 
the difference between samples (ns: non-significant, p>0.05, *p≤0.05 **p≤0.01, ***p≤0.001) was 
assessed using One-way ANOVA coupled with Dunnett’s Multiple Correction test. Samples having an 
inhibitory effect were compared to the control sample FL-CTPR6. The results in A were obtained in 
collaboration with Dr. Piyush K. Chaturbedy. (B) Effect of small molecule TNKSi tested 
interventionally. Cells were first treated overnight with Wnt conditioned medium only and then TNKSi 
were added and incubated for an additional 6 h. Final concentration was 1 µM for all the small molecule 
TNKSi tested, in 0.5% DMSO, equal to the highest 3TBP-CTPR6 concentration used in A. Data were 
normalised by the untreated control well, set at 100% (not shown). Error bars were determined from 
two independent sample measurements. The same statistical analysis was performed as in (A), 
comparing the small molecule samples to DMSO. 
 
8.3 Discussion 
In the previous Chapter, the linear nTBP-CTPR2n and trimeric nTBP-CTPR2n-foldon constructs 
were tested for their prophylactic effects on Wnt signalling using the TopFlash assay. However, 
to be of clinical use in a Wnt-activated disease, the drug needs to be used interventionally. 
Moreover, given their large size of the CTPR proteins and their inability to cross the plasma 
membrane, a delivery method is also required for therapeutic purposes and to allow them to 
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reach their intracellular target. For these reasons, the purified CTPR proteins were encapsulated 
within fusogenic liposomes and were tested for their interventional potential on Wnt-activated 
HEK293T cells. Liposomal formulations were stable at room temperature and easy to prepare, 
a prerequisite for pharmacological development. Encapsulation within fusogenic liposomes not 
only favours intracellular delivery bypassing endocytosis but will also protects the CTPR 
constructs from extracellular proteolytic degradation and adverse immune response, if any, 
when used therapeutically.218 
The results showed that fusogenic liposomes could effectively deliver 3TBP-CTPR6 
into the cytoplasm of cells, without inducing cytotoxicity effects. A variation of the previously 
adopted TopFlash assay allowed us to measure the interventional activity of 3TBP-CTPR6, 
delivered after Wnt activation. The protein construct elicited very significant inhibition of Wnt 
signalling, in a dose-dependent manner. This is a noteworthy result that demonstrates 
interventional inhibition of the pathway, the scenario for targeting tumours dependent on 
deregulated Wnt pathway activity in vivo. Moreover, the luciferase protein reporter of Wnt 
pathway activity has a relatively long half-life of approximately 12 hours, and therefore 
inhibition after 6 hours treatment likely reflects a much higher attenuation of Wnt pathway 
activity beyond the measured 50% inhibition. In other words, 3TBP-CTPR6 affects the firefly 
transcription rate only after its liposomal delivery, but does not interfere with those firefly 
molecules expressed beforehand that are still present within the cell and contribute to the 
overall luminescence signal. Therefore, in these experimental conditions, the luminescence 
levels cannot be completely abolished, but only reduced. Although this experimental set-up 
represents an improvement to the previously described TopFlash assay (Chapter 7), it still relies 
on cell transfection with two luciferase-expressing plasmids. Transfection efficiency can vary 
across experimental replicates and cell lines, can be affected by several factors (such as passage 
number and cell confluency) and might require selection of transfected cells using the 
appropriate antibiotic. Ideally, a stable cell line, which expresses a luciferase reporter under the 
control of a Wnt-responsive promoter, should be used instead. Apart from providing more 
accurate results, this Wnt reporter cell line would also prevent the need of transfecting cells 
with the control Renilla luciferase. 
According to my own (Figure 8.6B) and previously published results,139 the 
interventional activities of the small molecule TNKSi is much less effective than their 
prophylactic activities, due to a cell-intrinsic feed-forward mechanism preserving high Wnt 
pathway activity once over-activated.139 Importantly, 3TBP-CTPR6 delivered by fusogenic 
liposomes induced a higher extent of inhibition compared to all three small molecule TNKSi 
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tested interventionally at the same concentration. This striking result leads to the following 
conclusions. First, it shows that targeting the non-catalytic activity of TNKS can be an effective 
alternative to inhibiting PARP activity. Indeed, the former has multiple advantages over the 
latter: targeting the substrate-binding domain will enable inhibition of both catalytic and non-
catalytic (scaffolding) functions, and it will overcome the off-target effects of TNKSi on other 
PARP proteins. Second, the presence of multiple binding sites on 3TBP-CTPR6 might 
contribute to its enhanced interventional activity compared to small molecule inhibitors, 
through the formation of large macromolecular assemblies. Finally, it shows that Wnt 
signalling was inhibited irrespective of the format by which the protein binders were 
introduced, whether by DNA transfection or by protein delivery. As our aim was to test the 
possibility of delivering the TBP-CTPR proteins intracellularly, we looked at one protein only. 
However, in the future it would be worth testing the effect induced by other TNKS-binding 
CTPR constructs using this delivery approach, to efficiently compare their inhibitory potential 
(in particular compare the effects of single- and multi-valency) and further validate our 
conclusions. There is currently great interest in developing mRNA drugs, and a number of 
liposome encapsulated molecules are already in clinical trials and in the clinic.217,220 Having 
demonstrated that the CTPR proteins can be delivered into cells and are still active, future 
studies might consider delivering CTPRs as mRNA, as there are a number of advantages in 












Design of hetero-bifunctional CTPR proteins 
 
9.1 Introduction 
Viruses, as obligate intracellular parasites, have evolved clever ways to manipulate the host 
proteome, with the aim to maximise the viability of viral proteins and allow efficient viral 
replication. One striking class of example is viral proteins that are able to simultaneously 
recruit a host E3 ubiquitin ligase to a host target protein, leading to the poly-ubiquitination of 
the host protein and its subsequent proteasomal degradation.221 Copying nature, for the past 
few years, one of the new frontiers in drug discovery has been the production of hetero-
bifunctional compounds promoting selective degradation of a target protein, rather than simply 
inhibiting the target by binding to it.222 This approach is particularly applicable to those 
diseases caused by protein overexpression and accumulation, such as cancer and 
neurodegenerative disorders.  
 
9.1.1  Targeted protein degradation 
Degraders are hetero-bifunctional constructs designed to induce protein degradation of a target 
of interest. Two major types of degraders have been developed to date: proteolysis targeting 
chimeras (PROTACs) and molecular glues. A PROTAC is a compound consisting of two small 
molecule binders connected by a short linker. PROTACs are designed to recruit and bring into 
close proximity a target of interest and an E3 ubiquitin ligase, by forming a ternary complex.223 
Molecular glues, instead, are a smaller version of PROTAC comprising a single small molecule 
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that binds both the target and the E3 ligase “gluing” them together.224 The efficacy of degraders 
has already been proven in vivo against a variety of protein targets involved in several 
therapeutic areas and recently some PROTACs have entered clinical trials. These targets are 
all proteins for which there is already a small molecule ligand. Likewise, only a small number 
(<10) of the over 600 E3 ligases in the human proteome have so far been exploited, namely 
those with small molecule ligands. As it is very unlikely that any one E3 will be able to 
effectively degrade every target, access to as many E3s as possible is desirable. The advantages 
of degradation versus inhibition are numerous, including the fact that degradation is 
irreversible, PROTACs have been shown to act catalytically and they are likely to be more 
potent than the inhibitors from which they are built, and lastly the small molecule does not 
need to bind to a functional site on the protein but can bind anywhere meaning that more 
proteins can potentially be targeted with PROTACs. 
Taking advantage of the modularity and combinatorial assembly of the CTPR repeats, 
the CTPR platform was exploited to generate modular, hetero-bifunctional constructs having 
two binding moieties: the TBP loop to engage with TNKS, and one of the binding peptides, 
known as degrons, to recruit E3 ubiquitin ligases. Like for PROTACs and molecular glues, the 
proximity between TNKS and the E3 enzyme induced by the ternary complex formation is 
expected to facilitate the transfer of ubiquitin molecules from the E3 ligase to TNKS, followed 
by TNKS degradation via the ubiquitin-proteasome system (UPS) system. 
 
9.1.2 The UPS 
The ubiquitin-proteasome system (UPS) is a highly regulated process that coordinates 
intracellular protein turnover. The activity of the UPS is mediated by three enzymes acting 
sequentially and ubiquitin - a 76-amino acid co-factor that acts as a molecular recognition label. 
Once a substrate is conjugated with multiple ubiquitin molecules, it is recognised and degraded 
by the proteasome.225 The UPS enzymes consists of the E1 (ubiquitin activating enzyme), E2 
(ubiquitin conjugating enzyme) and E3 (ubiquitin ligases). In the first step, a cysteine residue 
in the E1 binds and activates a ubiquitin molecule at its C-terminal glycine in an ATP-
dependent manner. Ubiquitin is then transferred to the E2 enzyme and finally the E3 catalyses 
the transfer of the ubiquitin molecule from the E2 to an exposed residue within the protein 
substrate. Ubiquitin is mostly transferred onto lysine residues, and less frequently onto 
cysteine, serine and threonine residues or the amino group at the N-terminal end of the protein 
substrate. Ubiquitin itself has seven lysine residues that allow linkage of multiple ubiquitin 
Design of hetero-bifunctional CTPR proteins 
 
 147 
molecules onto the same substrate to form a polyubiquitin chain. The fate of the ubiquitinated 
substrate depends on the pattern and distribution of the ubiquitin chain. Chains with ubiquitin 
molecules linked through lysine at position 48 (K48) is associated with protein degradation, as 
it is recognised by the eukaryotic 26S proteasome. Subunits of the proteasome bind to the 
substrate, induce its de-ubiquitination, unfold it and feed it through the central pore of the 
proteasome where it is cleaved by proteases into small peptide fragments of 3-15 amino acids 
(Figure 9.1).226 
The human genome encodes for just a couple of E1 enzymes, ~40 E2s and over 600 
E3s. E3 ligases are the most heterogeneous class of enzymes in the UPS, as they are responsible 
for substrate recognition and specificity. Each E3 ligases recognises a short amino acid 
sequence, called a degron, on their protein substrates. 
 
 
Figure 9.1: The UPS system. Schematic representation of protein degradation mediated by the UPS. 
Figure adapted from Lee et al.227 




Each E3 engages with a specific set of substrates by recognising peptide sequences called 
degrons. Degrons are short sequences, typically of 5-15 amino-acids, and several have already 
been identified and structurally characterised in complex with their E3s. Many degrons are 
regulated by post-translational modifications, most commonly phosphorylation. Degrons can 
be located anywhere on the surface of the substrate protein, and some proteins contain more 
than one degron. The presence and type of degron is a factor contributing to the timing and rate 
of a protein’s degradation.228 
 
9.1.4 Hetero-bifunctional CTPR/RTPR constructs and experimental design 
The modular TPR platform allows the incorporation of one or more functions, such as target 
binding and E3 binding, in a combinatorial fashion by simply joining multiple binding modules 
in a specific order. Hetero-bifunctional constructs were therefore generated by introducing a 
degron at the C-terminal end of the linear 2TBP-CTPR4 construct. Control constructs having 
no TBP loop or no degron sequence were also made. The gene fragments encoding the degrons 
of interest were already available in the Itzhaki lab and consist of a degron sequence grafted as 
a solvent-exposed loop or as a C-terminal α-helix on a RTPR scaffold. The RTPR is a variant 
of the CTPR scaffold designed in the Itzhaki lab, where all lysine residues have been replaced 
by arginine residues (R, hence the name RTPR) (Figure 9.2). 
 
 
Figure 9.2: RTPR sequence design. The RTPR sequence was generated by mutating the three lysine 
(K) residues into arginine (R) from the CTPR sequence (2) optimised in the Itzhaki lab. 
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The rationale for grafting degrons onto the RTPR rather than the CTPR scaffold was to 
minimise the likelihood of lysine-mediated ubiquitination of the scaffold itself upon E3 
recruitment. In this way, the RTPR hetero-bifunctional constructs could potentially act 
catalytically, meaning that they could be recycled to promote ubiquitination of several target 
molecules in a consecutive manner, as it was proven for the PROTACs molecules (Figure 9.3). 
 
 
Figure 9.3: Schematic representation of a hetero-bifunctional CTPR/RTPR degrader and its intended 
mechanism of action. The TNKS-binding degrader is represented as a CTPR/RTPR chimera, by 
colouring the scaffold in different shades of yellow. Upon ternary complex formation between the 
degrader, TNKS and the E3-E2 complex, ubiquitin molecules are transferred onto TNKS. TNKS is then 
recognised and degraded via the proteasome, and the degrader can be recycled. 
 
Preliminary results were obtained by co-transfecting HEK293T cells with a plasmid encoding 
HiBiT-tagged TNKS2 in combination with a single- or hetero-bifunctional CTPR/RTPR 
construct. The HiBiT-mediated luminescence signal was then compared across samples. In this 
experimental set-up, successful TNKS2 degradation is expected to lead to a reduction in the 
luminescence signal. 
 




9.2.1 Molecular biology for hetero-bifunctional constructs generation  
Hetero-bifunctional constructs were obtained by introducing an RTPR-degron encoding 
cassette between the 2TBP-CTPR4 gene and the HA tag in the pcDNA3.1(-) plasmid (Thermo 
Fisher). Given the diversity of E3 ligases, varying in localisation and concentration in different 
cell lines and throughout the cell cycle, a selection of degrons, and therefore E3 ligases, was 
adopted to enhance the chances of successful TNKS2 degradation. The degrons used in this 
study are listed in Table 9.1 and named according to the substrate in which they have been 
found. The corresponding E3 ubiquitin ligase recruited by each degron is also listed. As 
controls, constructs having no TBP loops (CTPR2) or no degron sequence were also generated 
for comparison. For simplicity, hetero-bifunctional constructs were named 2TBP-CTPR4-
“degron” and the control constructs CTPR2-“degron”. The protein sequence of the hetero-
bifunctional and control constructs is provided in Appendix B. 
 
Degron Sequence E3 ligase E3 cellular localisation Site of grafting 
ABBA SLSSAFHVFEDGNKEN APC/C dynamic Loop  
DBOX PRLPLGDVSNN APC/C dynamic Loop 
KEN SEDKENVPP APC/C dynamic Loop 
Nrf2 DPETGEL Keap1 Cytoplasm, nucleus Loop 
p27 AGSNEQEPKKRS Skp2 Nucleus, cytoplasm Loop 
p53 FxxxWxxL MDM2 Nucleus α-helix  
PHYL LRPVAMVRPTV SIAH Cytoplasm, nucleus Loop 
Puc LACDEVTSTTSSSTA SPOP Nucleus Loop 
Table 9.1: List of degrons (names after the substrates from which they were derived) and their 
corresponding E3 ubiquitin ligases used in this study. The degron sequences and an indication of the 
cellular localisation of the E3 ligases (according to the UniProt database) are provided. The site of 
grafting (loop or α-helix) within the RTPR scaffold is also listed.  
 
The hetero-bifunctional constructs therefore obtained are CTPR/RTPR chimeras, as they 
consist of four CTPRs including the two TBP loops, followed by the RTPRs onto which the 
degron is grafted (Figure 9.3). 
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9.2.2 HiBiT-tagged TNKS2 degradation assay  
A simple assay involving co-transfection of HEK293T cells with a HiBiT-tagged TNKS2 and 
a hetero-bifunctional construct was first attempted. The HiBiT-mediated luminesce readout 
allows us to quantify the levels of the HiBiT-TNKS2 construct. The assay was multiplexed 
with the CellTiter-Fluor Cell Viability assay to evaluate in parallel any cytotoxicity effect of 
the constructs, and the luminescence values were then normalised by the cell viability. 
Although it does not correspond to the ideal experimental set-up, this assay was designed to 
provide a quick evaluation over the possibility of degrading TNKS2 using hetero-bifunctional 
constructs, in order to identify the degron with the highest activity for further studies. Hetero-
bifunctional constructs were compared to those having no degron peptide (RTPR2) or no TBP 
loop (CTPR2). No cytotoxicity effects were observed for any of the constructs tested (data not 
shown). The normalised data were plotted as a percentage relative to the control well treated 
with empty vector, as shown Figure 9.4. Although all hetero-bifunctional constructs (except 
for 2TBP-CTPR4-p27) appear to cause a reduction in the HiBiT luminescence signal, a similar 
reduction was also observed with the control construct 2TBP-CTPR4 having no degron (in 
plain orange in Figure 9.4). The control CTPR2-degron constructs (containing no TBP) do not 
appear to cause a reduction in HiBiT-TNKS2 luminescence, but the data were highly variable. 
 




Figure 9.4: Effect of hetero-bifunctional and control CTPR/RTPR constructs on HiBiT-TNKS2 
luminescence. Dotted bars correspond to CTPR/RTPR constructs containing a grafted degron. Data 
were normalised to cell viability and plotted as a percentage relative to the control well treated with 
empty vector, set at 100%. Error bars corresponding to the standard deviation were determined from 
three independent sample measurements. 
 
Unfortunately, the results obtained from this assay indicated that none of the degrons when 
incorporated into the TNKS-binding TPR protein is able to induce a reduction in HiBiT signal 
above that of the control construct 2TBP-CTPR4. This observation, however, raised the 
possibility that the TBP loop itself might, somehow, induce lower HiBiT-TNKS2 levels by an 
unknown mechanism, possibly correlated with the macromolecular assembly formation (as 
observed in Chapter 6). With this hypothesis in mind, we tested the effect of the different linear 
nTBP-CTPR2n and trimeric nTBP-CTPR2n-foldon constructs (used in Chapter 5-7) on the 
HiBiT-TNKS2 protein levels. Here, cells were co-transfected with the HiBiT-TNKS2 
encoding plasmid in combination with one of the CTPR constructs. In addition, the assay was 
modified to have the following plasmid combinations both tested on the same plate: 
1) HiBiT-TNKS2 + CTPR 
2) HiBiT-TNKS2 + HiBiT-CTPR 
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The higher luminescence intensity observed for the second set of transfections is the sum of 
HiBiT-tagged TNKS2 and HiBiT-tagged CTPR construct. The assay was designed so that the 
difference in luminescence between the two sets of transfections should provide a measure of 
the HiBiT-tagged CTPR proteins levels, assuming that the 11 amino acid HiBiT tag does not 
alter their expression levels. Results from the first set of transfections are shown in Figure 9.5A. 
They show reduced levels of HiBiT-tagged TNKS2 in the presence of all of the linear nTBP-
CTPR2n or trimeric nTBP-CTPR2n-foldon constructs. This result is in agreement with the 
previously observed effect of 2TBP-CTPR4 on the HiBiT-TNKS2 signal (Figure 9.4), but it 
does not provide any additional insights into the underlying mechanism. When the difference 
in luminescence readout between the two identical sets of transfections was calculated, the 
signal corresponding to the amount of each HiBiT-tagged CTPR construct is obtained (Figure 
9.5B). The CTPR protein levels obtained are consistent with those observed in the TopFlash 
assay (i.e. levels were higher for the larger and trimeric TBP-CTPR constructs, as shown in 
Chapter 7, Figure 7.5C). Overall, with this assay it is not possible to conclude whether any 
degron sequence or the TBP itself have an effect on TNKS2 protein levels. It is also possible 




Figure 9.5: Effect of single-functional linear nTBP-CTPR2n and trimeric nTBP-CTPR2n-foldon 
constructs on HiBiT-TNKS2 protein levels. (A) Effect of CTPR constructs on the HiBiT-TNKS2 
mediated luminescence. Data were normalised to cell viability and plotted as a percentage relative to 
the control well treated with empty vector, set at 100%. Error bars corresponding to the standard 
deviation were determined from three independent sample measurements. (B) Luminescence difference 
between the two sets of transfections (HiBiT-CTPR vs CTPR). Error bars corresponding to the standard 
deviation were determined from three independent sample measurements. 




In this Chapter, the design of hetero-bifunctional TPR proteins was described. This approach, 
as with PROTACs, has tremendous potential because of its fundamental advantage in inducing 
target degradation rather than just inhibition. This approach should provide a more robust and 
durable pharmacological effect compared to target inhibition, that more often leads to a 
transient response and is unable to prevent the scaffolding functions of a target protein. 
Moreover, as degraders can act catalytically, they can be administered at a lower dose, therefore 
causing fewer side effects, if any. 
There are several important differences between PROTACs and our hetero-bifunctional 
proteins. For PROTACs, fewer than ten of the over 600 E3s in the human proteome have small 
molecule ligands available, meaning that the E3 toolbox is extremely limited. It is very unlikely 
that a single E3 will be able to effectively degrade every target, and therefore access to as many 
E3s as possible is desirable. Unlike small molecules, there are naturally occurring and 
structurally characterised degrons for many E3s that can be grafted onto our platform, 
expanding its E3 repertoire compared to PROTACs. Additionally, PROTACs can be designed 
only against those protein targets for which a selective small molecule is already available. Our 
approach instead has no such limitations, because we can exploit the much larger number of 
known short binding peptides to many targets identified from naturally occurring protein-
protein interactions. This is particularly relevant for those target proteins considered 
undruggable by conventional small molecules. 
An alternative TPR scaffold, named RTPR, in which lysine residues were replaced with 
arginine (R), was designed in the Itzhaki group to prevent poly-ubiquitination and degradation 
of the protein scaffold. This should prevent degradation of the hetero-bifunctional RTPR 
protein and potentially allow it to act catalytically. In order to do so, the construct will need to 
disengage from one target molecule to engage with another. For this reason, it has been 
proposed that the binding affinity between the hetero-bifunctional construct and its targets 
should not be too high. Indeed, a recent study showed that there was little correlation between 
target engagement and potency of degradation.229 The TBP loop, with its TNKS-binding 
affinity of 14 μM, might fulfil this requirement. Overall, it may be challenging to achieve 
ternary complex formation between the degrader, the target and the E3 ligase that is productive 
for target degradation. Several factors need to be considered: 
- Each component of the complex needs to be positioned in such a way as to avoid steric 
hindrance but at the same time facilitate the efficient transfer of ubiquitin onto the 
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target. To date, researchers in the PROTAC field cannot predict the best geometrical 
arrangement (which will be different for each target and for each E3) for achieving 
ubiquitination. Moreover, not all ubiquitination will lead to degradation – the site of 
ubiquitination on the target will affect how the target is presented to the proteasome 
and thereby how easily it is unfolded and degraded. Thus, we currently need to find the 
best combination of target binder, E3-binder and ‘linker’ empirically. 
- The presence of the E3 ligase in the correct cellular localisation and at levels required 
to elicit successful degradation need to be confirmed. The appropriate degron needs to 
be identified, grafted onto the RTPR scaffold, and characterised biophysically. Further 
work may be needed to also identify the optimal degron-E3 binding affinity. 
- Finally, the choice of the protein target might also influence the effectiveness of the 
strategy. TNKS2 is a very large (127 kDa) protein and its degradation via the 
proteasome might be more challenging to achieve through an artificial system than for 
degradation of smaller proteins. 
Unfortunately, due to the short time available for this part of the project, it was not possible to 
evaluate in detail each of the factors mentioned above. From an experimental perspective, 
cellular co-transfection in combination with the HiBiT technology was developed as a high-
throughput screening method to identify successful degron sequences and provide a quick 
indication on the possibility of targeting TNKS to the proteasome. However, plasmids co-
transfection does not represent the ideal scenario for testing protein degradation. Although 
using the HiBiT tag provides sensitive, quantitative and highly specific measurements (unlike 
anti-TNKS antibodies), TNKS2 protein produced via the transfected pcDNA3.1(-) plasmid is 
expressed throughout the incubation time, potentially masking any degradation. A better 
experimental set-up would take advantage of the CRISPR/Cas9 technology to generate a 
genetically modified cell line expressing the target of interest fused to the HiBiT tag, as has 
been done by Promega.203 Alternatively, an inducible system for target expression could be 
used. In addition, the dose- and time-dependent effects of the degraders will need to be 
assessed. Thus, the data shown in this Chapter are preliminary results that need to be further 
validated in combination with assay development, before drawing any conclusions. All these 
considerations taken together laid the foundation for a spin-out company, PolyProx 
Therapeutics, focusing on discovering biotherapeutic molecules against hard-to-drug targets 













Final discussion and future work 
 
10.1 General discussion 
Engineered tandem repeat proteins have been exploited recently by several groups for 
biotechnological purposes ranging from biomaterials to biotherapeutics development.38,44,79 
Despite their advantageous properties, CTPR repeats have been extensively used as building 
blocks for novel biomaterial applications but very little as scaffolds for biotherapeutic 
development. In this proof-of-concept study, we demonstrated the tremendous potential of the 
CTPR as a novel biotherapeutic scaffold. Using a simple “cut-and-paste” approach, CTPRs can 
be engineered to display single or multiple copies of short peptide motifs of known binding 
activities. Moreover, the simple loop and helix grafting approaches adopted by the Itzhaki 
group may require little or no in silico design procedures and should be generalisable to any of 
the 100,000+ motifs present in the human proteome. Thus, the platform has the potential to 
provide a useful tool for various cellular applications ranging from target validation, pathway 
modulation and ultimately molecular therapeutics. 
Grafting binding motifs onto a structural scaffold has several uses: it increases the 
peptides’ resistance to proteolysis and allows one to control their conformation and, when 
multiple peptides are grafted, their orientation relative to each other. The CTPR scaffold also 
provides additional advantages over other scaffolds:  
- CTPR proteins are small and ultra-stable. As a result, they can accommodate small or 
even large sequence insertions yet remain folded and stable. As they do not require disulphide 
bonds for stability, they are not affected by the redox environment inside and outside the cells. 
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- As a result of their high stability and absence of disulphide bonds, they can be easily 
and cheaply produced recombinantly in E. coli in very high yields. 
- The repetitive, modular nature of the scaffold is a particularly unique selling point, as 
each repeat can be engineered to display the same or different binding motifs and then 
combined to create multivalent or multi-functional molecules, or repeats can act as a spacer 
between the different binding motifs, all without compromising the overall fold. The rigidity 
of the CTPR scaffold ultimately works as a molecular ruler of predefined length and pitch, 
providing the possibility to control the geometrical arrangement in which the binding moieties 
are displayed. 
- Lastly, unlike other artificial binding proteins, the modular CTPR scaffold allows 
multi-valency and multi-functionality to be achieved without having to join two separate 
domains together (which can create liabilities in terms of protease sensitivity of the linker 
between the domains). 
Here we have shown that the multivalent capability of the CTPR scaffold can be 
achieved by grafting multiple TBPs (TNKS binding peptides) onto a CTPR array and can be 
further enhanced by trimerisation through the foldon motif. As detailed in Chapter 3, CTPRs 
can be functionalised by grafting binding motifs onto the loops between adjacent repeats or 
onto the terminal helices. Examples of both grafting methods were provided: the TBP was 
grafted onto alternating inter-repeat loops, and the foldon domain was grafted onto a C-terminal 
helix. In Chapters 4 and 5, we have shown that CTPR proteins with grafted TBP motifs are 
stable, correctly folded and can bind TNKS in vitro and in the cell. Interestingly, the binding 
between multivalent TBP-CTPR proteins and full-length TNKS resulted in the formation of 
large macromolecular assemblies with diverse internal dynamics depending on the linear or 
trimeric configuration of the TBP-CTPR proteins (Chapter 6). In Chapter 7 these engineered 
TBP-CTPR proteins were shown to inhibit TNKS activity and thereby the Wnt signalling 
pathway by blocking the substrate-binding ARC subdomains rather than inhibiting the catalytic 
activity of TNKS. Moreover, experiments using fusogenic liposomes to deliver the multivalent 
3TBP-CTPR6 protein (Chapter 8) demonstrated rapid inhibition of Wnt pathway activity 
within six hours of treatment. The greater effectiveness of liposome-delivered 3TBP-CTPR6 
for interventional inhibition of Wnt pathway activity compared to the small molecules TNKSi 
further highlights the potential of this strategy for targeting TNKS. It is likely that the high 
level of TNKS inhibition observed is a result of the combination of the multivalency of the 
constructs and the sequestering of TNKS within macromolecular assemblies. Such a 
mechanism of action warrants further investigation and should be explored for future 
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therapeutic efforts against TNKS and other multivalent targets. Only recently, in 2019, the 
Guettler group published a study aimed at identifying small molecule TNKS antagonists 
targeting the substrate-binding ARC subdomains using fragment-based screening.230 The small 
molecule inhibitors identified bind the ARCs at the same site as the TBP but with a very low 
affinity (Kd values higher than 1 mM), and no functional data were provided.230 The study 
further underlines the need for a peptide- or protein-based biotherapeutic to enable extended 
and higher-affinity binding interactions with the ARC subdomains and thereby inhibit TNKS 
function. Last, in Chapter 9, the ability to graft multiple peptides into the same CTPR protein 
was exploited to generate hetero-bifunctional constructs. Hetero-bifunctional biotherapeutics 
aiming to bridge a TNKS molecule to an E3 ligase were designed as degraders to enhance their 
inhibitory effect relative to the TBP-CTPR proteins. Preliminary results did not show 
degradation of TNKS, and further work will be needed to pursue this aim. 
 
10.2 Future work 
Future work should be focused on further optimisation of the TNKS-binding CTPR protein 
design and on improving TNKS inhibition via multivalency. 
 
Such optimisation could be achieved from multiple approaches:  
1. Computational modelling of the multivalent TBP-CTPR constructs to redesign them so 
that the spacing of the TBPs matches the spacing and orientation of the consecutive 
ARCs of TNKS, with the aim to increase the binding affinity and achieve avidity of 
binding. However, it will be challenging to determine the exact arrangement required 
because of the lack of a crystal structure of the full-length TNKS ANK domain and its 
known high degree of flexibility. Eisemann et al. recently tested the functional 
cooperation between different ARC combinations when binding the multivalent Axin1 
substrate.89 A similar analysis of the interaction of the current and redesigned TBP-
CTPR proteins could help us to understand how many TBP loops can engage with the 
target simultaneously and whether the multivalency results in avidity of binding. 
2. It is clear from the crystal structure of TNKS2 ARC4 in complex with TNKS-binding 
peptides that the peptides bind in an extended conformation. The CTPR scaffold might 
be constraining the TBP sequence in a sub-optimal, turn-like conformation, possibly 
explaining the weaker TNKS-binding affinity observed for the CTPR-grafted TBP 
compared with the isolated peptide and the chemically constrained peptides generated 
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in our previous study.46,85 Therefore, it is possible that the TBP loop in the CTPR 
scaffold should be lengthened by introducing additional flanking residues at either side 
of the 8-residue TBP so that it can adopt a more extended, elongated conformation. 
This might result in an increase in binding affinity. Ideally, a computational protein 
design algorithm like Rosetta should also be used to find the optimal grafting of the 
TBP onto the CTPR scaffold.231,232 
 
Future work investigating the effect of multivalency on TNKS inhibition should, instead, look 
at the following: 
1. The formation of the large, intracellular assemblies observed for the overexpressed 
TNKS in the presence of the multivalent TBP-CTPR proteins should be characterised 
further. In particular, it will be important to determine whether these assemblies also 
form with the endogenous rather than the overexpressed TNKS. This would validate 
our hypothesis that the potent TNKS inhibition observed with the multivalent TBP-
CTPRs occurs by sequestering TNKS into these assemblies. In addition, their 
biophysical properties should be studied further, in particular to determine whether they 
undergo liquid-liquid phase separation and form membraneless organelles. A recent 
paper showed that small molecule TNKSi (G007-LK) result in the formation of 
cytoplasmic puncta (degradasomes) comprising the inactivated TNKS and components 
of the ß-catenin destruction complex (ßDC), thereby leading to enhanced degradation 
of ß-catenin. Degradasomes are highly dynamic, mobile and membrane-free structures, 
in which ß-catenin is rapidly turned over.233 It is possible that the large assemblies that 
we have observed also contain components of the ßDC. Alternatively, our TNKS 
inhibitors could be acting by sequestering TNKS in macromolecular assemblies distinct 
from the ßDC, and thus the composition of our assemblies warrants further 
investigation. These studies may also help us to determine how our TNKS inhibitors 
can act interventionally, whereas colorectal cancer cells and cells after prolonged Wnt 
stimulation are unresponsive to small molecule TNKSi. 
2. Additional hetero-bifunctional TBP-CTPRs should be designed to inhibit TNKS by 
inducing its degradation. First, it would be useful to identify the most appropriate E3 
ligase for TNKS, according to expression levels in cancer versus normal cells for 
example. Second, structural modelling would be useful to predict the conformation of 
the ternary complex and thereby help to design the hetero-bifunctional CTPR proteins. 
However, in the case of TNKS, its very large size and the absence of the full-length 
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crystal structure would make this approach impossible. Nevertheless, modelling could 
be used to understand how the binary complexes (CTPR and E3, CTPR and TNKS 
ARC subdomain) also form. Third, if we verify that the multivalent TBP-CTPR 
proteins form biomolecular condensates in the presence of endogenous TNKS, then 
hetero-bifunctional degraders might have enhanced activity within these condensates 
as the enzyme (the E3) and the substrate (TNKS) are present at higher concentrations. 
This approach is currently being explored in the Itzhaki lab. Lastly, an improved 
experimental method will be required to evaluate the proteasomal degradation of 
TNKS. One option would be to generate a clinically relevant cell line stably expressing 
HiBiT-tagged TNKS in which hetero-bifunctional constructs in variable concentrations 
could be tested. If successful, constructs could then be tested in higher complexity 
models, such as organoids, and animal models. 
 
In the long term, several other properties of the CTPR scaffold need to be investigated. 
First, the consensus CTPR sequence and the RTPR might require optimisation to avoid the 
possible activation of the human immune response. Second, the delivery method is most likely 
to rely on encapsulation of mRNA rather than protein (preliminary findings from PolyProx 
Therapeutics). Third, pharmacokinetics and biodistribution of these biotherapeutics will also 
need to be tackled using the most up-to-date technologies. Finally, resistance to intracellular 
proteolytic and proteasomal degradation should be evaluated.  
To conclude, the exciting results obtained in this thesis pave the way to further 
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Amino acid sequences of the CTPR constructs generated in this study are listed. The TBP is in 
red, the RL is in green, the solvating helix is in orange and the foldon domain is in purple. 
Schematic representations of each construct are also shown, with the CTPR repeat shown as a 
yellow rectangle. 
 






































































































































Amino acid sequences of the hetero-bifunctional CTPR constructs in this study are listed. 
Sequence corresponding to the TBP is in red, the degron in shades of blue. Schematic 
representations of each construct are also shown, with the CTPR repeat shown as a yellow 
rectangle and the RTPR repeat as a brown rectangle. 
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Engineering mono- and multi-valent inhibitors on
a modular scaffold†
Aurora Diamante,a Piyush K. Chaturbedy,a Pamela J. E. Rowling,a Janet R. Kumita, a
Rohan S. Eapen, a Stephen H. McLaughlin,b Marc de la Roche,c Albert Perez-
Riba ‡*a and Laura S. Itzhaki *a
Here we exploit the simple, ultra-stable, modular architecture of consensus-designed tetratricopeptide
repeat proteins (CTPRs) to create a platform capable of displaying both single as well as multiple
functions and with diverse programmable geometrical arrangements by grafting non-helical short linear
binding motifs (SLiMs) onto the loops between adjacent repeats. As proof of concept, we built synthetic
CTPRs to bind and inhibit the human tankyrase proteins (hTNKS), which play a key role in Wnt signaling
and are upregulated in cancer. A series of mono-valent and multi-valent hTNKS binders was assembled.
To fully exploit the modular scaffold and to further diversify the multi-valent geometry, we engineered
the binding modules with two different formats, one monomeric and the other trimeric. We show that
the designed proteins are stable, correctly folded and capable of binding to and inhibiting the cellular
activity of hTNKS leading to downregulation of the Wnt pathway. Multivalency in both the CTPR protein
arrays and the hTNKS target results in the formation of large macromolecular assemblies, which can be
visualized both in vitro and in the cell. When delivered into the cell by nanoparticle encapsulation, the
multivalent CTPR proteins displayed exceptional activity. They are able to inhibit Wnt signaling where
small molecule inhibitors have failed to date. Our results point to the tremendous potential of the CTPR
platform to exploit a range of SLiMs and assemble synthetic binding molecules with built-in multivalent
capabilities and precise, pre-programmed geometries.
Introduction
The relationship between protein structure and function has
been a cornerstone of biology for decades. However, in recent
years, the unstructured or intrinsically disordered regions of the
eukaryotic proteome (40% in humans) have gained increasing
interest. This is due in part to the abundance in these regions of
short independently functioning binding modules known as
MoRFs (molecular recognition features) or SLiMs (short linear
motifs).1 One approach to exploit these motifs for inhibiting
protein–protein interactions (PPIs) is to chemically synthesise
them in combination with modications such as cross-linking
and macrocyclisation designed to improve affinity, half-life
and cell penetration.2 However, in nature high-affinity and
high-specicity interactions and more complex regulatory
mechanisms are achieved through multivalency and avidity,
neither of which are straightforward to realise with conven-
tional peptide technologies. It is also uncertain whether small
molecules could ever act as effective inhibitors of such complex
networks of multivalent contacts.3,4 Consequently, in order to
interrogate and ultimately to drug such intricate networks of
inter-linked motifs, new technologies are needed. There are
many multivalent antibody technologies leveraging the natural
modularity (i.e. multi-domain nature) of immunoglobulins.5,6
However, multivalency has been less successful in antibody-like
domains, where it has only been achieved by connecting
monovalent units in “beads-on-a-string” or by directly assem-
bling them on antibody scaffolds.7–10 Likewise, functional
peptide motifs have been assembled on synthetic chemical
scaffolds,11,12 DNA13,14 and protein scaffolds,15–21 but no modular
platform has been developed to date that is capable of combi-
natorial incorporation of multiple SLiMs in a single stable and
reliable scaffold as well as presenting them with varied, precise
and programmable geometries. Here we show that tandem-
repeat proteins possess all the necessary features with which
to build such a platform.
Tandem-repeat proteins comprise tandem arrays of small
structural motifs that pack in a linear fashion to produce
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regular, elongated, quasi-one-dimensional architectures and
function in binding to other proteins, small molecules or
nucleic acids. The repetitive modular organisation of this
architecture makes it straightforward both to dissect and to
redesign the biophysical properties.22–27 One of the simplest
repeat structures is the tetratricopeptide repeat (TPR),28,29 a 34-
residue motif comprising two antiparallel a-helices with
adjacent repeats connected by a short turn (Fig. 1A, bottom).30
Articial proteins comprising multiple copies of a consensus-
designed TPR (CTPR) sequence have been shown to be
extraordinarily stable.31 Moreover, the modular nature of the
architecture means that consensus repeats are self-compatible
and can be individually designed and put together in any
order. We recently showed that the CTPR scaffold can
Fig. 1 Design of hTNKS-binding CTPR proteins in different formats and valencies. (A) (Top) Domain architecture of hTNKS1 and hTNKS2,
comprising a histidine, proline, serine-rich (HPS) domain, a substrate-binding ankyrin-repeat (ANK) domain made up of five ankyrin-repeat
clusters (ARC), a sterile alpha motif (SAM) and the catalytic PARP domain. (Bottom) Schematic representation of 1TBP-CTPR2 construct, showing
the hTNKS-binding peptide (TBP) grafted onto the loop between adjacent CTPR repeats (PDB 2HYZ) in order to inhibit hTNKS activity. As denoted
by the semi-circular cut-outs, four of the five ARCs can bind to the TBP. (B) Sequence of the CTPRmotif designed byMain and co-workers (1) and
that used for this study (2).31,63,64 Secondary structural elements are shown. (C) Schematic representation of the nTBP-CTPR2n constructs. Each
CTPR is shown as a yellow rectangle, and the TBP grafted onto the inter-repeat loops are in red. The amino-acid sequence of each construct is
provided in Table S1.† (D) Crystal structure of CTPR8 (PDB 2HYZ) viewed along the superhelical axis. CTPR helices are in yellow and the inter-
repeat loops, onto which the TBP sequence is grafted, are in red. (E) (Left) Schematic representation of CTPR2-foldon. Each CTPR is represented
by a yellow rectangle and the foldon domain by a purple triangle. (Middle and Right) Different views of the modelled structure of CTPR2-foldon.
The model was generated by grafting the foldon helix (PDB: 1OX3) onto the CTPR helix (PDB: 2HYZ) using the UCSF Chimera software 1.8.1.65
CTPR helices are shown in yellow, the inter-repeat loops, onto which the TBP is grafted, are in red.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 880–895 | 881

























































































accommodate peptide extensions in the loop between adjacent
repeats up to as many as 25 amino acids without compromising
the native structure.32,33 We then demonstrated that we could
gra a SLiM from the protein Nrf2 that recognises the onco-
genic protein Keap1 onto the scaffold and that we could not
only recapitulate the native binding affinity but also improve it
without need of sophisticated computational modelling. Thus,
by combining this modular scaffold with SLiM graing we
potentially have the capacity for diverse functionalization.33
As proof of concept, we herein construct a set of monovalent
andmultivalent CTPR proteins to bind and inhibit the human poly
(ADP) ribose polymerase (PARP) proteins tankyrase 1 and tank-
yrase 2 (referred to subsequently as hTNKS). hTNKS are unique in
the PARP family in having a series of ankyrin-repeat cluster (ARC)
subdomains (Fig. 1A).34,35 Four of the ve ARCs (ARCI, ARCII,
ARCIV and ARCV) mediate protein–protein interactions including
substrate recognition by binding short (8 residue) peptide
motifs.36–39 hTNKS has been implicated in the regulation of
a number of cellular processes,40–43 but more recently the role of
hTNKS in the regulation of Wnt pathway activity has received
particular attention.44,45 The Wnt pathway is the principle driver of
colon cancer, and a number of studies have reported the devel-
opment of smallmolecule inhibitors of the hTNKS catalytic activity
as a means of modulating Wnt pathway activity.44,46–49 However, by
targeting the catalytic PARP domain these small molecules may
lack specicity for hTNKS over other PARP family members.50–52
Moreover, they can only inhibit the catalytic function of hTNKS but
not the well-documented non-catalytic functions.53,54 To overcome
these limitations, our aim was to target the unique substrate-
binding ARC subdomains and thereby block both catalytic and
non-catalytic functions. Guettler et al. previously determined
a consensus sequence that is recognised by the ARC subdomains
(referred to subsequently as the tankyrase-binding peptide or
TBP)36 (Fig. 1A), and we have shown that macrocyclised TBPs are
able to bind hTNKS and inhibit Wnt signalling.55
We graed the TBP onto the inter-repeat loop of the CTPR
scaffold to generate a series of mono- and multi-valent binding
proteins (nTBP-CTPR2n). Our aim was to explore the effects of
multivalency on the biophysical properties of the proteins and on
their interactions with and cellular inhibition of hTNKS, which is
itself multivalent. Further motivation came from the fact that
several hTNKS substrates are themselves multivalent as they
contain multiple TBPs.56 In order to further extend the multivalent
capabilities and to produce more complex binding geometries
beyond what is possible with the linearly arrayed nTBP-CTPR2n
format, we engineered a trimeric ‘foldon’motif into the constructs
(nTBP-CTPR2n-foldon).57–61 Our results highlight the power of
multivalent inhibitors for targeting complex protein–protein
interactions, where occupancy-driven inhibition using simple
monovalent molecules is unlikely to be effective.
Results
nTBP-CTPR2n proteins: design of mono- and multi-valent
tankyrase inhibitors
We functionalised the CTPR scaffold by graing an 8-residue
hTNKS-binding consensus peptide (TBP), REAGDGEE,
identied from a mutational analysis of hTNKS substrates,36
onto the loop between two adjacent repeats (Fig. 1A). This
minimal hTNKS-binding unit was then tandemly repeated to
generate a series of mono- and multi-valent molecules named
nTBP-CTPR2n, with n between one and four (Fig. 1C). The CTPR
proteins adopt a superhelical conformation with eight repeats
required to complete a superhelical turn.62 Thus, in the nTBP-
CTPR2n construct design, the TBP loops will be offset from each
other by approximately 90 (Fig. 1D). All nTBP-CTPR2n
constructs could be expressed and puried in high yields in E.
coli (20 mg per litre of culture). All proteins were soluble in
solution.
Effect of TBP insertions on CTPR folding and stability
We rst investigated the effects on protein stability of graing
the TBP sequence onto the inter-repeat loop using far-UV
circular dichroism (CD). Given the high a-helical content of
the nTBP-CTPR2n constructs, all CD spectra have the expected
double minima at 208 nm and 222 nm similar to those observed
previously for the CTPR proteins (Fig. S1A,† le),32 conrming
that all nTBP-CTPR2n constructs were correctly folded. There
was a linear increase in the molar ellipticity at 222 nm with
increasing size of the CTPR construct, which further conrms
that the proteins were natively folded (Fig. S1A,† right).
Next, thermal unfolding was performed to investigate the
stability of the nTBP-CTPR2n constructs. We used the ellipticity at
222 nm as a measure of a-helical content. All proteins were found
to be extremely thermostable, with only the smallest protein, 1TBP-
CTPR2, undergoing complete denaturation. The larger nTBP-
CTPR2n proteins remained partly folded even at the highest
temperature, conrming that the stability increases with
increasing number of repeats. The midpoint of the unfolding
transition (TM) is therefore provided only for 1TBP-CTPR2 and
corresponds to 75 C (Fig. S1B†). Following thermal denaturation,
the samples were allowed to return to 20 C, and the CD spectra re-
measured to evaluate the reversibility of the reaction. For all of the
proteins, there was no signicant difference between the CD
spectrum before and aer thermal denaturation, indicating that
unfolding is reversible (Fig. S1C†).
Chemical-induced denaturation experiments were also per-
formed, monitoring the uorescence of the tryptophan residues
(one per repeat) (Fig. S2†). A single transition was observed for
all of the constructs, and the data were tted to a two-state
model to give the midpoints of unfolding (D50%), m-values
(mD–N, a parameter related to the change in solvent-exposure
upon unfolding) and the free energies of unfolding ðDGH2ODNÞ
(Table S2†). There was a signicant increase in D50% and m-
value between 1TBP-CTPR2 and 2TBP-CTPR4 and smaller
increases for the larger proteins. Lastly, the nTBP-CTPR2n
showed a decrease in the stability compared with their respec-
tive counterparts without the TBP loops. As previously shown,32
loop insertion has a destabilizing effect through both the
entropic cost of loop closure and a consequent weakened
coupling of adjacent repeats.
We next investigated whether all of the TBP loops in themulti-
valent constructs are accessible for binding by measuring the
882 | Chem. Sci., 2021, 12, 880–895 © 2021 The Author(s). Published by the Royal Society of Chemistry

























































































affinity and stoichiometry for each nTBP-CTPR2n construct
binding to hTNKS2 ARC4 (the fourth ankyrin-repeat cluster of
hTNKS2), which contains a single binding site for the TBP
(Fig. 2A). All nTBP-CTPR2n constructs showed similar low-
micromolar affinities, and the stoichiometry was found to
increase from 1TBP-CTPR2 to 3TBP-CTPR6 in proportion to the
number of TBP loops, conrming that all sites are available for
binding (Table 1). For 4TBP-CTPR8, the stoichiometry is lower
than 4, likely because steric hindrance precludes binding of four
hTNKS2 ARC4 molecules to one 4TBP-CTPR8 molecule. No
binding could be detected for a control CTPR6 protein containing
no TBP (Fig. S3†). The changes in the free energy (DG), enthalpy
(DH) and entropy (TDS) for the binding of the four nTBP-
CTPR2n proteins to hTNKS2 ARC4 are plotted in Fig. 2B and
Fig. 2 Binding of TBP-CTPR proteins to hTNKS2 in vitro and in the cell. (A) Representative ITC traces from left to right: hTNKS2 ARC4 (500 mM)
into 1TBP-CTPR2 (50 mM), hTNKS2 ARC4 (500 mM) into 2TBP-CTPR4 (25 mM), hTNKS2 ARC4 (500 mM) into 3TBP-CTPR6 (16.6 mM), hTNKS2 ARC4
(500 mM) into 4TBP-CTPR8 (12.5 mM); experiments were performed at 25 C. The concentrations of nTBP-CTPR2n used were chosen so that the
molar ratio between the number of TBP loops and TNKS2 ARC4 protein was constant. (B) Thermodynamic parameters (DG, DH and TDS)
obtained by ITC for the binding of the four nTBP-CTPR2n proteins to hTNKS2 ARC4. For each parameter, the average from two independent
experiments is plotted. (C) HiBiT-tagged hTNKS2 protein levels measured by luminescence intensity throughout each step of the HiBiT-qIP
method. IP was performed in the presence of HA-tagged 3TBP-CTPR6, CTPR6 and an empty vector. Average values and standard deviation from
two independent biological replicates are shown.
Table 1 Stoichiometry (N) and dissociation constant (Kd) obtained by
ITC for the binding of nTBP-CTPR2n proteins to hTNKS2 ARC4. For
each protein, the values listed are from two independent experiments
Protein Stoichiometry (N) Kd (mM)
1TBP-CTPR2 1.01  0.03 14.68  0.99
0.90  0.02 12.80  1.10
2TBP-CTPR4 2.18  0.02 11.89  0.26
2.05  0.01 18.59  0.39
3TBP-CTPR6 2.72  0.03 5.62  0.21
2.77  0.02 20.12  0.39
4TBP-CTPR8 3.38  0.01 13.61  0.19
2.91  0.03 15.48  0.43
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 880–895 | 883

























































































listed in Table S3.† The results show that in all cases the inter-
action is enthalpy-driven. There is a slight tendency for both the
enthalphic gain and entropic cost of binding to increase with
increasing number of hTNKS2-binding loops. The increase in
enthalpy with increasing number of binding loops is to be ex-
pected, as having multiple binding sites in close proximity
should make it more likely for the protein to bind a target again
aer dissociation. The greater entropic cost of ordering a greater
number of loops upon binding is also as expected. The greater
entropic cost is offset by the greater enthalpic gain, and hence the
values of DG are similar for all four nTBP-CTPR2n proteins.
nTBP-CTPR2n proteins and hTNKS interact in the cell
Binding between hTNKS and nTBP-CTPR2n in the cell was
conrmed using a modied version of the HiBiT-based quan-
titative immunoprecipitation (HiBiT-qIP) method, that provides
a much faster and more sensitive read-out than conventional IP
by western blot.66 The method relies on the split luciferase
complementation of the two NanoLuc fragments, HiBiT and
LgBiT, providing a sensitive and quantitative method to track
any HiBiT-tagged protein.67 HA-tagged nTBP-CTPR2n was used
as bait to pull-down HiBiT-tagged hTNKS2 using an anti-HA
resin. The presence of HiBiT-tagged hTNKS2 was followed and
quantied through the luminescence signal generated by the
HiBiT technology, allowing a real-time measurement of the
pulled-down target throughout the process. The results show
that HiBiT-tagged hTNKS2 is pulled down by 3TBP-CTPR6 but
not by the control CTPR6 construct, conrming that the graed
TBP loop mediates the binding to hTNKS2 within the cellular
environment also. Moreover, no non-specic binding of HiBiT-
tagged hTNKS2 to the Anti-HA Agarose resin was detected
(Fig. 2C). Nano-Glo HiBiT blotting further conrmed the pres-
ence of HiBiT-tagged hTNKS2 in the eluted samples (Fig. S4†).
Likewise, the bait constructs and tubulin were detected by
standard western blot methods (Fig. S4†).
Design of trimeric nTBP-CTPR2n-foldon constructs
We introduced the foldonmotif at the C-terminus of each nTBP-
CTPR2n construct to induce trimerisation. In this way, each
homo-trimeric construct will display up to twelve TBP loops and
in a different geometry compared to the corresponding mono-
meric constructs. The foldon is a short (30 residue) but highly
stable motif of the protein britin from the T4 bacteriophage.57
The so-called ‘NCCF’ construct of britin contains an N-
terminal trimeric coiled-coil region followed by the C-terminal
foldon.68 Here, we introduced the foldon and part of its
preceding coiled-coil domain into the nTBP-CTPR2n constructs
by graing the helical coiled-coil onto a newly introduced C-
terminal CTPR helix (Fig. S5,† top). This helix corresponds to
an extra helix A (i.e. half of one CTPR). As all a-helices share the
same heptad conformation, it is possible to gra residues of
a particular heptad position from a ‘guest’ helix onto a ‘host’
helix. When graing a new site onto a CTPR helix, the native
residues at the interface between the helix and the neighbour-
ing repeat need to be preserved in order for the graed helix to
remain folded onto the rest of the CTPR scaffold. These residues
were identied as Ala3, Leu7 and Ala10 of helix A, which are
involved in the inter-repeat interface with the helix B of an
adjacent repeat. Part of the remaining residues of helix A were
substituted with the residues of the britin NCCF coiled-coil
domain (residues 65 to 77) involved in the trimeric interface.
This was followed by an insertion of the remaining C-terminal
end of the coiled-coil domain and the foldon (NCCF residues
78 to 109) (Fig. S5,† top). The resulting constructs are referred as
nTBP-CTPR2n-foldon, and the protein sequences are given in
Table S1.† A model of the trimeric CTPR2-foldon protein is
shown in Fig. 1E. This protein is expected to display the TBP
loops at an angle of 120 to one another. The nTBP-CTPR2n-
foldon proteins were expressed and puried as for their
monomeric counterparts. Analysis by native gel electrophoresis
is consistent with trimerisation of those proteins that contain
the foldon domain (Fig. S5,† bottom). The series lacking the
foldon domain (1TBP-CTPR2, 2TBP-CTPR4, 4TBP-CTPR8,
calculated molecular weights 11.3 kDa, 20.6 kDa and 39.4
kDa, respectively) run at increasing molecular weights between
the 20 kDa and 66 kDa molecular weight markers. In contrast,
those with the foldon domain (1TBP-CTPR2-foldon, 2TBP-
CTPR4-foldon, 4TBP-CTPR8-foldon, calculated molecular
weights as trimers 49.2 kDa, 77.4 kDa and 133.5 kDa, respec-
tively) run at higher molecular weights between the 66 kDa and
146 kDa markers.
The oligomerization was further analysed by size-exclusion
chromatography coupled with multi-angle light scattering
(SEC-MALS). The results show that 3TBP-CTPR6 and 3TBP-
CTPR6-foldon (representative of the two types of nTBP-
CTPR2n constructs) are, respectively, monomeric and trimeric
in solution (Fig. S6†). The average molecular weight obtained
for 3TBP-CTPR6 (30 kDa calculated molecular weight) is 38 kDa,
consistent with it being monomeric. The majority of the 3TBP-
CTPR6-foldon sample (105 kDa calculated molecular weight as
a trimer) elutes at an average molecular weight of 131 kDa,
consistent with it forming a trimer with some less-populated
oligomeric species at lower and higher molecular weight also
present (99, 204 and 321 kDa, respectively).
Multivalent interactions induce the formation of large
macromolecular assemblies with variable internal dynamics
When two multivalent proteins interact, they have the potential
to engage with multiple partners simultaneously, leading to the
formation of large supramolecular assemblies (see for example
work by Rosen and colleagues69). This is indeed what we observe
with hTNKS2 and the multivalent tankyrase-binding CTPR
proteins (schematically represented in Fig. 3A). These species
could be detected using a co-precipitation assay, in which the
multivalent 3TBP-CTPR6 and 3TBP-CTPR6-foldon constructs,
chosen as representatives of the linear and trimeric arrays,
respectively, co-precipitate in the presence of the multivalent
hTNKS2 construct corresponding to the rst three ARC sub-
domains (hTNKS2 ARC1–3). It is worth noting that, despite
3TBP-CTPR6 and 3TBP-CTPR6-foldon being incubated at the
same TBP molar concentration, the trimeric 3TBP-CTPR6-
foldon construct precipitated to a higher extent and lead to an
884 | Chem. Sci., 2021, 12, 880–895 © 2021 The Author(s). Published by the Royal Society of Chemistry

























































































increased precipitation rate of hTNKS2 ARC1–3. In contrast, the
mono-valent 1TBP-CTPR2 construct and the control CTPR6
construct remained in the supernatant, conrming that multi-
valency of TBP loops is required for the formation of a large
supramolecular assembly with multivalent hTNKS2 (Fig. 3B).
Titration of increasing concentrations of 3TBP-CTPR6 or
3TBP-CTPR6-foldon proteins into hTNKS2 ARC1–3 showed that
the extent of co-precipitation was dependent on the molar ratio
of the two interacting molecules, until saturation is reached.
Analysis of the gel band intensities allowed us to calculate the
molar concentration of each species in the pellet, providing an
estimation of the stoichiometries of the macromolecular
complexes that had precipitated (Fig. S7 and Table S4†). The
results indicate a 1 : 1 stoichiometry for the 3TBP-
Fig. 3 Multivalent interactions between TBP-CTPR proteins and hTNKS2 ARC1–3 analysed using a co-precipitation assay. (A) Schematic
representation of the macromolecular assemblies formed by the interaction of the multivalent hTNKS2 protein and the 3TBP-CTPR6 protein
(used as representatives of the multivalent CTPR arrays). (B) After centrifugation, supernatant (S) and pellet (P) were separated and run on a 12%
(top) or 16% (bottom) SDS polyacrylamide gel. For co-sedimentation, proteins were mixed in equal volumes at the following concentration: 10
mM 3TBP-CTPR6 (30 mM TBP loop concentration), 3.3 mM 3TBP-CTPR6-foldon (30 mM TBP loop concentration), 10 mM CTPR6 and 10 mM
hTNKS2 ARC1–3 (20 mM TBP-binding sites). Gel images were obtained using Li-COR Odyssey Fc Imaging System.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 880–895 | 885

























































































CTPR6 : hTNKS2 ARC1–3 complex, and a higher stoichiometry
of 1 : 2 for the 3TBP-CTPR6-foldon : hTNKS2 ARC1–3 complex,
explaining why the trimeric 3TBP-CTPR6-foldon can induce
a greater extent of hTNKS2 ARC1–3 co-precipitation than the
linear 3TBP-CTPR6.
Next, these protein assemblies were examined using negative
stain Transmission Electron Microscopy (TEM). The results
shown in Fig. S8† conrm that the large, macromolecular
clusters are formed only when both interacting partners are
multivalent.
To visualise the effect of multivalency inside the cell,
HEK293T cells were co-transfected with an hTNKS2
construct encoding the ARC1–5 subdomains fused to eGFP
(referred to as hTNKS2 ARC1–5–eGFP) and the multivalent
3TBP-CTPR6 or 3TBP-CTPR6-foldon constructs fused to
mCherry. Large, polymeric species were visible in the cyto-
plasm, where the signals of eGFP and mCherry perfectly co-
localised (Fig. 4). In agreement with the ndings of the co-
precipitation assays, these large assemblies were formed
only when the multivalent 3TBP-CTPR6 and 3TBP-CTPR6-
foldon proteins were co-expressed with hTNKS2 ARC1–5,
which is also multivalent. In contrast, when the same CTPR
proteins were co-expressed with a monovalent hTNKS2
construct comprising only the rst ARC domain (hTNKS2
ARC1–eGFP), no polymeric assemblies were observed
(Fig. S9†). Likewise, when the multivalent hTNKS2 was co-
expressed with the monovalent 1TBP-CTRP2, no polymeric
species were observed (Fig. 4). To further compare the
properties of the macromolecular assemblies generated in
the cell by 3TBP-CTPR6 and 3TBP-CTPR6-foldon bound to
hTNKS2 ARC1–5, Fluorescence Recovery Aer Photo-
bleaching (FRAP) was used to assess the dynamics by
measuring the recovery rate of the eGFP signal (Fig. 5). The
assemblies induced by 3TBP-CTPR6 showed uorescence
recovery within 30 seconds, suggesting that the proteins
within the assembly are dynamic in nature. In contrast, the
assemblies generated by the 3TBP-CTPR6-foldon showed no
uorescence recovery within the same timeframe, suggest-
ing that the presence of nine hTNKS binding sites on 3TBP-
Fig. 4 Fluorescencemicroscopy of HEK293T cells co-transfected with mCherry-tagged CTPR proteins and eGFP-tagged hTNKS2 ARC1–5. Co-
localisation in large macromolecular clusters is observed for eGFP-tagged hTNKS2 ARC1–5 in combination with mCherry-tagged 3TBP-CTPR6
or with mCherry-tagged 3TBP-CTPR6-foldon. These clusters are not observed for the mono-valent mCherry-tagged 1TBP-CTPR2 protein or
the control mCherry-tagged CTPR6 protein. Scale bars for all images are 10 mm.
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CTPR6-foldon leads to the formation of a more inter-
connected, rigid assembly.
nTBP-CTPR2n and nTBP-CTPR2n-foldon proteins inhibit Wnt
signalling
We next evaluated the inhibitory capabilities of the monomeric
and trimeric nTBP-CTPR2n constructs on Wnt signalling using
the TOPFLASH reporter assay. Treatment of HEK293T cells with
all the nTBP-CTPR2n constructs, with the exception of 1TBP-
CTPR2, led to a reduction in Wnt pathway activity compared
with the controls (empty vector, CTPR2 and CTPR6 and 3RL-
CTPR6 containing a non-binding peptide named ‘RL’, random
loop) (Fig. 6A). To assess the levels of nTBP-CTPR2n proteins in
the cell during the TOPFLASH assay, we used N-terminally
HiBiT-tagged nTBP-CTPR2n proteins. The 11-amino-acid
HiBiT tag allows a more sensitive and quantitative measure-
ment than western blot via the antibody-free split NanoLuc®
luciferase technology (Promega). The results show that the
extent of Wnt inhibition is proportional to the nTBP-CTPR2n
protein levels as quantied 24 h aer transfection (Fig. S10†). In
particular, it is clear that the CTPR2 protein, whether in the
monomeric or the trimeric format, is present at much lower
levels than the larger proteins. To test whether the CTPR2
constructs are subject to proteasome-induced degradation,
transfected wells were incubated with the proteasome inhibitor
MG132 for 5 hours. The results show that there is an approxi-
mate 3-fold increase in protein levels in the presence of MG132,
the exceptions being the two smallest constructs 1TBP-CTPR2
and CTPR2, whose levels are affected to a greater extent
(Fig. S11†). Thus, the smallest, least thermodynamically stable
CTPR protein is the most susceptible to proteasome-mediated
degradation, and the foldon domain enhances its intracellular
stability. In addition, the formation of the large macromolec-
ular assemblies is likely to protect the multivalent hTNKS-
binding CTPR proteins from proteolysis, further explaining
why the monovalent 1TBP-CTPR2 and the non-binding control
CTPRs do not accumulate in the cell. Lastly, we conrmed that
none of the constructs showed cytotoxicity (Fig. S12†).
Intracellular delivery of 3TBP-CTPR6 by encapsulation with
fusogenic liposomes induces high levels of Wnt inhibition
Intracellular delivery of proteins is challenging.70 We used an
encapsulation approach in which puried protein (3TBP-
CTPR6) was loaded into fusogenic liposomes. Fusogenic lipo-
somes have been shown to merge with the cell membrane and
deliver their cargo directly into the cell cytoplasm.71 Encapsu-
lation of 3TBP-CTPR6 in liposomes could minimise their
premature degradation and adverse immune response, if any.72
Liposomal formulation of 3TBP-CTPR6 (FL-3TBP-CTPR6) and
control liposomes without protein (FL) were prepared as
Fig. 5 FRAP analysis of the assemblies formed between hTNKS2 ARC1–5 and TBP-CTPR proteins. (A) FRAP analysis was performed on seven
individual Regions of Interest (ROI) selected within macromolecular assemblies induced by eGFP-tagged hTNKS2 ARC1–5 in complex with
3TBP-CTPR6 (orange) or 3TBP-CTPR6-foldon (green). HEK293T cells were bleached in the ROI and fluorescence recovery of eGFP-tagged
hTNKS2 ARC1–5 was monitored over 90 seconds. (B) Representative ROI selected within three independent macromolecular assemblies are
shown before, during and post bleaching.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 880–895 | 887

























































































Fig. 6 The effect on Wnt-activated HEK293T cells following treatment with the indicated HiBiT-tagged nTBP-CTPR2n constructs. (A) TOP-
FLASH reporter assay for HEK293T cells transfected with TCF-Firefly and Renilla reporter gene vectors and an expression vector encoding the
constructs listed. For each sample, Luciferase activities were normalised with the Renilla values and the ratio was expressed as relative luciferase
activity to the control well transfected with the empty HiBiT vector set at 100% (not shown in the graph). The monomeric constructs, trimeric
constructs and controls are shown in different shades of orange, green and blue, respectively. F indicates the foldon motif, H indicates the N-
terminal HiBiT tag. Standard deviation was calculated from triplicate sample measurements. The significance of the difference between samples
(ns: non-significant, p > 0.05, *p # 0.05 **p # 0.01, ***p # 0.001) was assessed using One-way ANOVA coupled with Dunnett's Multiple
Correction test. 1TBP-CTPR2 and 1TBP-CTPR2-F were compared to CTPR2. Multivalent linear and trimeric constructs were compared to 1TBP-
CTPR2 and 1TBP-CTPR2-F, respectively. (B) (left) The figure on the left shows the effect on Wnt signaling of treatment with fusogenic liposome-
encapsulated 3TBP-CTPR6. Each treatment was with 20 mL of liposomes. In brackets are the concentrations of the proteins used. For each run,
data were normalised by the untreated control well, set at 100%. Bars with diagonal stripes correspond to samples treated with liposomes. No
Wnt: cells without Wnt pathway activation and not treated with liposomes. Untreated cell: cells not treated with liposomes. FL: empty liposomes.
Error bars were obtained from triplicate sample measurements from two independent experiments. The same statistical analysis was performed
as in (A), comparing the samples to FL-CTPR6. (B) (right) For comparison, the figure on the right shows the effect onWnt signaling of hTNKS small
molecule inhibitors used interventionally at the indicated concentration. Data were normalised relative to the untreated control well, which was
set at 100% (not shown in the graph). Error bars were determined from two independent samplemeasurements. The same statistical analysis was
performed as in (A), comparing the small molecules to DMSO.
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described in the experimental section. Both FL and FL-3TBP-
CTPR6 had highly positive surface with zeta potential (ZP)
values of +126 mV and +75.7 mV, respectively, at pH 7.4
(Fig. S13†). The lower ZP of FL-3TBP-CTPR6 is due to
encapsulation/association of the negatively charged 3TBP-
CTPR6 (pI  4.8) with liposomes. The hydrodynamic sizes of
FL and FL-3TBP-CTPR6 were similar, at106 nm (Fig. S13†). FL
and FL-3TBP-CTPR6 did not show any signicant cytotoxicity
even for amounts three times higher than those used in our
experiments (Fig. S14†). To visualize intracellular delivery under
the confocal microscope, 3TBP-CTPR6 was uorescently
labelled with rhodamine. Liposomes were prepared using the
labelled protein and designated as FL-3TBP-CTPR6-RITC.
Confocal images of HEK293T cells treated with FL-3TBP-
CTPR6-RITC (Fig. S15†) clearly suggest that protein is inside
the cells and is distributed throughout the cytoplasm. Cells
treated with FL did not show any signal for 3TBP-CTPR6-RITC
(Fig. S16†).
We next tested the effect of liposome-delivered 3TBP-CTPR6
on Wnt signaling using the TOPFLASH assay. A decrease in the
TOPFLASH activity was observed, reaching around 50% aer 6
hours incubation. Importantly, decreasing TOPFLASH activity
correlated with increasing concentration of 3TBP-CTPR6
(Fig. 6B, le), indicating a dose-dependent inhibition of
hTNKS. Treatment with free 3TBP-CTPR6 did not affect the
luciferase expression levels as the protein cannot enter cells on
its own. Also, FL did not alter luciferase expression, indicating
that membrane fusion of liposomes does not interfere with the
intracellular Wnt signalling. Further, control protein, CTPR6,
lacking hTNKS-binding units and delivered using liposomes,
did not change the intracellular luciferase levels.
For comparison, we also performed the TOPFLASH assay in the
presence of three well-characterized small molecule hTNKS
inhibitors (XAV939, IWR-1 and G007) that bind the catalytic
domain of hTNKS. Critically, whereas the small molecule inhibi-
tors are effective when used prophylactically (i.e. before Wnt
pathway activation) (Fig. S17†), they are ineffective when used
interventionally, i.e. aer Wnt pathway activation (as would be the
case in the clinic, since patients will have elevated Wnt signaling)
(Fig. 6B, right). Strikingly, FL-3TBP-CTPR6 at the highest dose had
a signicantly greater inhibitory effect than any of the small
molecule hTNKS inhibitors (Fig. 6B). This result shows that tar-
geting the non-catalytic activity of hTNKS could be an effective
treatment where small-molecule inhibitors have so far failed.
Discussion
In this study, we created potent hTNKS inhibitors by combining
target specicity with multivalency, two features that have not been
explored in previous drug development efforts against this target.
We demonstrate that modular CTPR proteins can be engineered to
display both single as well as multiple copies of short hTNKS
bindingmotifs by graing the TBP onto the loops between adjacent
repeats. Helical graing was also applied to engineer trimeric CTPR
constructs with enhanced multivalent capabilities. We show that
CTPR proteins with one or more graed hTNKS-bindingmotifs are
stable, correctly folded and exceptionally active in inhibiting Wnt
signalling. The effect of multivalency in both partners of the
interaction – hTNKS and the designed nTBP-CTPR2n proteins –
manifests in the formation of large, intracellular macromolecular
assemblies with different dynamics dependent on the congura-
tion (i.e. monomeric versus trimeric). Thus, hTNKS inhibition by
these multivalent molecules is enhanced by clustering of the
protein within these structures. Such a mechanism of action
warrants further investigation and should be explored for future
therapeutic efforts against hTNKS and other multivalent targets.
Our experiments using fusogenic liposome delivery of 3TBP-CTPR6,
one of our most potent molecules, further demonstrated rapid
inhibition of Wnt pathway activity within 6 hours of treatment of
HEK293T cells pre-stimulated with Wnt3A ligand. This is a note-
worthy result that demonstrates interventional inhibition of the
pathway, the scenario required for targeting tumours dependent on
deregulated Wnt pathway activity in vivo. Moreover, the luciferase
protein reporter of Wnt pathway activity has a relatively long half-
life of approximately 12 hours, and therefore inhibition aer 6
hours treatment likely reects a much higher attenuation of Wnt
pathway activity beyond the measured 50% inhibition.
We compared our molecules with three well-characterised
small molecule hTNKS inhibitors and, in agreement with
previous studies, we observed around 90% inhibition of Wnt
pathway activity for two of them when used prophylactically: i.e.
when they are applied either before Wnt pathway activation by
Wnt3A ligand or in combination with it. Critically, however, to
be of clinical use, such drugs will need to work interventionally;
interventional treatment with these small molecule hTNKS
inhibitors has been shown by our group and others to be much
less effective due to a cell-intrinsic feed-forward mechanism
preserving Wnt pathway activity.73 Thus, the effectiveness of
liposome-delivered 3TBP-CTPR6 for interventional inhibition of
Wnt pathway activity demonstrated here further highlights the
power of our approach.
The work presented here points to the tremendous potential
of the repeat-protein scaffold for the rational design of multi-
valent – and thereby potentially multi-specic – molecules for
inhibiting PPIs: (1) First, CTPR proteins are small and ultra-
stable without need of disulphide bonds. As a result, they can
accommodate small or even large sequence insertions yet
remain folded and stable.32,74 Moreover, multiple such inser-
tions are also possible without compromising the fold; it is
doubtful whether other small single-domain scaffolds based on
globular structures could do the same. (2) The second key
consequence of the repeat-protein stability is that they can be
produced recombinantly in very high yields. (3) Lastly, the
repetitive, modular nature of the scaffold is a particularly
unique selling point; we have shown here that we can exploit
these characteristics to display one or multiple binding motifs
in a precise and programmable manner. It has been estimated
that there are around 100 000 such SLiMs in the human pro-
teome,75 each one of which provides a potential starting point
for drug discovery. The simple cut-and-paste approach used
here, requiring little or no in silico design procedures, could be
applied to harness some of these SLiMs, and the platform thus
has potential to be used as a synthetic tool in diverse
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 880–895 | 889

























































































applications ranging from target validation to PPI inhibition,
pathway modulation and ultimately molecular therapeutics.
Our condence in the broad applicability of the scaffold to
the display of diverse SLiMs arises from the nding that we
could effectively gra two SLiMs with very different binding
conformations onto the CTPR loops. The Keap1-binding
peptide from Nrf2 adopts a tight turn-like conformation,33
whereas the TBP in this work binds to ARC domains in a highly
extended conformation.36,55
It might appear that a limiting factor in this multivalent
platform would be the potential for steric clashes between
target and scaffold as well as between targets in a multivalent
display. The rst challenge should be approached on a case-by-
case basis, as it is common to all peptide display methodology.
The second problem can bemitigated by exploiting the modular
nature of this technology. For example, the ITC data show that
both 3TBP-CTPR6 and 4TBP-CTPR8 bind to approximately three
hTNKS2 ARC4 molecules, suggesting that a maximum has been
reached. We limited our graing to one peptide for every two
repeats, but peptides could be set further apart by increasing
the number of intervening repeats. The rigidity of the CTPR
scaffold ultimately works as a molecular ruler of predened
length and pitch. Furthermore, we have shown that trimerisa-
tion by means of the small foldon domain enhances the
multivalent capability of the CTPR scaffold, presumably by
providing more degrees of freedom for the formation of
macromolecular complexes. Future work will focus on building
bi- and multi-functional CTPR arrays using multiple SLiMs to
bring two or more different targets together in a predened
geometry, for example to redirect enzyme activity, alter sub-
cellular localisation or reprogramme signaling pathways.
Experimental section
Molecular biology
The gene encoding 1TBP-CTPR2 was synthesised by Integrated
DNA Technologies. It was designed with appropriate restriction
sites at each terminus to allow ligation and the generation of
multivalent constructs by concatemerisation.76 We used
a variant of the original CTPR sequence developed by Regan and
coworkers modied at two positions (D18Q and E19K)63,64 to
further enhance the stability of the CTPR scaffold. Our CTPR
proteins do not have the extra C-terminal helix that has been
used by some groups to improve solubility (Fig. 1B).25,31,77,78
Likewise, the gene encoding the foldon motif was synthesized
and ligated at the 30 end of each nTBP-CTPR2n construct using
the appropriate restriction enzymes (Thermo Fisher Scientic).
The genes encoding hTNKS2 fragments were also amplied and
ligated using the same method. Different combinations of tags
(His, HA, HiBiT, eGFP, mCherry) were fused at the N- or C-
terminal end of each construct. Genes were ligated into
a modied pRSRET B vector (Thermo Fisher Scientic) for
bacterial expression, or into the pcDNA3.1() vector (Thermo
Fisher Scientic) for mammalian expression. Correct clones
were conrmed by DNA sequencing (Eurons Genomics).
Protein sequences of all of the generated CTPR constructs are
listed in Table S1.† An E. coli expression plasmid encoding
TNKS2 ARC4 was previously generated.55
Protein purication
The pRSET B vectors encoding the His-tagged nTBP-CTPR2n
constructs were transformed into chemically competent
Escherichia coli C41 cells. Colonies were grown at 37 C in 2xYT
media (Formedium) containing ampicillin (50 mg mL1),
shaking at 220 rpm until the optical density at 600 nmwas0.6.
Protein expression was induced with 0.5 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) for 16–20 hours at 20 C. Cells
were harvested and resuspended in buffer A (50 mM Tris–HCl,
150 mM NaCl, pH 8.0) including EDTA-free SIGMAFAST
protease inhibitors (Sigma-Aldrich), Lysozyme and DNase I.
Cells were lysed by high-pressure homogenization using an
Emulsiex C5 homogenizer (Avestin) at 15 000 psi, and cell
debris was removed by centrifugation steps at 40 000g for 40
minutes. nTBP-CTPR2n constructs were puried by immobi-
lised metal ion affinity chromatography (IMAC) on a 5 mL
HisTrap Excel column according to the manufacturer's
instructions (Cytiva). The column was washed with 20 CV of
buffer A containing 20 mM imidazole to prevent nonspecic
interaction of lysate proteins to the beads. Proteins were eluted
with buffer B (50 mM Tris–HCl, 150 mM NaCl, 500 mM imid-
azole, pH 8.0). All proteins were subsequently puried by size-
exclusion using a HiLoad 16/600 Superdex 75 pg column
(Cytiva) pre-equilibrated in buffer A. Puried protein was ash-
frozen and stored at 80 C until further use.
Proteins to be analysed by size-exclusion chromatography
coupled with multi-angle light scattering (SEC-MALS) were further
puried by SEC using a Superdex 200 10/300 GL (Cytiva) pre-
equilibrated in buffer A. Puried protein samples (100 mL) were
subjected to SEC-MALS, performed on a SEC Superdex 200
increase 10/300 GL column (Cytiva) preequilibrated in buffer A, in
line with a multi-angle light scattering module (DAWN-8+; Wyatt
Technologies) and a differential refractometer (Optilab T-rEX;
Wyatt Technologies). The light scattering and protein concentra-
tion at each point across the peaks in the chromatograph were
used to determine the absolute molecular mass from the intercept
of the Debye plot using Zimm's model as implemented in the
ASTRA v7.3.0.11 soware (Wyatt Technologies). To determine
interdetector delay volumes, band-broadening constants and
detector intensity normalization constants for the instrument, BSA
(Thermo Fisher Scientic) was used as a standard prior-to sample
measurement. Data were plotted with the program PRISM 8
(GraphPad Soware Inc.).
His-tagged Tankyrase-2 Ankyrin Repeat Cluster 4 (residues 488-
649, referred to as hTNKS2 ARC4) and Tankyrase-2 Ankyrin Repeat
Clusters 1–3 (residues 2-485, referred to as hTNKS2 ARC1–3) were
expressed and puried as reported above and previously,55 with all
buffers containing 2 mM DTT. To remove the His tag, proteins
were incubated with 125 U of thrombin (Sigma-Aldrich) overnight
at RT on a rotating mixer. Cleaved protein was further run over
IMAC, and the ow-through was collected. The nal purity and
identity of all the proteins were determined by SDS-PAGE and
MALDI mass spectrometry (PNAC, Department of Biochemistry,
890 | Chem. Sci., 2021, 12, 880–895 © 2021 The Author(s). Published by the Royal Society of Chemistry

























































































Cambridge, UK), respectively. Concentrations were determined by
absorbance at 280 nm using the calculated extinction coefficient
(ExPaSy ProtParam)79 for each protein.
Circular dichroism spectroscopy (CD) and thermal
denaturation experiments
All protein samples were prepared in 10 mM sodium phosphate
buffer, 150 mM NaCl, pH 7.4, at a nal concentration of 20 mM.
Circular dichroism (CD) measurements were performed on
a Chirascan CD spectrophotometer (Applied Photophysics) at
20 C. CD spectra were acquired at wavelengths between 200 nm
and 280 nm using a 1 nm bandwidth at a scan speed of 120 nm
per minute. Readings were repeated in triplicate and the data
averaged. Thermal denaturation experiments were carried out
by increasing the temperature of the protein samples from 20 C
to 92 C in 1 C steps, and the ellipticity at 222 nm was moni-
tored. Readings were repeated ve times, averaged and tted to
a sigmoidal Boltzmann equation including a sloping baseline
term using PRISM (GraphPad Soware Inc.). Subsequently, the
sample was allowed to cool back to 20 C and the CD spectrum
was re-acquired.
Equilibrium denaturation monitored by uorescence
spectroscopy
High-throughput equilibrium denaturation experiments were
performed as previously described.74 All protein samples (at
concentrations between 6–10 mM) were prepared in 50 mM
sodium phosphate buffer, 150 mM NaCl, pH 6.8. Protein
samples were dispensed into 96-well, half-area, black poly-
styrene plates (Corning) using a Microlab ML510B dispenser
(Hamilton) containing different concentrations of guanidinium
hydrochloride (GdmHCl) between 0 M and 6M in increments of
0.1 M per well. Plates were covered with 96-well Microplate
Aluminium Sealing Tape (Corning) to avoid evaporation and
incubated at 25 C for 1 hour. Plate measurements were carried
out on a CLARIOstar Plate Reader (BMG LABTECH) with
a tryptophan-detection lter set consisting of an excitation lter
(275–285 nm), a dichroic PL325 nm, and an emission lter
(350–370 nm) at 25 C. Each measurement was performed in
triplicate. The plots of uorescence intensity versus denaturant
concentration were tted to a two-state model with sloping
baselines, in which only fully folded and fully unfolded states
are populated, using the following equation:80
lobs ¼







1þ exp½mDNð½D  ½D50%Þ
where aN and aD are the state signal at the lowest and highest
concentration of denaturant, respectively, bN and bD are the
slopes of the native and unfolded state baseline, respectively,
mD–N is a constant related to the change in solvent accessible
surface area upon unfolding, [D] is the denaturant concentra-
tion and [D]50% is the midpoint of the unfolding transition. The
free energy of unfolding, DGH2ODN, was calculated as the product
of the midpoint of unfolding ([D]50%) and the m-value (mD–N),
a constant proportional to the surface area exposed upon
unfolding.
Isothermal titration calorimetry (ITC)
ITC was performed at 25 C using a MicroCal VP-ITC (Malvern
Panalytical). Proteins were dialysed into 10 mM sodium phos-
phate buffer, 150 mMNaCl, 0.5 mM TCEP, pH 7.4. TNKS2 ARC4
was titrated into the sample cell containing one of the nTBP-
CTPR2n constructs. Injections of TNKS2 ARC4 into the cell were
initiated with one injection of 5 mL over 6 seconds, followed by
29 injections of 10 mL over 12 seconds. Raw data were rst
subjected to baseline determination using NITPIC soware81
and were tted using the OneSite model within Origin 7.0
soware to a non-linear regression.
Immunoprecipitation (IP)
HEK293T cells were cultured in 15 mL cell growth media
(Dulbecco's Modied Eagles Medium (DMEM), high glucose,
pyruvate, (Thermo Fisher Scientic) supplemented with 10%
Fetal Bovine Serum (Sigma-Aldrich) and 1 Penicillin/
Streptomycin (Gibco). HEK293T cells in 10 cm dishes were
transfected with 3.5 mg of pcDNA3.1() vector encoding HiBiT-
tagged hTNKS2 and 3.5 mg of pcDNA3.1() vector encoding
a HA-tagged 3TBP-CTPR6, CTPR6 or empty vector. Transfection
was performed using Lipofectamine 2000 transfection reagent
according to the manufacturer's protocol (Thermo Fisher
Scientic). Following 48 hours from transfection, cells were
washed twice in PBS and lysed for 30 minutes in 1 mL cold lysis
buffer (50 mM Tris–HCl, 225 mM KCl, 1% NP-40, pH 7.5)
including protease inhibitor cocktail (Sigma-Aldrich), 10 mM
NaF, 1 mM Na3VO4, 1 mM PMSF. Cell debris was removed by
centrifugation at 16 000g for 20 minutes. IP of HiBiT-tagged
hTNKS2 bound to HA-tagged 3TBP-CTPR6 was performed by
incubating the supernatant for 4 hours with 20 mL monoclonal
anti-HA Agarose (Sigma-Aldrich), pre-equilibrated in lysis
buffer. Anti-HA agarose resin was washed 4 times with 500 mL
lysis buffer. Elution was performed by adding 20 mL 2 loading
dye containing denaturant SDS to the settled resin. All steps
following cell washing were performed at 4 C. The presence of
HiBiT-tagged hTNKS2 throughout the IP process was detected
by mixing 5 mL of each sample with the Nano-Glo HiBiT Lytic
Detection System according to the manufacturer's instructions
(Promega). The amount of HiBiT-tagged hTNKS2 bound to the
beads was quantied by mixing 5 mL of 50% anti-HA Agarose
resin slurry with the Nano-Glo HiBiT Lytic Detection System
before elution. Data were obtained from two biological
replicates.
Samples for western blot were transferred from a 10% poly-
acrylamide gel to a nitrocellulose membrane (pore size 0.20 mm,
Pharmacia Biotech). HiBiT-tagged hTNKS2 was visualised using
the Nano-Glo HiBiT Blotting System according to the manu-
facturer's instructions (Promega). HA-tagged 3TBP-CTPR6 and
CTPR6 were detected using anti-HA-Tag (C29F4, 1 : 1000 dilu-
tion) rabbit monoclonal antibody (cell signaling). Tubulin was
identied using anti-alpha Tubulin antibody (ab7291, 1 : 10 000
dilution) mouse monoclonal antibody (Abcam). HRP-
conjugated goat anti-mouse (P0447, 1 : 10 000 dilution) and
swine anti-rabbit (P0399, 1 : 10 000 dilution) were used as
secondary antibodies (Dako). The membrane was developed
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 880–895 | 891

























































































using Amersham ECL western blotting Detection Reagent and
ECL select western blotting Detection Reagent (Cytiva) on a LI-
COR Odyssey Fc Imaging System.
Co-precipitation assay
20 mL of 10 mM hTNKS2 ARC1–3 was mixed with an equal
volume of 1TBP-CTPR2, 3TBP-CTPR6, 3TBP-CTPR6-foldon or
CTPR6 at the indicated concentration in co-precipitation buffer
(50 mM Tris–HCl, 150 mM NaCl, 0.5 mM TCEP, pH 7.3).
Samples were incubated at room temperature for 1 hour and
centrifuged at 20 000g for 30 minutes at room temperature. The
supernatant was collected and the pellet resuspended in an
equal volume of buffer. Samples were run on a polyacrylamide
gel, and the gels were imaged using the Li-COR Odyssey Fc
Imaging System and protein band densities were analysed using
the Image Studio Lite 5.2 soware.
Fluorescence microscopy and FRAP
1  105 HEK293T cells were seeded overnight in 700 mL of cell
growth media in a m-Slide (Ibidi). The following day, cells were
transfected with 400 ng of m-Cherry tagged nTBP-CTPR2n,
nTBP-CTPR2n-foldon or the control CTPR construct in combi-
nation with 600 ng of eGFP-tagged TNKS2 ARC1–5 or 100 ng of
TNKS2 ARC1, using 1.75 mL lipofectamine 2000 transfection
reagent according to the manufacturer's protocol (Thermo
Fisher Scientic). Following 48 hours from transfection, cells
were imaged on a Leica TCS SP5 confocal microscope with
a 100 oil-immersion objective lens (1.4 numerical aperture).
Excitation and lters were as follows: eGFP, excitation at
488 nm, emission from 500–540 nm; mCherry, excitation at
543 nm, emission from 600–630 nm. For FRAP, individual
circular regions of interest (ROI) were bleached using the 488
laser at 100% power for 5 seconds. Fluorescence intensity
changes were recorded comparing 5 pre-bleaching frames with
60 post-bleaching frames (1.3 seconds per frame). Data were
analysed using Leica LAS AF suite soware and data were
normalised.
Transmission electron microscopy (TEM)
hTNKS2 ARC1–3 was mixed with an equal volume and
concentration (5 mM) of 1TBP-CTPR2, 3TBP-CTPR6, 3TBP-
CTPR6-foldon, CTPR6 or co-precipitation buffer. Samples were
incubated at room temperature for 1 hour. They were then
dispensed on carbon support lm, 400 mesh, 3 mm nickel grids
(EM Resolutions Ltd, Saffron Walden, UK) and stained with 2%
uranyl acetate (w/v). The samples were imaged on a FEI Tecnai
G2 transmission electron microscope in the Cambridge
Advanced Imaging Centre (CAIC, University of Cambridge,
Cambridge, UK). Images were analysed using the SIS Megaview
II Image Capture system.
TOPFLASH dual-luciferase reporter assay of activity of
transfected CTPR constructs
Wnt pathway activity was induced by treating cells with condi-
tioned media obtained from L-cells expressing Wnt3A (ATCC
CRL-2647) for 8 days, according to ATCC guidelines. For the
TOPFLASH assay, HEK293T cells in 24-well plates were trans-
fected with 100 ng of TCF7L2-Firey plasmid, 10 ng of CMV-
Renilla plasmid and 100 ng of pcDNA3.1() vector encoding
HiBiT-tagged nTBP-CTPR2n, nTBP-CTPR2n-foldon or the
control CTPR constructs using 0.5 mL lipofectamine 2000
transfection reagent according to the manufacturer's protocol
(Thermo Fisher Scientic). Transfected cells were allowed to
recover in cell growth media for 8 hours, followed by treatment
with Wnt-conditioned media (derived from L-cells expressing
Wnt3A; ATCC CRL-2647) at a 1 : 1 ratio for a further 16 hours.
The TOPFLASH assay was performed using the Dual-Luciferase
Reporter Assay System (Promega), as previously described.82
Relative luciferase values were obtained from three indepen-
dent experiments by dividing the Firey luciferase values by the
Renilla luciferase values. The luminescence intensity of each
HiBiT-tagged construct was measured by mixing 20 mL of the
same cell lysate with the Nano-Glo HiBiT Lytic Detection System
according to the manufacturer's instructions (Promega).
Measurements of cellular levels of HiBiT-tagged CTPR
proteins
HEK293T cells in 96-well plates were transfected with 30 ng of
pcDNA3.1() vector encoding HiBiT-tagged nTBP-CTPR2n,
nTBP-CTPR2n-foldon or the control CTPR constructs using
Lipofectamine 2000 transfection reagent according to the
manufacturer's protocol (Thermo Fisher Scientic). Following
19 hours incubation, cells were treated with 10 mM MG132
(Calbiochem) for 5 hours. The number of viable cells was
measured using the CellTiter-Fluor Cell Viability Assay (Prom-
ega) according to the manufacturer's instructions. HiBiT-tagged
constructs were quantied using the Nano-Glo HiBiT Lytic
Detection System (Promega) as above. HiBiT values obtained
from three independent replicates were normalised using the
corresponding cell viability measurements.
Liposomal formulation of 3TBP-CTPR6 protein
Fusogenic Liposomes (FL) containing 3TBP-CTPR6 (FL-3TBP-
CTPR6) were prepared using a previously reported method.71
In a typical procedure, 250 mg of 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), 250 mg of 1,2-Dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE), and 25 mg of 1,10-
dioctadecyl-3,3,30,30-tetramethylindotricarbocyanine iodide
(DiR) (Avanti Polar lipids) were dissolved in 250 mL of chloro-
form (Merck). The solution was dried overnight inside a vacuum
desiccator and the resulting lipid lm was hydrated with 125 mL
of 25 mM 3TBP-CTPR6 (in 10 mM HEPES, pH 7.4). This
dispersion was rst vortexed for 2 minutes and then ultra-
sonicated for 20 minutes at room temperature. Control FL were
prepared similarly by hydrating the lipid lm with 125 mL of
10 mM HEPES, pH 7.4. The liposomes were stored at 4 C until
further use. The zeta potential and hydrodynamic size of the FL
were measured at 25 C and pH 7.4 in 10 mM HEPES buffer
using a Zetasizer Nano ZS (Malvern Instruments).
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Intracellular delivery of liposome-encapsulated 3TBP-CTPR6
protein
To directly visualise intracellular protein delivery using confocal
microscopy, 3TBP-CTPR6 was labelled with rhodamine B iso-
thiocyanate (RITC) (Sigma). In a typical procedure, 50 mL of
RITC (1 mgmL1 in DMSO) was slowly added to a 1 mL solution
of 3TBP-CTPR6 (2 mg mL1) in 0.1 M sodium carbonate buffer
pH 9.0, with stirring. The solution was stirred at 4 C for 8 hours
and ammonium chloride (Sigma) was added to a nal concen-
tration of 50 mM and stirring was continued for a further 2
hours. RITC labelled 3TBP-CTPR6 (3TBP-CTPR6-RITC) was
isolated from unreacted RITC using a PD10 desalting column
(Cytiva). Liposomal formulation of 3TBP-CTPR6-RITC (FL-3TBP-
CTPR6-RITC) was performed as described above. 1.4  105
HEK293T cells were seeded overnight in 700 mL of cell growth
media in a m-Slide (Ibidi). The following day, medium was
replaced with 700 mL cell growth media without FBS and con-
taining 28 mL of FL-3TBP-CTPR6-RITC. Samples were incubated
for 15 minutes at 37 C and then washed twice with 1 PBS.
Confocal images were acquired using a Leica TCS SP5 confocal
microscope.
Cell viability assay
4 104 HEK293T cells were seeded for 24 hours in 100 mL of cell
growth media in a 96-well plate. Cells were incubated with 100
mL liposomes in cell growth media without FBS and containing
different volumes (1–12 mL) of FL and FL-3TBP-CTPR6 for 15
minutes at 37 C. Aer washing twice with 1 PBS, 100 mL of
CellTiter-Glo Reagent (Promega) was added, and luminescence
was measured using a Clariostar microplate reader (BMG LAB-
TECH) according to the manufacture's protocol. Untreated cells
were used as control. Data were obtained from triplicate
samples, and the standard deviation was calculated from two
independent experiments.
TOPFLASH assay of cellular activity of liposome-encapsulated
3TBP-CTPR6 protein and small molecule hTNKS inhibitors
HEK293T cells were seeded in 24-well plates as described above.
Cells were transfected with 100 ng of TCF7L2-Firey plasmid, 10
ng of CMV-Renilla plasmid per well using Lipofectamine 2000
transfection reagent according to the manufacturer's protocol
(Thermo Fisher Scientic). Transfected cells were allowed to
recover in cell growth media for 8 hours, and treated with
Wnt3A-conditioned media, as above. 16 hours post Wnt
pathway activation, proteins were delivered into the cells by
liposomal treatment. Cells were incubated with cell growth
media minus FBS containing 20 mL of liposomes, for 15minutes
at 37 C. Following one wash in 1 PBS, Wnt3A conditioned
media was added and cells were incubated for 6 hours. The
TOPFLASH assay was performed, as described above, in tripli-
cate (from two independent experiments).
For the dose-dependence analysis, the volume of liposome
added was kept constant (20 mL) and the protein concentration
was varied. The FL-3TBP-CTPR6 samples were prepared in the
following way: lipid cakes were hydrated with 10 mMHEPES pH
7.4 and 3.125 mM, 6.25 mM, 12.5 mM, and 25 mM3TBP-CTPR6. 20
mL of these liposomes in 500 mL cell growth media resulted in
3TBP-CTPR6 concentrations of 0.125 mM, 0.25 mM, 0.5 mM and 1
mM respectively. Samples of the liposome-encapsulated
unfunctionalised control protein, referred to as FL-CTPR6,
were prepared by hydrating lipid cake with 25 mM CTPR6 in
10 mM HEPES pH 7.4.
For testing the small molecule hTNKS inhibitors XAV939,
IWR-1 and G007 in the TOPFLASH assay, cells were treated
prophylactically with inhibitors mixed with Wnt-conditioned
media and incubated for 16 hours, or interventionally with
inhibitors added aer overnight treatment with Wnt-
conditioned media and incubated for another 6 hours. All
small molecule hTNKS inhibitors were used at a nal concen-
tration of 1 mM in 0.5% DMSO. The TOPFLASH assay was then
completed as described above.
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V. Tolmachev, S. Ståhl and A. Orlova, Sci. Rep., 2017, 7,
43118.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 880–895 | 893

























































































9 F. Fleetwood, S. Klint, M. Hanze, E. Gunneriusson,
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